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Abstract 
Frontotemporal Dementia (FTD) is a neurodegenerative disorder that results in atrophy 
within the frontal and/or temporal lobes. Clinically, patients with FTD present with progressive 
deterioration in behaviour and/or language abilities. FTD has a strong genetic component with 
approximately 40% of patients reporting a family history. Specifically, mutations in microtubule-
associated protein tau (MAPT), progranulin (GRN) and expanded repeats in the chromosome 9 
open reading frame 72 (C9orf72) are the main genetic causes of FTD. Currently, no disease-
modifying treatments exist, and off-label medications have been used for symptomatic 
management of behaviours. Substantial progress has been made to understand the underlying 
pathology of the disease and clinical trials targeting FTD are in progress. As clinical trials begin, 
the identification of disease markers will be critical to measure treatment effects, indicate when 
treatments should be initiated and serve as potential targets for treatments. Therefore, there is a 
critical need to identify disease markers in FTD.  
The present work aimed to elucidate behavioural, structural, and functional changes in 
FTD from the preclinical to the symptomatic disease stage. Study I delineated the initial 
symptoms in patients with genetic FTD and in at-risk gene mutation carriers (preclinical 
mutation carriers and non-mutation carriers). This study revealed gene-specific patterns of initial 
symptoms during the preclinical and symptomatic disease period. Study II examined the brain’s 
ventricular volumes in genetically at-risk mutation carriers. Preclinical mutation carriers 
exhibited larger ventricular volume (i.e. greater neuronal atrophy), relative to biologically related 
mutation non-carriers. Study III delineated the functional neural correlates underlying 
disinhibition and behavioural flexibility in patients with FTD. Relative to healthy controls, 
patents with FTD exhibited decreased activity within the ventral and dorsal lateral regions of the 
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prefrontal cortex. This study reveals that patients with FTD exhibit aberrant neural functioning 
relative to healthy controls in a task indexing behavioural flexibility. 
Overall, this work suggests that behavioural and neuroanatomical disease-alteration occur 
during the preclinical disease stage and functional neural deficits underlying behavioural 
difficulties can be detected in symptomatic patients. These results may be applied to future 
clinical trial designs to assess the efficacy of treatments and determine potential treatment 
targets.   
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Summary for Lay Audience  
 
Frontotemporal Dementia (FTD) is a specific type of dementia that leads to brain tissue 
loss. Patients with FTD demonstrate behaviour and/or language problems including disinhibition, 
loss of empathy, difficulty attributing the correct meaning to words and word production. 
Although no disease-modifying treatments exist, substantial progress has been made to 
understand the pathology of the disease. As clinical trials begin, the identification of biomarkers 
will be essential to: (1) indicate disease presence and progression, (2) measure treatment 
effectiveness, (3) indicate when treatments should be administered, and (4) lead to the selection 
of treatment targets. Thus, there is a critical need to identify disease markers of FTD. 
The present thesis examined the behavioural, structural, and functional changes in FTD 
from the preclinical (prior to disease occurrence) to the disease stage. Study I examined the 
initial symptoms in patients with FTD and in preclinical mutation carriers (individuals with the 
disease-causing mutation but who do not yet meet the criteria for the disease), and non-mutation 
carriers (individuals who are not carrying the disease-causing mutation). This study found that 
patients’ initial symptoms differ based on the underlying genetic mutation, and preclinical 
mutation carriers show unique symptoms relative to mutation non-carriers. Study II examined 
the volumes of the brain’s ventricles (cavities filled with cerebrospinal fluid) in genetically at-
risk mutation carriers. Preclinical mutation carriers exhibited greater brain tissue loss relative to 
biologically related mutation non-carriers. Study III assessed the functional neural correlates 
underlying poor behavioural flexibility in patients with FTD. Relative to healthy controls, 
patients with FTD showed decreased activity within the regions of the frontal lobe known to be 
important for appropriate decision-making.  
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Overall, this work suggests that disease-alterations in behaviour and brain structure occur 
and can be detected during the preclinical disease stage prior to the onset of the disease. 
Furthermore, this work also demonstrates that problems in brain function related to behaviour 
flexibility can be detected in patients with FTD. These results may inform the selection of 
disease markers for clinical trial designs.  
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Chapter 1: Introduction 
1.1 Frontotemporal Dementia 
Frontotemporal Dementia (FTD) is a heterogenous neurodegenerative disorder resulting 
in progressive deterioration in behaviour and/or language abilities. FTD includes three core 
subtypes: behavioural variant (bvFTD) and two primary progressive aphasias (PPA), semantic 
variant PPA (sv-PPA) and nonfluent/agrammatic variant PPA (nfvPPA). Related disorders 
include FTD with motor neuron disease (FTD-MND), progressive supranuclear palsy syndrome 
(PSP-S), and corticobasal syndrome (CBS). Although distinct clinical subtypes exist, the 
presenting phenotype often converges with other sub-types as the disease progresses [1,2], which 
may complicate diagnosis if not recognized early.  
 
1.2 Epidemiology 
FTD is the second most prevalent early onset dementia occurring before the age 65 [3], 
with a prevalence of 18 to 36 per 100,000 in individuals 45-64 years of age [4]. FTD is primarily 
diagnosed between the ages of 45-65, with approximately 10% of cases occurring in individuals 
younger than 45 years of age [4], and the prevalence more than doubling amongst those older 
than 65 years of age [4,5]. Importantly, though the prevalence is likely underestimated due to 
lack of expertise by primary care physicians with limited expertise in behavioural neurology [4], 
and the absence of validated biomarkers to distinguish FTD from other neurologic and 
psychiatric disorders [6]. 
 
1.3 Burden 
FTD causes a substantial economic and social burden to the caregiver, patient and 
society. The mean age of disease onset occurs during a time when an individual’s contribution to 
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society is at its greatest, as many patients are in their prime earning years and have dependent 
children [7]. Overall household income decreases significantly after diagnosis, and the total 
annual per-patient cost is nearly two times higher than the reported cost for Alzheimer’s Disease 
(AD) [7]. In addition to the contribution to society, the burden to the caregiver is substantial: 
67% of caregivers of patients with FTD reported a notable decline in their own health and 53% 
reported increased personal health care costs [7]. Relative to carers of patients with AD, 
caregivers of people with FTD report greater burden [8,9], and experience twice the levels of 
depression, even after controlling for age and duration of symptoms [10].  
 
1.4 Prognosis 
Across the syndromes, the mean survival time of patients with FTD is approximately 7-8 
years from diagnosis [11]. In a sample of 124 patients, the most common cause of death was 
respiratory system disorder (27%), circulatory system disorder (19%) and cachexia (14%). 
Additionally, 11.5% of patients died from cancer, and in 11.5% of patients, the cause of death 
was unknown [12]. Having genetic FTD has been found to be associated with a shorter survival 
time [13]; other demographic characteristics including age at illness onset or severity of 
dementia at the time of diagnosis have not been found to be associated with survival [12,14].  
 
1.5 What causes FTD? 
1.5.1 Genetic FTD 
FTD has a strong genetic component with approximately 40% of patients reporting a family 
history and approximately 10% demonstrate an autosomal dominant pattern of inheritance [15]. 
Importantly, the exact percentage of cases with a family history may vary as inaccurate reporting 
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of family history of FTD may be attributed to psychiatric disease, another dementia or other 
diagnoses. Heritability varies across the clinical subtypes with the bvFTD phenotype showing 
the strongest heritability and the language variants showing the least [15-17]. Mutations in three 
genes have been shown to be the most frequent genetic causes of FTD including microtubule-
associated protein tau (MAPT) [18,19], progranulin (GRN) [20,21], and expanded repeats in the 
chromosome 9 open reading frame 72 (C9orf72) [22,23] (Table 1.1). Together, these genes 
account for 5-10% of all FTD with some variability depending on the case series [24].  
 
Table 1.1: Summary of FTD-related genetic mutations 
FTD gene Frequency[25,26] Age at symptom 
onset (years)[27] 
Disease duration 
(years)[27] 
Pathology[26] 
MAPT Familial: 5-20% 
Sporadic: 0-3% 
49.5 
Range: 17-82 
9.3 
Range: 0-45 
Tau protein deposits 
GRN Familial: 5-10% 
Sporadic: 1-5% 
61.3 
Range: 25-90 
7.1 
Range: 0-27 
Accumulation of TAR 
DNA-binding protein 43 
(TDP-43) 
C9orf72 Familial: 21% 
Sporadic: 6% 
58.2 
Range: 20-91 
6.4 
Range: 0-36 
Accumulation of TAR 
DNA-binding protein 43 
(TDP-43) 
 
1.5.1.1 Microtubule-associated Protein Tau (MAPT) 
The MAPT gene located on chromosome 17 was the first pathological mutation found to 
cause FTD [18,19]. To date, 63 different MAPT mutations have been identified in patients with 
FTLD [24]. Patients often present with bvFTD [28], though some may develop semantic 
impairments and parkinsonism as the disease progresses [29]. Importantly, significant variability 
remains in the presenting phenotype, even between families carrying the same mutation [30]. 
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1.5.1.2 Progranulin (GRN)  
Mutations in the GRN gene lead to haploinsufficiency, resulting in reduced levels of 
progranulin protein, a growth factor involved in regulating developmental events, inflammation 
and wound repair [31]. To date, 114 different GRN mutations causing FTD have been identified 
[24]. There is considerable variability in the age of disease onset, even for patients carrying 
identical GRN mutations [32]. As well, the presenting phenotype in the setting of a GRN 
mutation is quite heterogeneous with patients exhibiting Alzheimer’s Disease, Corticobasal 
Syndrome, or nfvPPA, with the majority of patients exhibiting bvFTD phenotype [27,33].  
 
1.5.1.3 Chromosome 9 open reading frame 72 (C9orf72) 
Pathogenic hexanucleotide (GGGGCC) repeat expansion of the C9orf72 gene is a major 
genetic cause of FTD [22]. The normal hexanucleotide repeat size is quite variable across 
individuals and the smallest repeat size to confer risk is currently unknown [34]; however, most 
consider > 30 repeats as pathogenic [33]. The most common phenotype is bvFTD, followed by 
mild cognitive impairment (MCI), then FTD with ALS [28].  
 
1.5.2 Sporadic FTD 
Approximately, 60% of patients report no family history of FTD and are considered 
“sporadic” [15]. A pathogenic variant is found in 5% of sporadic cases with mutations in the 
C9orf72 being the most frequent [26,28]. Furthermore, previous head trauma has been found to 
be a significant risk factor for the development of sporadic FTD when compared with age and 
gender-matched controls [35]. Although the majority of familial and sporadic cases arise from 
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different underlying pathologies and genetic factors, both forms show similar behavioural, 
cognitive and motor measures [36].  
 
1.6 FTD Syndromes 
Although there are three distinct clinical variants of FTD, each presenting with a unique 
phenotype, the clinical profile within each variant is quite heterogenous. Nevertheless, the 
subtypes are categorized under the broader name of FTD due to the shared clinical features, high 
degree of anatomical overlap in structural and functional brain imaging and overlap in 
pathologies [37]. Furthermore, as FTD progresses, the symptoms of the three variants converge 
as the focal neural degeneration progresses through the networks of the frontal and temporal 
lobes [38].  
 
1.6.1 Behavioural Variant FTD (bvFTD) 
bvFTD is the most common variant and accounts for approximately 60% of cases [39]. 
The clinical symptomatology of bvFTD is quite heterogeneous and is characterized by a 
deterioration of behaviour and/or cognition that begins insidiously and progresses gradually over 
time. The core diagnostic features include behavioural disinhibition, apathy, loss of sympathy, 
hyperorality, and/or perseverative or compulsive behaviours [40]. Additionally, patients may 
also demonstrate frontal and/or anterior temporal atrophy, hypoperfusion or hypometabolism 
[40].  
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1.6.2 Semantic-variant Primary Progressive Aphasia (sv-PPA) 
Sv-PPA accounts for 20% of FTD cases [39] and is clinically characterized by a loss of 
semantic knowledge resulting in word comprehension difficulties and anomia [41]. Early during 
the disease, comprehension for high frequency words is intact but patients may experience 
difficulty understanding low frequency words. Patients may also present with surface dyslexia 
and dysgraphia where atypical spelling or pronunciation of words are regularized, for example 
island is pronounced “is” – “land” [41]. Imaging features include hypoperfusion, 
hypometabolism, and/or atrophy of the dominant anterior temporal lobe, with common 
involvement of the non-dominant side as well [41]. Adding to the complexity, as the atrophy 
progresses, behavioural symptoms emerge including emotional withdrawal, disinhibition, apathy 
[42].  
 
1.6.3 Nonfluent/agrammatic-variant Primary Progressive Aphasia (nfvPPA) 
nfvPPA accounts for 25% of all FTD cases [39]. The hallmark features of nfvPPA are the 
presence of agrammatic and effortful speech, and apraxia of speech [41]. Patients may make 
inconsistent phonemic errors including deletions, distortions, insertions, substitutions or 
transpositions of speech sounds [41]. As the disease progresses, patients will make grammatical 
and spelling errors and comprehension of complex sentences is reduced [43]. Imaging-supported 
diagnosis involves predominant left posterior fronto-insular atrophy or hypoperfusion or 
hypometabolism [41]. 
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1.7 Current Challenges 
1.7.1 Diagnostic Delay and Misdiagnosis 
Although the current diagnostic criteria demonstrates good sensitivity to detect FTD [40], 
the vast heterogeneity in clinical presentation across and within syndromes, and the significant 
overlap in symptom dimensions with other diseases, poses a challenge in accurately detecting 
patients early. There is a delay of nearly 6-7 years before patients receive an accurate diagnosis 
[42,44]. As well, patients with FTD, especially those with bvFTD subtype, are commonly 
misdiagnosed with a psychiatric illness [45,46], leading to incorrect disease prognosis and 
unnecessary treatments. Ultimately, the identification of FTD-related biomarkers sensitive to 
early disease onset would help mitigate this diagnostic challenge.  
 
1.7.2 Current Treatment Interventions 
At present, there are no U.S. Food and Drug Administration (FDA) or Health Canada  
approved therapies for FTD, and no treatments exist that can stop or slow the progression of this 
disease. Off-label medications have been used for symptomatic management of behaviours; 
however, there is little evidence from randomized, placebo-controlled trials supporting their use 
[47]. Nonpharmacological interventions targeting environment adaptation, behaviour strategies 
and caregiver training and education have also been employed [48]. Although these interventions 
alleviate some of the caregiver burden, they do not modify the course of the disease as they do 
not target the underlying pathology of FTD [6]. Currently, some of the first clinical trials 
targeting FTD are in progress or anticipated (Table 1.2). Importantly though, one key remaining 
challenge in clinical trial design for FTD is the vast heterogeneity of clinical symptoms, even in 
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individuals with the same mutation or underlying pathology, making it difficult to measure 
treatment effects and identify appropriate outcome measures [6].  
 
Table 1.2: Current drugs in clinical trials for FTD 
Drug Population Status Phase Identifier 
AL001  Healthy participants and 
carriers of GRN 
Recruiting Phase 1 NCT03636204 
AL001  Carriers of GRN or pathogenic 
forms of C9orf72 
Recruiting Phase 2 NCT03987295 
AL001  Carriers or at-risk carriers of 
GRN 
Not yet 
recruiting 
Phase 3 NCT04374136 
Metformin ALS/FTD with C9orf72 Recruiting Phase 2 NCT04220021 
Novolin-R 
insulin 
FTD Recruiting Phase 2 NCT04115384 
Syntocinon Probable FTD Recruiting Phase 2 NCT03260920 
AADvac1 Non-fluent PPA Active, not 
recruiting 
Phase 1 NCT03174886 
Lithium 
carbonate 
Participants with a diagnosis of 
bvFTD, sv-PPA or nfv-PPA 
Recruiting Phase 2 NCT02862210 
Based on clinicalTrials.gov, accessed May 25 2020 
 
1.8 Knowledge Gaps for Optimization of Clinical Trials in FTD 
1.8.1 The Need for Biomarkers 
With the development of symptomatic and disease-modifying treatments, the 
identification of biomarkers will be critical for clinical trial efficiency. Biomarkers may facilitate 
earlier detection of symptoms and diagnosis prior to irreversible neuronal loss. Furthermore, by 
improving diagnostic accuracy, recruited study populations will be more homogenous and thus, 
the necessary sample size needed to detect treatment effects will be reduced [49]. As well, the 
identification of biomarkers that can predict disease progression and symptom severity may act 
as outcome measures to indicate when treatments should be initiated and to assess treatment 
efficacy. To date, promising fluid biomarkers including cerebrospinal fluid and serum/plasma 
levels of neurofilament chains and progranulin are being explored [6,50]. As well, the 
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quantification of individualized patterns of atrophy has been shown to be another potential 
candidate [6,51]. Importantly, though, no validated markers for FTD have been established for 
clinical trials [52,53]. Consequently, it is critical to identify potential biomarkers that can be 
applied to develop efficient clinical trials, monitor disease progression, and evaluate treatment 
effects.  
 
1.9 Early Clinical Features in FTD 
Prediction of the initial symptoms of FTD in an individual patient remains a critical 
challenge both for clinical trial design and diagnosis of FTD. The initial symptoms are a critical 
milestone that will require correlation with other potential biomarkers. However, in line with the 
differing diagnostic criteria for the sub-types, the predominant initial symptoms in FTD differ 
according to the clinical syndrome [54,55]. Importantly though, there remains substantial 
heterogeneity in the initial symptom endorsement even within an FTD subtype. For example, 
patients with bvFTD may also endorse memory, language, or other cognitive symptoms as the 
initial symptom(s). Likewise, patients with SD may also report behavioural, memory and other 
cognitive problems as the initial symptom(s) [54,55]. Furthermore, the initial symptoms of FTD 
reported by caregivers are not always congruent with the most common symptoms observed 
during the first clinic assessment [56,57]. Moreover, patients often develop overlapping 
symptoms of different FTD subtypes as the disease progresses [58].  
 
1.9.2 Initial Symptoms in Symptomatic Genetic FTD 
Assessing the initial symptoms based on genetic mutation offers a unique opportunity to 
examine the behavioural, cognitive and neuropsychological disease-related changes that are 
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associated with a known underlying pathology. Studies assessing symptomatic carriers of 
C9orf72 or GRN have found that behavioural/personality changes are a common initial 
complaint (C9orf72: [58,59]; GRN: [57,60]). As well, problems with memory and language may 
also occur (C9orf72: [61,62]; GRN: [57,63]). In carriers of MAPT, behavioural symptoms are 
reported to be the most common symptom [64-67], with memory and language impairments 
occurring at a lower frequency [64,67].  Currently, no study has evaluated and systematically 
compared the initial symptoms across the three main FTD-causing genetic mutations in a large 
cohort of patients. This knowledge will be instrumental in determining which biomarkers are 
most sensitive to each genotype, and for the design of clinical trials targeting preclinical 
mutation carriers and conversion to the symptomatic state. 
 
1.9.3 Initial Symptoms in Asymptomatic Genetic FTD  
It is currently unclear whether other neuropsychiatric, behavioural or cognitive changes 
may occur in FTD mutation carriers in the preclinical period, before the first classic symptoms of 
FTD are clearly present. Although studies have evaluated cognitive and neuropsychiatric 
alterations during the preclinical period [68-72], the occurrence of these symptoms across the 
three main mutation groups during the preclinical period has not been established. Moreover, 
other symptoms prevalent in FTD including disinhibition, apathy, social inappropriateness and 
altered food preferences have not been thoroughly explored in preclinical mutation carriers. 
Assessing the occurrence of FTD-related symptoms during the preclinical disease stage will 
indicate whether related measurements may be utilized to inform the initiation of treatments. 
Overall, identifying gene-specific patterns of symptom endorsement during the 
preclinical period can inform outcome measures to assess the effectiveness of symptomatic 
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or disease-modifying treatments targeting different pathologies. Additionally, this 
knowledge can inform the selection of outcome measures in basket-design trials where the 
targeted therapy is assessed across different mutations with the same underlying pathology. 
Furthermore, evaluating the endorsement of FTD-related symptoms during the preclinical 
period across multiple domains of functioning can help determine whether specific 
symptom occurrence is related to the underlying pathology of FTD, a consequence of 
normal aging or due to the stress/burden of having a family member with FTD.  
 
1.10 Brain Volumetric Changes in FTD 
1.10.1 Grey Matter Atrophy Patterns in FTD 
Frontal and/or temporal atrophy are the classic neuroimaging features in FTD. Early 
changes are evident within the orbitofrontal cortex, anterior cingulate cortex, superior temporal 
gyrus, medial frontal gyrus, insula, hippocampus, ventral striatum and thalamus [73,74]. Over 
time, atrophy progresses within the frontal, temporal and parietal lobes, specifically within the 
temporal lobes (bilaterally), left inferior frontal gyri, posterior cingulate (bilaterally), and right 
parietal lobe [75,76]. Despite the level of heterogeneity in imaging findings, there is a general 
consensus in the regional pattern of atrophy in each of the clinical syndromes. The bvFTD 
syndrome is characterized by volume loss in the frontal and temporal lobes, particularly in the 
prefrontal cortex, anterior temporal lobes, insula, anterior cingulate, striatum and thalamus. 
Atrophy in sv-PPA is predominant within the left temporal lobe, including the inferior temporal 
and fusiform gyri, temporal pole and the parahippocampal and entorhinal cortex. As well, left 
temporal lobe involvement is also found in nfvPPA, though mainly involves the inferior frontal 
gyrus, dorsolateral PFC, superior temporal gyrus and insula [77].   
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1.10.1.1 Grey Matter Atrophy Patterns by Gene 
Distinct associations have been found between regional brain atrophy and the underlying 
pathogenic mutation. Relative to MAPT and C9orf72 carriers, GRN mutation carriers 
demonstrate a faster rate of whole brain atrophy and asymmetry, with greater left versus right 
side involvement [78-80]. As well, in GRN carriers, grey matter loss is predominantly in the 
inferior and posterior temporal lobes, parietal lobes, posterior cingulate and precuneus [80-82]. 
Carriers of the C9orf72 expansion show more wide-spread atrophy with involvement in the 
frontal lobes (orbitofrontal, medial prefrontal and dorsolateral PFC), temporal parietal, occipital 
lobes and cerebellum [81,83]. In MAPT carriers, grey matter loss is predominant in the anterior 
and medial temporal lobes [81-83]. Overall, there appears to be some overlapping yet distinctive 
patterns of atrophy across the main genetic forms of FTD.  
 
1.10.1.2 Preclinical Grey Matter Changes.  
Studies investigating asymptomatic genetic mutation carriers have found subtle brain 
volume alterations occurring prior to clinical onset. Specifically, as a group, preclinical mutation 
carriers exhibit significant grey matter loss relative to mutation non-carriers [84-86]. 
Furthermore, grey matter volume changes have been found to emerge 2 years prior to expected 
disease onset [68]. Within each genetic mutation cohort, the cortical atrophy in preclinical 
participants is similar to the expected pattern found in symptomatic patients [80,84,86-88]. 
Overall, the pathological process of FTD that results in atrophy begins during the preclinical 
period in genetic mutation carriers, prior to the onset of clinical symptoms.  
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1.10.2 Ventricular Volume in FTD 
In addition to grey matter volume, one emerging marker of atrophy in neurodegenerative 
disease is the measure of ventricular volume. As ventricular volume expansion is consistently 
seen across the heterogenous clinical and genetic syndromes, ventricular volume may serve as a 
single measure to detect changes in FTD. Specifically, the contrast in intensity between the 
cerebrospinal fluid and surrounding tissue makes the ventricles an ideal region for automatic 
segmentation procedures [89], highlighting the efficiency as a potential neuroimaging tool. 
Furthermore, the position of the ventricles makes them less susceptible to distortions due to 
gradient non-linearity [89], and inhomogeneity artifacts compared to whole brain volume [90], 
supporting reliability of this method across clinical centres and scanners.  
Across the FTD subtypes and genetic mutations, ventricular expansion is evident across 
the heterogenous clinical and genetic subtypes of FTD [56,79,91-95]. Only one study to date has 
examined ventricular expansion in preclinical mutation carriers and reported stable volumes over 
a 6-month follow-up period [96]; however, this study only assessed a single mutation group 
(C9orf72) and included a small sample (n=7).  
Importantly, aside from Floeter, Bageac, Danielian, Braun, Traynor and Kwan [96], 
no study has assessed the sensitivity of ventricular volume measurements in preclinical 
mutation carriers in FTD. Identifying ventricular volume changes in genetically at-risk 
individuals could predict when the pathophysiology can be detected prior to disease onset. 
This knowledge may inform the timing of future therapeutic interventions and be used as 
outcome markers to assess treatment efficacy. 
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1.11 Functional Neural Changes in Symptomatic Frontotemporal Dementia 
1.11.1 Behaviour Flexibility in FTD 
Despite facing negative social, legal and physical consequences, patients with FTD 
exhibit difficulty modifying their behaviour. For example, patients with disinhibited symptoms 
continue to engage in inappropriate social behaviour (e.g. aggression, over-familiarity with 
strangers), exhibit a loss of manners (e.g. making insensitive comments, lack of social etiquette), 
or continue to overspend or gamble despite severe debt accumulation [40,97]. Pathophysiologic 
changes and atrophy in the frontal and temporal lobes have been found to be associated with 
these prevalent disinhibited behaviours. In patients, reduced cerebral blood flow within the OFC, 
bilateral inferior frontal gyrus (BA 47), left anterior cingulate gyrus (BA 32) and right caudate 
nucleus and left insula (BA 13), have been associated with greater engagement of antisocial 
behaviours [98]. Additionally, atrophy in the orbital and inferior frontal cortex, insula and right 
middle temporal regions has been associated with caregiver-reported disinhibited behaviours 
[99]. As disinhibition is one of the earliest symptoms to emerge in patients with FTD [40], and 
poses a great stress to caregivers [99], identifying effective treatments for these behaviours is 
essential. Furthermore, given the existing challenges in clinical trial design due to the relatively 
low base-rates of FTD and the diagnostic challenges, leading to recruitment challenges, the 
heterogeneity of clinical symptoms , and the time-intensive and costly nature of conducting 
trials, it is critical to identify markers that can guide treatment selection and be used as efficient 
outcome measures for clinical trials (i.e. proof of concept or challenge study) [6].  
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1.11.2 Reversal Learning 
Reversal learning is a measure of adaptive behavioural flexibility that assesses the ability 
to alter behaviour when reinforcement contingencies change [100]. Performance on reversal 
learning task is associated with the degree of disinhibited and socially inappropriate behaviours 
exhibited by patients with frontal lobe lesions [100]. Through trial and error, participants learn 
stimulus-reward contingencies (acquisition phase), selecting stimuli associated with reward and 
avoiding stimuli associated with punishment. During the reversal phase, the reinforcement 
contingencies change, such that the stimuli that were previously associated with punishment are 
now associated with a reward, and those initially associated with punishment are now rewarded. 
The underlying neural regions and neurotransmitters mediating successful reversal learning are 
well-characterized in healthy populations. In conjunction with the extent literature, delineating 
the underlying neural deficits associated with reversal learning in FTD can determine the 
mechanisms mediating the associated behavioural deficits, and can inform potential targets for 
treatment interventions.  
 
1.11.2.1 Neural Correlates of Reversal Learning 
Based on fMRI and lesion studies in non-human primates and humans, specific neural 
regions have been found to be involved and/or make critical contributions to successful reversal 
learning including the orbital frontal cortex/ventromedial prefrontal cortex (OFC/vmPFC), 
ventrolateral PFC (vlPFC), dorsolateral PFC (dlPFC), and regions of the striatum.  
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1.11.2.2 OFC/vmPFC 
Patients with OFC damage report awareness of the reversed feedback contingencies but 
are unable to adjust their behaviours accordingly [100,101]. It has been suggested that the 
OFC/vmPFC is critical when adjustments of behaviour are prompted following changes in 
reward contingency [100-104]. 
fMRI studies demonstrate that during the omission of an expected reward, the 
OFC/vmPFC demonstrates a decrease in signal from baseline (negative prediction error), 
whereas the presentation of an unexpected reward results in an increase in activity (positive 
prediction error) [103]. Following this, it has been suggested that the OFC/vmPFC encodes the 
reward values of objects/responses, as well as violations in this encoding through a prediction 
error which signals the discrepancy between the expected and actual reward [103]. In line with a 
prediction error formulation, the OFC/vmPFC has been found to be less active during reversal 
errors relative to rewarded correct responses [105,106].  
 
1.11.2.3 Lateral PFC 
The dlPFC has been found to be integral for aspects of cognition that are important 
during successful reversal learning including attention shifting [107,108], and learning reward 
and punishment information for decision making [102,108]. Lesion studies have reported mixed 
findings regarding the necessity of the lateral frontal cortex in reversal learning. Studies have 
reported that lesions to the dlPFC does not impact reversal learning [102,107]. However, during 
more complex reversal learning tasks that include probabilistic feedback, the dlPFC seems to be 
critical for successful performance [101,109].  
Functional neuroimaging studies have implicated the role of the lateral PFC during 
reversal learning. Specifically, the dlPFC has been found to respond to decision conflict during 
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reversal of a reward [105,110,111], and when differentiating between two reward options that are 
similar in value [110]. As the dlPFC responds to decision conflict, it has been argued that this 
region augments the representation of relevant stimuli and reinforcement information to guide 
subsequent behaviours [105,112]. The vlPFC has been shown to be engaged when suboptimal 
responses have been made (a reversal error), and thus, an alternative behaviour is warranted 
[105,110,111]. Specifically, Cools, et al. [113] demonstrated that the vlPFC responded to the last 
reversal error preceding a successful reversal in behaviour. Thus, it has been proposed that this 
region is involved in selecting appropriate behaviours/motor responses. In fact, Budhani, Marsh, 
Pine and Blair [105] suggested that following a conflict (e.g. reversal error), the dlFC 
representing the stimulus features of the object within the vlPFC which then control motor 
responding to alter subsequent behaviour.  
 
1.11.2.4 Striatum 
Lesion studies also propose a fronto-striatal circuit that is critical for processing reward 
and punishment and mediating behaviours during reversal learning [114,115]. For example, 
Divac, et al. [116] demonstrated that monkeys with lesions to the ventrolateral region of the head 
of the caudate, a region which receives connections from the OFC, experience deficits in the 
reversal learning component of the Wisconsin General Test. Furthermore, excitotoxic lesions to 
the striatum or the OFC impaired the ability to reverse stimulus-reward contingencies [115]. 
Overall, functional and lesion studies suggest that the striatum interacts with regions within the 
frontal cortex to mediate subsequent responding when a behavioural adjustment is warranted. 
Functional neuroimaging studies have also implicated the involvement of the striatum in 
response to reversal errors [117-119]. In particular, the ventral striatum has been shown to be 
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engaged during the final reversal error prior to a behavioural change [113]. Other studies have 
reported the engagement of the caudate during punished reversal errors [105] and when new 
searches are initiated (e.g. during reversal or stimulus-set change) [120]. Dissociable regions of 
the striatum have been shown to be engaged in separate elements of stimulus-response learning. 
Specifically, the dorsal striatum has been shown to be engaged during response selection and is 
proposed to mediate decision making. In contrast, the ventral striatum has been found to be 
engaged during feedback and is proposed to underlie learning associations between stimuli and 
responses [121]. Likewise, O'Doherty [103] suggested the role of the ventral striatum in 
representing predicted future reward values, and the dorsal striatum in learning the specific 
actions that need to be performed to obtain the reward (stimulus-response associations). As well, 
it has been proposed that the caudate is involved in maintaining adaptive goal-directed behaviour 
by evaluating action-outcome contingencies [122]. During reversal learning tasks, it has been 
proposed that the caudate interacts with the vlPFC during instances of response conflict (i.e. 
receiving negative feedback), to augment motor responses [105,118]. In line with this model, 
Mitchell, Rhodes, Pine and Blair [118] demonstrated increased activity within the vlPFC and 
caudate during instances of conflict (e.g. reversal errors, non-reversal errors and correct reversal 
responses).  
 
1.11.3 Neurotransmitters involved in Reversal Learning 
Pharmacological studies have revealed a differential contribution of monoamine 
neurotransmitters during reversal learning. Serotonin depletion in the marmoset PFC results in 
perseverative responding to previously rewarded stimuli, suggesting a role for serotonin in 
behavioural flexibility [123]. This role of serotonin has been suggested to be specific to the OFC 
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as serotonergic depletion in the medial caudate does not impact reversal learning performance 
[124], or attentional set-shifting, which is mediated by the dlPFC [107,125].  
 Dopamine neurons encode prediction error signalling [126] which has been found to be 
mediated by the OFC, amygdala and ventral striatum [103]. Dopaminergic depletions of the 
marmoset OFC do not impact reversal learning performance [127]; however, depletion in the 
medial caudate leads to reversal deficits [124]. Studies in Parkinson’s Disease (PD) have 
suggested that dopaminergic medication may overdose brain regions with relatively intact levels 
of dopamine including the ventromedial caudate, and replete dopamine-depleted regions 
including the dorsal striatum [128,129]. Consequently, patients with PD exhibit impaired 
reversal learning performance on dopaminergic medication relative to off medication [129,130]. 
As well, in healthy controls with presumably optimal baseline dopamine levels, administration of 
levodopa resulted in greater reversal errors relative to when participants were on placebo [131].  
 
1.11.4 Reversal Learning in FTD 
Consistent with the suggestion that patients with FTD exhibit deficits in flexibly 
modifying behaviour, the available evidence suggests that FTD is associated with reversal 
learning impairments [132-134]. Although patients adequately associate each stimulus with its 
reinforcement value, when the reward contingencies change, patients continued to select the 
previously rewarded stimulus, and thus make more reversal errors relative to controls [132,134]. 
One study has found an association between the number of reversal errors made and atrophy 
within the anterior cingulate cortex (BA 24) and the medial/lateral OFC (BA 11, 47) [133]. This 
suggests that the inability to suppress a previously rewarded behaviour in favour of an alternative 
behaviour may be associated with degeneration of the frontal cortex.  
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 To date, no study has evaluated the functional neural correlates of reversal learning 
in FTD. Delineating the pathophysiology of impaired behavioural flexibility in FTD can 
inform whether reversal learning deficits are the result of impaired prediction error 
signalling during an unexpected reinforcement (vmPFC), impaired conflict processing 
(dmPFC), and/or implementing alternative motor responses (caudate/vlPFC). These 
findings may provide targets for future pharmacological or behavioural interventions 
mediating these underlying cognitive functions.  
 
1.12 Thesis Objectives and Hypothesis 
The overall objective of this thesis is to elucidate behavioural, structural and functional 
changes in FTD from the preclinical to the symptomatic disease stage. This goal was addressed 
using a multifaceted approach whereby three independent studies were conducted in patients 
with FTD and/or individuals who are genetically at-risk for developing FTD. The central 
hypothesis is that potential markers and outcome measures for clinical trial designs will be 
identified in preclinical and symptomatic individuals. Ultimately, the results of these studies will 
extend previous work on the potential candidate biomarkers sensitive to FTD to help diagnose 
patients earlier and more accurately, and characterize the functional processes that underlie 
symptoms of FTD to identify potential targets for treatments, and inform clinical trial designs. 
Additionally, these results may help delineate the natural progression of this disease from the 
preclinical, prodromal and affected stages and supplement our knowledge on the vulnerable 
brain networks that can be targets for future therapies. 
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Study 1: Early Symptoms in Symptomatic and Preclinical Genetic Frontotemporal Lobar 
Degeneration 
Identification of the initial symptoms that represent the earliest functional manifestations 
of the pathophysiology of FTD are a critical outcome measure for future interventions aiming to 
prevent conversion to clinical FTD. The first objective of this study was to evaluate whether 
preclinical carriers of a pathogenic mutation demonstrate greater or unique symptoms relative to 
biologically related mutation non-carriers. The second objective was to evaluate whether the 
initial symptoms differed as a function of the specific genetic mutation during the preclinical and 
symptomatic period. Although some symptoms may be present in both familial mutation carriers 
and non-carriers due to shared environmental factors and stress/burden of having a family 
member with FTD, we hypothesize that as preclinical carriers approach the time of expected 
disease onset, they will endorse greater FTD-related symptoms relative to non-carriers. 
Additionally, consistent with the previous literature [83], we predict that specific symptom 
endorsement will differ across the genetic mutations within the preclinical and symptomatic 
mutation carriers.  
 
Study 2: Ventricular Volume Expansion in Preclinical Genetic Frontotemporal Dementia 
Some work has evaluated ventricular volume in patients with FTD and has found greater 
ventricular expansion in FTD relative to healthy controls [56,95]; however, no study has 
assessed ventricular volume expansion in preclinical mutation carriers in FTD. Ventricular 
volume measures are robust to scanner inhomogeneities and are amenable to robust automatic 
segmentation due to the intense contrast in intensity between the ventricles and surrounding 
tissue (Nestor et al, 2008). Investigating ventricular volume measurements during the preclinical 
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disease period will inform whether these measurements can be used to identify pathogenic 
changes prior to disease onset. The objective of the present study was to examine ventricular 
volume change over a one-year period in carriers of an FTD-causing mutation and non-carriers, 
to determine its potential utility as a biomarker of early preclinical disease. In line with previous 
research showing smaller cortical volumes during the preclinical period in mutation carriers 
[135], we hypothesize that mutation carriers (symptomatic and preclinical mutation carriers) will 
show greater ventricular expansion relative to non-carriers. Additionally, we predict that 
preclinical mutation carriers alone will show greater ventricular expansion relative to non-
carriers.  
 
Study 3: Neural Correlates of Reversal Learning in Frontotemporal Dementia 
Disinhibition and poor behaviour flexibility is an early and debilitating symptom in FTD; 
thus, investigating the neural mechanisms mediating these symptoms is warranted. Specifically, 
assessing the underlying neural correlates can inform whether these behavioural deficits are the 
result of impaired prediction error signalling during an unexpected reinforcement (vmPFC), 
impaired conflict processing (dmPFC), and/or deficits in implementing alternative motor 
responses (caudate/vlPFC). Delineating the aberrant pathophysiology may inform potential 
pharmacologic or behavioural interventions. With this, the objective of this study to identify 
whether patients with FTD reveal abnormal neural deficits in an fMRI-reversal learning task. We 
hypothesize that patients with FTD will reveal abnormal activity in areas important in reversal 
learning including the mPFC (dorsal and ventral regions), and ventrolateral PFC, during the 
reversal learning task, especially during the reversal trials. 
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Chapter 2: Early Symptoms in Symptomatic and Preclinical Genetic Frontotemporal 
Lobar Degeneration1 
2.1 Introduction 
Frontotemporal dementia (FTD) is a neurodegenerative disorder with approximately 40% 
of patients showing a strong family history, with mutations in the chromosome 9 open reading 
frame 72 (C9orf72), progranulin (GRN) or microtubule-associated protein tau (MAPT) genes 
each accounting for 5-10% of patients with FTD [1]. While therapies targeting the underlying 
pathology are in development [2], currently, no treatments are available to prevent or alter the 
course of disease progression. 
Even during the early stages of disease, symptoms of FTD are quite impairing [3]; thus, 
treatments will likely need to be administered during the preclinical stage, before a patient meets 
the current international consensus criteria [4,5]. Consequently, there is a growing interest in 
identifying biomarkers and clinical endpoints that can best inform when to administer these 
interventions and how to track treatment efficacy. A major challenge in designing clinical trials 
and the designation of clinical endpoints is the heterogeneity of genetic FTD at the phenotypic 
[6], and pathological levels [7,8]. For instance, clinical symptoms in genetic FTD range from 
language disturbances [5] to behavioural and neuropsychiatric features [4], which occur at 
various frequencies and ages even within families, and have different neuroanatomic associations 
[9,10]. Furthermore, at present, it is not yet known whether or when symptoms associated with 
 
1 A version of this chapter has been  published: Tavares TP, Mitchell DGV, Coleman KKL, Coleman BL, Shoesmith 
C, Butler C, Santana I, Danek A, Gerhard A, de Mendonça A, Borroni BL, Tartaglia C, Graff C, Galimberti D, 
Tagliavini F, Moreno F, Frisoni G, Rowe J, Levin J, van Swieten J, Otto M, Synofzik M, Sanchez-Valle R, 
Vandenberghe R, Laforce R, Ghidoni R, Sorbi S, Ducharme S, Masellis M, Rohrer JD, Finger EC, on behalf of the 
Genetic FTD Initiative, GENFI. Early Symptoms in Symptomatic and Preclinical Genetic Frontotemporal Lobar 
Degeneration. Journal of Neurology, Neurosurgery, and Psychiatry. [Epub ahead of print]. DOI: 10.1136/jnnp-2020-
322987 
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genetic FTD may occur during the prodromal period, and whether such symptoms may be 
specific to the later development of clinical FTD.  
To inform clinical endpoint selection for future clinical trials in at-risk cohorts, the first 
objective of the current study was to evaluate the most frequent initial symptoms in patients with 
symptomatic genetic FTD due to C9orf72, GRN or MAPT mutations. The second objective was 
to evaluate whether preclinical mutation carriers demonstrate greater or different symptoms 
relative to biologically related non-carriers during the preclinical period.  
 
2.2 Method 
2.2.1 Participants 
The current study used data from the Genetic Frontotemporal Dementia Initiative 
(GENFI) multicentre cohort study, which consists of research centres across Europe and Canada 
(http://genfi.org.uk/). This dataset is comprised of (1) known symptomatic carriers of a 
pathogenic mutation in the GRN or MAPT genes or with a pathogenic expansion in the C9orf72 
gene (greater than 30 repeats) with clinical diagnoses based on the international consensus 
diagnostic criteria [4,5], and (2) first-degree biological family members of a known GRN, MAPT 
or C9orf72 mutation carrier who are at-risk for developing FTD and were not yet demonstrating 
evidence of progressive cognitive or behavioral symptoms (including both preclinical carriers 
and non-carriers). All eligible and interested participants were enrolled in the study. Importantly, 
the majority of at-risk family members in the GENFI study, and the local GENFI research teams, 
were not aware of their genetic status at the time of the assessments. After their baseline visit, 
participants were followed for up to five annual visits. All participants had an identified 
informant who completed clinical scales (see below). Participants with completed study 
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measures were included in the analysis; information on other demographic variables was 
complete for all participants in the study. The data was part of the GENFI data freeze 4 collected 
at 22 GENFI sites (2012-2018). Local ethics committees at each site approved the study and all 
participants provided written informed consent at enrollment. 
 
2.2.2 Study Measures 
GENFI Symptom List: The initial 37-symptom list was designed to include a variety of 
FTD-related symptoms based on standardized rating scales (Appendix A: method section 1.0, 
Table A.1, A.2 and result section 2.0). Informants of symptomatic patients (typically a spouse or 
sibling) described the initial symptom and trained research coordinators selected the 
corresponding symptom from the list. For at-risk family members, clinicians completed the 
GENFI symptom list with the at-risk family member and their study informant, and evaluated the 
presence of each symptom using a 5-point Likert scale (0=absent, 0.5= questionable/very mild, 
1=mild, 2=moderate, 3=severe). Symptom ratings of questionable/very mild, mild, moderate, 
severe were coded as symptom endorsement and absent coded as symptom absent. 
 
2.2.2.1 Cambridge Behavioural Inventory Questionnaire-Revised (CBI-R) 
Informants of at-risk family members completed the CBI-R [11]. This questionnaire was used to 
evaluate the at-risk groups’ symptoms within the past 4 weeks. Each question is evaluated on a 
5-point scale, where higher scores indicate greater symptom endorsement and severity. Symptom 
domains included memory and orientation, everyday skills, self-care, abnormal behaviour, mood, 
beliefs, eating habits, sleep, stereotypic and motor behaviours and motivation. Each domain 
includes 2 to 8 sub-items.  
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Years from expected onset was used to determine whether participants who were closer to the 
age of anticipated clinical onset endorsed greater symptoms. Years from expected onset (YEO) 
was calculated by subtracting the mean age of clinical onset within the family from the 
participant’s current age [10,12]. Negative values denote that the participant is at an age prior to 
expected clinical onset; positive values indicate that the participant is at an age after expected 
clinical onset.  
 
2.2.3 Statistical Analysis 
GENFI Symptom List: Descriptive statistics were used to illustrate the most frequent 
symptoms endorsed at participants’ initial visits. Differences amongst the three genetic groups in 
the frequency of the most prevalent sub-symptoms were examined using Chi-squared test or 
Fisher’s exact test for the symptomatic patients and at-risk individuals, and separately comparing 
preclinical mutation carriers and non-carriers for each gene mutation. Mixed models were not 
used to account for potential clustering effects of family membership and site, due to the low 
symptom endorsement (creating small samples) by patients and at-risk family members.  
For symptomatic and at-risk family members, a composite index was created for each 
gene based on three most frequently endorsed initial symptoms for each of the symptomatic 
genetic groups (C9orf72 & MAPT: disinhibition, apathy, memory; GRN: apathy, articulation, 
fluency). For each composite, participants attained a score of 1 if they endorsed at least one 
symptom within each composite (0=no symptoms endorsed, 1= at least one symptom endorsed). 
Note only the predominant initial symptom was recorded in the GENFI intake for affected 
participants. To evaluate the effectiveness of this composite to differentiate between mutation 
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carriers and non-carriers, sensitivity and specificity values were computed 
(https://www.medcalc.org/calc/diagnostic_test.php).  
 To evaluate changes in symptom endorsement over time in at-risk family members who 
had at least one follow-up visit, a difference score was calculated by subtracting symptom 
endorsement at the final visit from symptom endorsement at the first visit (0=not endorsed, 
1=symptom endorsed). This resulted in three categories for each symptom: decrease in symptom 
endorsement over time (score of -1), no change in symptom endorsement over time (score of 0), 
increase in symptom endorsement over time (score of 1). Calculating change scores enabled all 
participants to be included in the analysis, regardless of the number of follow-up visits. Chi-
squared tests/Fisher’s Exact tests were completed to assess group differences.  
To evaluate whether the initial symptoms were similar amongst patients from the same 
family, a congruency score was calculated as the number of pairwise comparisons in which 
family members shared an initial symptom, divided by the total number of possible pairwise 
comparisons. A congruency score was also calculated to evaluate the congruency of initial 
predominant symptoms for specific GRN and MAPT mutations. 
 
2.2.3.1 Cambridge Behavioural Inventory Questionnaire-Revised 
A generalized linear mixed model with a Laplace likelihood approximation function was 
used to examine differences in the total CBI-R scores between preclinical mutation carriers vs. 
non-mutation carriers at the initial GENFI visit as a function of years from expected clinical 
onset. This analysis accounted for potential clustering effects based on family membership. Plots 
of the CBI-R total scores suggested a Poisson distribution; however, due to overdispersion as 
indicated through the Pearson Chi-Square/DF (4.62), a negative binomial distribution with a log 
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link function was used. For the total score, no participant had studentized residuals greater than 
+/- 3.. Predictor variables included random effects [family membership] and fixed effects 
[genetic status (preclinical vs. non-carriers), years from expected onset, and an interaction 
between genetic status and years from expected onset]. Examination of the residuals suggested 
the use of weights to account for the within-family correlation in the model. Given the variability 
in contribution of family membership to predicting age of onset by mutation group [10], a 
confirmatory analysis was conducted substituting years from expected onset with the 
participant’s age. Of note, as age was highly correlated with years from expected onset (r=0.84, 
p<0.001), participant’s age could not be included in the model due to multicollinearity. However, 
when age was substituted for estimated years from expected onset, the pattern of results was 
similar (Table A.3).  
Change scores (symptom score at final visit – score at first visit)/ time interval) were 
calculated to compare longitudinal data. Participants with studentized residuals greater than +/- 3 
were removed (Table A.4), and a linear mixed model was used (see Appendix A, method section 
3.0 on the description of the model formation). Predictor variables included random effects 
[family membership] and fixed effects [genetic status (preclinical vs. non-carriers), years from 
expected onset or participant’s age, CBI total score at baseline, and an interaction between 
genetic status and years from expected onset]. A confirmatory analysis was run substituting 
participant’s age at baseline for the years from expected onset (Table A.3). As differences 
between the preclinical and non-carriers in the total CBI scores may be obscured by opposed 
group differences in the sub-scale scores, we also examined group differences at baseline and 
longitudinally for each of the sub-scales by using the model developed for the total score. For 
these models, the same parameters were used with one exception: the sub-scale score at baseline 
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was used as a fixed effect instead of the CBI total score at baseline. For both the baseline and 
change score analysis, the potential influence of specific FTD-causing mutations was examined 
by assessing the impact of genetic mutation type as the grouping variable (C9orF72, GRN, 
MAPT, mutation non-carriers), and post-hoc comparisons were conducted between each genetic 
group and non-carriers. For brevity, the results from the models with the genetic mutation group 
are reported in the manuscript.  
 
2.3 Results 
2.3.1 Participants 
185 patients diagnosed with FTD (C9orf72 n=87, GRN n=65, MAPT n=33) were 
included in the analysis. Additionally, two groups of at-risk family members completed the 
GENFI symptom list and CBI-R scales: 637 at-risk family members (317 preclinical mutation 
carriers, 320 mutation non-carriers) and 588 at risk individuals (294 preclinical carriers, 294 non-
carriers) completed the GENFI symptom list and CBI-R scales, respectively (Table 2.1).  
 
2.3.2 Predominant Initial Symptoms in Symptomatic Patients 
Across the entire cohort the most frequently endorsed initial symptoms were apathy 
(23%), disinhibition (18%), memory impairments (12%) decreased fluency (8%) and impaired 
articulation (5%; Figure 2.1, Table A.5). When the most frequent initial symptoms were 
compared amongst the mutation groups, patients with MAPT mutations presented with 
disinhibition more frequently relative to C9orf72 and GRN carriers, and displayed memory 
impairments more frequently than GRN carriers. GRN carriers exhibited impaired articulation 
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and decreased fluency more often than C9orf72 and MAPT carriers. No group differences were 
observed for apathy.  
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Table 2.1: Demographics table for symptomatic and at-risk family members 
 
 Symptomatic Patients At-risk Family Members 
 Total C9orf72 GRN MAPT Contrasts Preclinical& Non-carrier& Contrasts& Preclinical^ Non-carrier^ Contrasts^ 
N 185 87 65 33  317 320  294 294  
Handedness     p=0.02*#   p=0.16*#   p=0.14*# 
Right 174 80 65 29  282 298  275 262  
Left 9 5 0 4  31 20  17 28  
Ambidextrous 2 2 0 0  4 2  2 4  
Sex     X2=6.2, 
p=0.045 
  X2=0.90, 
p=0.34 
  X2=0.86, 
p=0.35 
Male 108 57 30 21  123 136  112 123  
Female 77 30 35 12  194 184  182 171  
Genotype        X2=0.21, 
p=0.90 
  X2=0.58, 
p=0.75 
C9orf72      117 115  104 103  
GRN      144 144  138 132  
MAPT      56 61  52 59  
Maximum 
number of visits 
           
1      121 118  124 122  
2      80 98  80 95  
3      72 58  60 38  
4      30 27  22 23  
5      10 15  7 16  
6      4 4  1 0  
Diagnosis            
bvFTD  62 33 31        
PPA 
 
 4 28 0        
FTD-ALS  9 0 0        
ALS  6 0 0        
PSP  1 0 0        
CBS  0 2 1        
AD  0 1 0        
Dementia- NOS  3 1 1        
Other  2 0 0        
Time interval for 
change score (SD) 
     2.6 (1.4) [n=196] 2.5 (1.5) 
[n=202] 
t(394.7) = -0.6, 
p=0.54 
2.5 (1.3) [n=170] 2.4 (1.5) [n=172] t(340)= -0.7, 
p=0.49 
Age (SD) 62.3 
(8.5) 
63.7 (8.3) 63.5 
(6.9) 
56.2 (9.5) F(2,184)=11.5, 
p<0.001# 
C9> MAPT 
GRN > MAPT 
44.0 (11.8) 46.3 (14.0) t(619)=2.3, 
p=0.03 
44.0 (11.9) 46.7 (14.1) t(570.1)=2.6, 
p=0.01 
Age at onset (SD) 58.1 
(8.8) 
58.8 (9.0) 60.6 
(7.2) 
51.1 (7.7) F(2,184)=11.5, 
p<0.001# 
C9>MAPT 
GRN >MAPT 
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Education, Yrs, 
(SD) 
12.2 
(4.0) 
12.6 (4.0) 11.2 
(4.0) 
13.2 (3.6) F(2,184)=3.5, 
p=0.03# 
MAPT> GRN 
(p=0.065) 
14.3 (3.3) 13.9 (3.6) t(635)= -1.5, 
p=0.13 
14.3 (3.3) 13.9 (3.6) t(586)= -1.58, 
p=0.1 
Years from 
expected disease 
onset (SD)** 
     -14.4 (11.8) -13.2 (14.1) t(618.5) = 1.17, 
p=0.24 
-14.5 (12.0) -12.9 (14.2) t(569.3)= 
1.51, p=0.13 
• Chi-squared (X2), Fisher’s Exact tests (if expected cell count was less than 5), independent sample t-tests or one-way analysis of variance were used to discern 
group differences for relevant variables 
• # Bonferroni correction applied 
• &At-risk participants from 248 families. Participants completed the GENFI symptom list  
• ^At-risk participants from 228 families. Participants completed the CBI questionnaire 
• *#Fisher’s Exact Test was used 
• **Years from expected onset was calculated by subtracting the participant’s age at the time of participation from the mean age of disease onset within the family 
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Figure 2.1. Symptom endorsement in symptomatic patients and at-risk family members 
 
 
 
 
 
 
 
 
 
 
Percentage of patients and at-risk individuals that endorsed symptoms identified as the most frequent symptoms in symptomatic patients. 
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2.3.3 Symptom Congruency 
Fourteen families had at least two related patients in the study cohort; amongst these 
families, the average percentage congruency for first symptom similarity was 19% (Table A.6). 
Five families with a MAPT mutation and 7 families with a GRN mutation had at least two 
related symptomatic patients in the study cohort and the specific genotype was known. Of the 
specific genotypes, the average congruency score was 33% for MAPT and 20% for GRN 
mutations (Table A.7). 
 
2.3.4 Symptom Endorsement in at-risk Family Members (GENFI symptom list) 
There were no significant differences between at-risk individuals (preclinical C9orf72, 
GRN, MAPT vs. non-carriers) or between preclinical genetic groups in the proportion of 
participants who endorsed the initial symptoms most commonly reported in affected patients (i.e. 
apathy, disinhibition, decreased fluency, impaired articulation and memory impairments) (Figure 
2.2 & Table A.5, A.8). Overall, at-risk genetic groups (preclinical C9orf72, GRN, MAPT vs. 
non-carriers) showed a similar pattern of symptom endorsement over time, with a very low 
proportion of participants reporting changes in the most common initial symptoms (Table A.9).  
 
3.3.5 Composite Scores 
The sensitivity and specificity values indicate the composite indices differentiate between 
symptomatic FTD and mutation non-carriers  for each of the gene groups with sensitivities from 
94% to 97% and specificities of 80%. For at-risk family members, the composite indices showed 
low sensitivity (8-33%), with medium specificity (76-91%) to differentiate between preclinical 
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mutation carriers from non-carriers beginning from -5, -2 and 0 years to expected age of onset 
(Table A.10, A.11).  
 
Figure 2.2. Baseline symptom endorsement by genotype in at-risk family members 
 
  
 
 
 
 
 
 
 
 
 
Percentage of preclinical and non-mutation carriers that endorse each of the sub-symptoms 
identified as the most frequent symptom in symptomatic patients 
 
 
2.3.6 Symptom Endorsement & Severity in at-risk Family Members (CBI-R questionnaire) 
CBI-R scores at baseline: As participants approached the anticipated time of onset there 
was a significant increase in the reported total symptom score, memory and orientation, sleep, 
motivation, eating habits, and stereotypic and motor behaviours scores. When adjusting for 
expected years to onset and relative to non-carriers, post-hoc contrasts showed that MAPT 
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carriers experienced greater mood, sleep, and motivation symptoms; C9orf72 carriers endorsed 
greater abnormal behaviour and stereotypic & motor symptoms; and GRN carriers had lower 
mood scores (Table 2.2; Figure 2.3).  
Longitudinal CBI scores: Improved symptoms over time (negative change scores) were 
associated with greater symptom scores at baseline when adjusted for expected years to onset 
and carrier status across all participants. There were also significant associations between 
expected years to onset and memory and orientation scores, stereotypic and motor behaviours, 
but also for eating habits (Table 2.2). Within the sub-scales, GRN and C9orf72 preclinical 
carriers demonstrated worse everyday skills over time relative to mutation non-carriers, but only 
the GRN carriers’ scores met statistical significance (Figure 2.4).  
 
2.4 Discussion 
As the first study to compare initial symptoms in symptomatic and at-risk patients with 
genetic FTD across the three main genetic mutations MAPT, C9orf72 and GRN, our findings 
demonstrate the overlap and differences in the presence and frequencies of specific FTD-related 
symptoms. We also report the first longitudinal differences between preclinical mutation carriers 
in comparison to familial non-carriers in the endorsement of symptoms prior to diagnosis. 
Important to the interpretation of symptom reports and design of clinical trials, we found that 
preclinical MAPT and C9orf72 mutation carriers endorsed greater symptoms at the initial 
assessment (approximately 14 years prior to anticipated age of onset), and over time GRN and 
C9orf72 mutation carriers exhibited poorer everyday skills. The direct comparison of symptoms 
among mutation groups may be important in the consideration of basket-design clinical trials 
where, for example, patients with TDP-43 pathology arising from different mutations (C9orf72 
& GRN) may be grouped together. 
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Table 2.2: CBI-R total and sub-scale scores at baseline and over time for at-risk family members 
by genetic group (no outliers included) 
. 
 Baseline# Change Score 
 N Estimate (95% CI) p-value N Estimate (95% CI) p-value 
Total Score  588   336   
C9orf72  104 1.34 (0.78, 2.31) 0.29  0.28 (-1.42, 1.97) 0.75 
GRN  138 0.95 (0.52, 1.73) 0.86  0.38 (-0.8, 1.56) 0.53 
MAPT  52 1.96 (0.88, 4.38) 0.1  0.39 (-1.37, 2.15) 0.66 
YEO  1.02 (1, 1.03) 0.02  0.03 (-0.01, 0.07) 0.11 
Baseline score  - -  -0.15 (-0.21, -0.1) <.0001 
C9orf72*YEO  1 (0.98, 1.03) 0.8  0.01 (-0.08, 0.11) 0.78 
GRN*YEO  1 (0.97, 1.03) 0.87  -0.02 (-0.08, 0.05) 0.63 
MAPT*YEO  1 (0.96, 1.05) 0.85  -0.01 (-0.12, 0.1) 0.86 
Memory and Orientation  588   334   
C9orf72  104 0.88 (0.51, 1.52) 0.65 49 -0.02 (-0.41, 0.37) 0.92 
GRN  138 1.03 (0.56, 1.89) 0.92 85 -0.03 (-0.3, 0.25) 0.85 
MAPT  52 0.89 (0.39, 2.03) 0.78 33 -0.01 (-0.42, 0.41) 0.98 
YEO  1.03 (1.01, 1.04) 0.001  0.01 (0.002, 0.02) 0.02 
Baseline score  - -  -0.18 (-0.23, -0.13) <.0001 
C9orf72*YEO  0.98 (0.96, 1.01) 0.29  -0.003 (-0.02, 0.02) 0.74 
GRN*YEO  1.01 (0.98, 1.04) 0.47  -0.002 (-0.02, 0.01) 0.78 
MAPT*YEO  0.99 (0.95, 1.03) 0.59  0.0003 (-0.02, 0.03) 0.98 
Everyday Skills 588   335   
C9orf72  104 0.77 (0.09, 6.56) 0.81 50 0.07 (-0.01, 0.14) 0.09 
GRN  138 0.71 (0.1, 4.92) 0.72 85 0.11 (0.05, 0.16) 0.0001 
MAPT  52 1.08 (0.05, 22.27) 0.96 32 0.03 (-0.06, 0.11) 0.53 
YEO  1.03 (0.97, 1.09) 0.34  0.001 (0, 0) 0.57 
Baseline score  
- - 
 
-0.5 (-0.55, -0.45) 
<.0001 
C9orf72*YEO  1 (0.89, 1.13) 0.96  0.003 (0, 0.01) 0.21 
GRN*YEO  1.05 (0.93, 1.2) 0.42  0.003 (0, 0.01) 0.07 
MAPT*YEO  0.96 (0.82, 1.11) 0.57  0.0002 (0, 0.01) 0.95 
Abnormal Behaviour 588   334   
C9orf72  104 2.16 (1.09, 4.26) 0.03 48 -0.02 (-0.3, 0.25) 0.86 
GRN  138 0.83 (0.36, 1.91) 0.67+ 86 -0.03 (-0.22, 0.15) 0.73 
MAPT  52 2.07 (0.8, 5.38) 0.14 33 -0.02 (-0.3, 0.26) 0.89 
YEO  1 (0.98, 1.02) 0.9  0.004 (0, 0.01) 0.19 
Baseline score  - -  -0.23 (-0.28, -0.18) <.0001 
C9orf72*YEO  1.02 (0.98, 1.06) 0.37  -0.006 (-0.02, 0.01) 0.47 
GRN*YEO  1 (0.96, 1.04) 0.99  -0.007 (-0.02, 0) 0.23 
MAPT*YEO  0.99 (0.95, 1.04) 0.77  -0.0033 (-0.02, 0.01) 0.71 
Mood 587   334   
C9orf72  104 1.22 (0.7, 2.12) 0.49 49 -0.07 (-0.47, 0.34) 0.75 
GRN  137 0.46 (0.23, 0.93) 0.03 84 0.18 (-0.11, 0.47) 0.2 
MAPT  52 2.75 (1.29, 5.89) 0.01 33 0.38 (-0.05, 0.81) 0.08 
YEO  1.01 (0.99, 1.03) 0.26  -0.002 (-0.01, 0.01) 0.7 
Baseline score  - -  -0.23 (-0.28, -0.18) <.0001 
C9orf72*YEO  1 (0.97, 1.03) 0.80  -0.018 (-0.04, 0) 0.11 
GRN*YEO  0.97 (0.94, 1) 0.05  -0.003 (-0.02, 0.01) 0.73 
MAPT*YEO  1.01 (0.97, 1.05) 0.58  0.0031 (-0.02, 0.03) 0.81 
Beliefs    340   
C9orf72     49 -0.004 (-0.02, 0.01) 0.56 
GRN     86 -0.01 (-0.02, 0.0014) 0.097 
MAPT     33 -0.01 (-0.02, 0.01) 0.46 
YEO     0.00007 (-0.0002, 0.0004) 0.62 
Baseline score     -0.38 (-0.41, -0.34) <.0001 
C9orf72*YEO     -0.00017 (-0.0009, 0.0005) 0.64 
GRN*YEO     -0.00017 (-0.0007, 0.0004) 0.52 
MAPT*YEO     -0.0001 (-0.0009, 0.0007) 0.86 
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Eating habits 588   335   
C9orf72  104 0.61 (0.16, 2.32) 0.46 49 -0.02 (-0.2, 0.16) 0.83 
GRN  138 1.57 (0.46, 5.39) 0.47 86 0 (-0.13, 0.1247) 0.99 
MAPT  52 0.68 (0.1, 4.82) 0.70 32 0.1 (-0.09, 0.29) 0.29 
YEO  1.05 (1.01, 1.09) 0.01  0.0041 (0.0001, 0.008) 0.04 
Baseline score  - -  -0.35 (-0.39, -0.31) <.0001 
C9orf72*YEO  0.96 (0.89, 1.03) 0.25  -0.006 (-0.02, 0.005) 0.28 
GRN*YEO  1 (0.94, 1.07) 0.91  -0.00002 (-0.007, 0.007) 0.996 
MAPT*YEO  0.95 (0.87, 1.05) 0.35  0.003 (-0.008, 0.01) 0.6 
Sleep 588   334   
C9orf72  104 1.4 (0.75, 2.64) 0.29 49 -0.13 (-0.39, 0.13) 0.33 
GRN  138 1.16 (0.56, 2.39) 0.68 86 0.05 (-0.14, 0.23) 0.62 
MAPT  52 3.37 (1.46, 7.74) 0.004 32 0.02 (-0.26, 0.3) 0.89 
YEO  1.03 (1.01, 1.05) 0.01  -0.0009 (-0.007, 0.005) 0.76 
Baseline score  
- - 
 -0.28 (-0.33, -0.22) <.0001 
C9orf72*YEO  1.01 (0.97, 1.05) 0.56  -0.008 (-0.02, 0.006) 0.25 
GRN*YEO  1 (0.96, 1.04) 0.86  0.003 (-0.008, 0.01) 0.63 
MAPT*YEO  1.03 (0.98, 1.08) 0.26  -0.005 (-0.02, 0.01) 0.54 
Stereotypic and motor 
behaviours 
588   335   
C9orf72  104 2.15 (1.05, 4.39) 0.04& 49 -0.12 (-0.42, 0.18) 0.44 
GRN 138 1.07 (0.46, 2.52) 0.87 86 0.08 (-0.13, 0.28) 0.47 
MAPT 52 1 (0.31, 3.23) 0.999 32 0.002 (-0.31, 0.32) 0.99 
YEO  1.02 (1, 1.05) 0.05  0.0079 (0.001, 0.01) 0.02 
Baseline score  
- - 
 -0.3 (-0.37, -0.24) <.0001 
C9orf72*YEO  1.03 (0.98, 1.07) 0.23  -0.01 (-0.03, 0.007) 0.23 
GRN*YEO  1 (0.96, 1.05) 0.96  0.0001 (-0.01, 0.01) 0.99 
MAPT*YEO  0.94 (0.89, 1) 0.05  0.002 (-0.02, 0.02) 0.86 
Motivation 587   330   
C9orf72  104 1.91 (0.72, 5.06) 0.19 49 0.093 (-0.19, 0.38) 0.52 
GRN  138 0.93 (0.31, 2.75) 0.9 84 0.02 (-0.19, 0.22) 0.88 
MAPT  52 3.68 (1, 13.52) 0.05& 31 0.0004 (-0.3, 0.3) 1 
YEO  1.05 (1.02, 1.08) 0.003  0.002 (-0.0047, 0.008) 0.62 
Baseline score  - -  -0.26 (-0.33, -0.19) <.0001 
C9orf72*YEO  0.98 (0.93, 1.04) 0.51  0.005 (-0.0109, 0.02) 0.54 
GRN*YEO  0.97 (0.92, 1.02) 0.26  0.006 (-0.0057, 0.02) 0.31 
MAPT*YEO  0.97 (0.9, 1.04) 0.41  -0.006 (-0.0247, 0.01) 0.49 
• Statistics are from the Solution for Fixed Effects Table 
• #Baseline data was modeled with a negative binomial distribution with a log link 
function. Estimates and confidence intervals of fixed effects are exponentiated (base e) 
and indicate the incident rates. Estimates below 1 indicate an inverse relationship 
between the variable and outcome 
• &Overall effect of genetic group was not statistically significant at p<0.05 (based on 
Type III Tests of Fixed Effects) 
• The model could not be run on some subscales after outliers were removed due to low 
symptom endorsement. At baseline, for the self-care sub-scale, 3 participants (3 
preclinical) had scores above zero after outliers were removed. At baseline, for the beliefs 
sub-scale, 4 participants (1 preclinical, 2 non-carrier) had scores above zero after outliers 
were removed. For the change score, for the self-care scale, 1 non-carrier endorsed a 
change in symptom.  
• For the main effect of genetic group and Gene*EYO interaction= reference group are the 
non-carriers 
• YEO= Years from estimated onset; CI=confidence interval 
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Figure 2.3. CBI-R baseline scores by years from expected onset in preclinical mutation carriers vs. non-carriers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CBI-R scores at baseline for (a) abnormal behaviours (b) mood and (c) sleep (d) stereotypic & motor (e) motivation sub-scales. Y-axis 
represents the scores as modeled through the generalized mixed models, and X-axis represents the expected years to onset. Blue =preclinical 
C9orf72 mutation carriers, red =preclinical GRN mutation carriers, green=preclinical MAPT carriers, and brown =non-carriers.
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Figure 2.4. Everyday skills change score by years from expected onset in preclinical mutation 
carriers vs. non-carriers 
 
 
 
 
 
 
 
 
 
 
 
 
CBI-R change score for everyday skills sub-scale. Y-axis represents the linear predicted scores 
as modeled by linear mixed models and X-axis represents the expected years to onset. Blue 
=preclinical C9orf72 mutation carriers, red =preclinical GRN mutation carriers, 
green=preclinical MAPT carriers, and brown=non-carriers.  
 
 
2.4.1 Symptomatic Period 
While apathy and disinhibition were the most frequent initial symptoms across the 
mutation groups, some gene specific patterns emerged. The relative proportion of MAPT carriers 
(46%) endorsing disinhibition as the initial complaint relative to C9orf72 carriers (15%) and 
GRN carriers (8%) is similar to group differences previously reported where 93% of MAPT 
carriers exhibited signs of disinhibition over the course of their disease relative to 63% of 
C9orf72 and 56% of GRN carriers [9]. GRN carriers endorsed impaired articulation and 
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decreased fluency most often, which corresponds with the language-based clinical presentation 
found in some patients in this mutation group [9,13]. C9orf72 expansion carriers reported motor 
symptoms most often which is consistent with reports of Amyotrophic Lateral Sclerosis found 
only in C9orf72 carriers and absent in GRN and MAPT [9]. Although the symptoms discussed 
above are characteristic of the specific gene affected, it is critical to recognize that these 
symptoms are not endorsed by all the participants in each genetic group. Utilizing the top three 
most frequently endorsed symptom to create a composite index for each genetic group 
differentiated symptomatic genetic carriers from non-carriers. Future research assessing the 
severity of these frequently endorsed initial symptoms may aid in the differentiation between the 
genetic groups, and thus may be considered as an outcome measure or clinical endpoint in future 
clinical trials for early stage FTD.  
 
2.4.2 Preclinical Period  
Overall, and counter to our predictions, the rates of initial symptoms as endorsed by 
affected patients (apathy, disinhibition, memory impairments, decreased fluency and impaired 
articulation), were similar between preclinical mutation carriers and non-carriers. As well, the 
composite indices did not differentiate the groups, further supporting and extending recent 
findings indicating that some behavioural and cognitive changes in genetic FTD are only 
detectable in close proximity to conversion to the clinically affected state. Our cohort included 
biologically related non-mutation carriers which enabled us to control for potential 
environmental influences that may impact symptom endorsement (e.g. worry about inheriting an 
FTD-causing mutation, stress from a family member with FTD). Although biomarkers in blood 
and cerebrospinal fluid, grey matter atrophy, white matter hyperintensities and hypometabolism 
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have been detected prior to cognitive impairments during the preclinical period [1], the present 
findings indicate that the behavioural and cognitive symptoms endorsed as initial symptoms by 
patients may not emerge until just a few years prior to clear disease onset. In a recent 
longitudinal study of 46 preclinical mutation carriers, 8 of which “converted” to symptomatic 
during follow-up, cognitive decline during the preclinical period was evident but were largely 
driven by the converters. Additionally, differences in cognitive decline between converters and 
preclinical mutation carriers who did not convert was detectable starting only 2 years prior to 
expected onset. This may suggest that cognitive performance may remain relatively stable during 
the preclinical period and cognitive decline may begin near or at disease onset [14]. This finding 
is also consistent with a recent study that used a classification model on longitudinal MRI data 
(anatomical, diffusion tensor imaging and resting-state) and reported that mutation carriers who 
converted during follow-up had a stronger classification score increase over time relative to non-
converting mutation carriers [15]. Overall, these results indicate that for some domains 
preclinical FTD mutation carriers may remain similar to controls until they are close to clinical 
disease onset.  
For the caregiver report, relative to non-carriers, preclinical MAPT carriers endorsed 
poorer mood and sleep symptoms, and C9orf72 carriers exhibited marginally greater abnormal 
behaviours. Moreover, GRN preclinical carriers endorsed fewer mood symptoms relative to non-
carriers. Given the natural co-occurrence of sleep and mood alterations, it is not surprising that 
MAPT carriers experienced symptoms in both domains. In line with our current findings, 
depressive disorder not otherwise specified has been found to be more prevalent amongst MAPT 
preclinical carriers relative to mutation non-carriers and the general population [16]. As well, 
over a 4-year follow-up, it was reported that MAPT preclinical carriers (n=15) developed more 
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depressive symptoms than GRN carriers (n=31) and healthy controls (n=39) [14]. In contrast to 
the current study, other reports have documented inconsistent findings on the prevalence of 
depressive and other neuropsychiatric symptoms during the preclinical period. For example, a 
greater lifetime prevalence of major depressive disorder, generalized anxiety disorder and panic 
disorder has previously been observed in non-carriers (n=46), but not in MAPT mutation carriers 
(n=12) [16]. Furthermore, other studies have found that neuropsychiatric features may not 
emerge until disease onset. For example, in a Dutch cohort of approximately 80 MAPT and GRN 
mutation and non-carriers, mutation carriers who “converted” from preclinical to symptomatic 
status (3 GRN and 5 MAPT) displayed greater depressive and general neuropsychiatric features 
relative to preclinical mutation carriers and mutation non-carriers at the time of clinical disease 
onset [17]. In our cohort of preclinical mutation carriers, as mood symptoms did not emerge as 
participants approached their expected time of disease onset, the endorsement of symptoms by 
mutation carriers’ may reflect a developmental predisposition.  
When symptom endorsement was examined longitudinally, preclinical GRN carriers 
endorsed worse Everyday Skills over time compared to mutation non-carriers. Relative to 
healthy controls and normative data, asymptomatic GRN carriers demonstrate poorer 
performance on a variety of cognitive domains including attention/processing speed [18], 
visuospatial and working memory [19], verbal fluency, emotion recognition [20], attention, 
mental flexibility and language [21]. With this, it is likely that the decline in Everyday skills in 
preclinical GRN carriers reflects subtle changes in a variety of cognitive domains. Therefore, as 
differences are evident between GRN preclinical mutation carriers and non-carriers, everyday 
skills as measured through the CBI-R may potentially be used as an end point for clinical trials in 
GRN preclinical individuals.  
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2.4.3 Limitations 
Potential clustering effects of family membership and testing site could not be accounted 
for in the clinician-rating scale, due to low symptom endorsement. As well, participant’s 
knowledge of their genetic status was not obtained and thus this potential effect could not be 
accounted for. Future clinical trial modeling may need to consider the participants’ knowledge of 
their genetic status when considering rates of symptom reporting [22]. Furthermore, although the 
different scales used in the current study allow for the assessment of symptom endorsement by 
multiple informants, we could not account for potential differences in reporting style based on 
the sex of the informant or the relationship of the informant to the at-risk family member. An 
additional potential limitation is the reliance on retrospective caregiver reports to acquire reports 
of the initial symptom in symptomatic mutation carriers, though the diagnosis of FTD is reliant 
on caregiver’s reports [23].  
 
2.4.4 Conclusions 
In conclusion, we report the frequencies of the most common initial symptoms for the 
main genetic forms of FTD and suggest that given the heterogeneity between gene groups, 
family members, and even specific mutations, composite measures of these symptoms may serve 
as clinical tools for detection of early conversion to symptomatic FTD. Of interest, we did not 
find differences between preclinical mutation carriers and non-carriers for the most common 
initial symptoms in affected patients. Future studies examining initial symptoms with additional 
longitudinal data points will aid in the understanding of the progression of these symptoms from 
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the preclinical, to affected diseases stages and further pinpoint the onset of initial symptoms 
heralding conversion to symptomatic FTD. 
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Chapter 3: Ventricular Volume Expansion in Preclinical Genetic Frontotemporal 
Dementia 2 
3.1 Introduction 
Frontotemporal Dementia (FTD) is a heritable neurodegenerative disorder characterized 
clinically by behavioral and/or language deficits and atrophy within the frontal and temporal 
lobes. Approximately 30% of patients with FTD present with an autosomal dominant family 
history with mutations in MAPT, PGRN and C9Forf72 each presenting in 5-25% of familial FTD 
[1]. Advances have been made in developing disease-modifying treatments that target the 
underlying pathology of FTD [2]. As the initiation of FTD-treatment is anticipated to be necessary 
during the preclinical or prodromal stages of the disease, biomarkers sensitive to these disease 
periods are needed. Brain volumetric measurements may be a promising candidate measure of 
disease onset and progression, as atrophy in regions of the frontal and temporal lobes may appear 
as early as 5 to 10 years before anticipated clinical disease onset in genetic FTD [3]. 
Changes in ventricular volume represent a particularly attractive candidate index of 
neuronal survival in FTD. Ventricular expansion is seen across the heterogenous clinical, 
molecular and genetic subtypes of FTD at the symptomatic stage [4,5]. Additional advantages 
include reduced image distortion from gradient non-linearities due to the proximity of the ventricle 
to the magnet’s isocenter, and high contrast in intensity between ventricles and tissue which 
facilitates automated segmentation techniques and implementation in large clinical trials [6,7]. 
Ventricular expansion during the preclinical stages of genetic FTD has not yet been 
characterized. The objective of the present study was to examine ventricular volume expansion 
 
2 A version of this chapter has been  published: Tavares TP, Mitchell DG, Coleman K, Shoesmith C, Bartha R, Cash 
DM, Moore KM, van Swieten J, Borroni B, Galimberti D, Tartaglia MC. Ventricular volume expansion in 
presymptomatic genetic frontotemporal dementia. Neurology. 2019; 93(18):e1699-706. 
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cross-sectionally and over a 1-year interval in carriers of an FTD-causing genetic mutation and 
biologically related non-carriers, to determine its utility as a measure of early or preclinical 
disease in genetic FTD. 
 
3.2 Methods 
3.2.1 Participants 
The data used in this study was obtained from the multi-center international Genetic 
Frontotemporal Dementia Initiative (GENFI). Participants were recruited from 12 research sites 
across Canada, Sweden, Italy, UK and Netherlands and were either a known symptomatic carrier 
of a pathogenic FTD causing mutation in MAPT, PGRN or C9orf72, or a first-degree relative of a 
known symptomatic mutation carrier. As described previously [3], all participants completed 
clinical interviews and standardized neuropsychological testing at baseline and at 1-year follow 
up. At-risk first-degree relatives underwent genetic testing to determine mutation carrier status. 
Therefore, the sample was composed of symptomatic mutation carriers, and biologically related 
preclinical mutation carriers and non-carriers. 
 
3.2.2 Imaging and Ventricular Volume Processing 
Volumetric T1-weighted scans were acquired from either a 3T Philips, Siemens Trio, 
Siemens Skyra or GE; 1.5 Siemens or GE were utilized if a 3T was not available. Scanning 
protocols were designed to accommodate the different scanners and field strengths [4]. 
Longitudinal scans collected approximately one year after baseline, using the same scanner and 
protocol as the baseline scan, were included in the analysis. 
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The default longitudinal stream in FreeSurfer, version 5.1 (http://surfer.nmr.mgh.harvard.edu/) 
was used for ventricular volume processing [8]. DICOM images were converted into NIfTI format 
using the mri_convert command available in FreeSurfer. An unbiased within-subject template was 
created using inverse consistent registration [9]. In addition, utilizing information from the 
within-subject template, processing steps including skull stripping, spatial transformation to MNI 
space, atlas registration, spherical surface maps, and parcellations were initialized to increase 
reliability and statistical power [8]. Ventricular segmentations of the lateral, inferior, third and 
fourth ventricles were visually checked and manually edited by TPT, while blinded to familial 
mutation group membership, mutation status (carrier vs. non-carrier) and study period (baseline or 
follow-up). Volumes of the left and right lateral and inferior ventricles, third and fourth ventricles, 
and total intracranial volume were extracted from aseg.txt longitudinal output files. 
 
3.2.3 Statistical Analyses 
Total ventricular volume was calculated as the sum of the left and right lateral (including 
inferior), third and fourth ventricles and was expressed as a percentage of the individual’s total 
intracranial volume. Main analyses compared ventricular volume in preclinical carriers vs. non-
carriers, collapsed across the mutation types to maximize sample size. Exploratory analysis 
included genetic mutation type (C9orf72, PGRN, MAPT) to compare ventricular changes across 
the three genes. 
Linear mixed models were used to examine differences in baseline ventricular volumes 
and change over 1-year. Preclinical carriers were compared to non-carriers to examine whether 
differences were detectable between asymptomatic carriers vs. non-carriers. Predictor variables in 
these analyses included random effects (family membership (variance components covariance 
structure) and each participant nested within the family (unstructured covariance structure), and a 
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random intercept for each) and fixed effects [visit (baseline, follow-up), genetic status (GS; 
carrier, non-carriers), years from expected disease onset, and an interaction term for genetic status 
and years from expected disease onset]. Years from expected age of disease onset were calculated 
by subtracting the mean age of disease onset within the family from the participant’s current age 
at the time of baseline scan and follow up scan [3]. As ventricular volume was predicted to change 
in a non-linear fashion over time as individuals approached the time of expected disease onset, a 
quadratic term for time from expected disease onset and its interaction with genetic mutation 
status were included. Thus, using ventricular volume at time 1 and 2 within individuals, the 
model could evaluate whether a linear or quadratic change in ventricular volume was present 
across individuals as a function of years to expected disease onset. To create parsimonious 
models, non-significant interaction terms were removed. The visit by genetic status interaction 
was examined in a separate model without the time to expected disease onset by genetic status 
interaction due to multicollinearity. Residual and influence analyses were conducted to examine 
model quality and to identify potential outliers. Studentized and conditional residuals were 
examined, along with several influence diagnostic measures including Cook’s D, COVRATIO, 
Restricted Likelihood Distance, the PRESS statistic, and MDFFIT. Given assumptions made in 
using the expected years to disease onset based on the average age of disease onset in the family, 
we also conducted a confirmatory analysis using the final model, substituting years to expected 
disease onset with the participants’ age. 
To examine differences in ventricular volume across the preclinical, prodromal and 
affected stages of the disease, similar models were included to compare all mutation carriers (both 
symptomatic, preclinical mutation carriers and progressors) relative to non-carriers. This model 
allows ventricular volume to be examined across the continuum of the disease and allowed an 
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opportunity to examine whether and how the model might change if symptomatic patients were 
included with preclinical carriers, as has been done in some prior studies (see Appendix B, Result 
Section 1.0). 
Significant interactions between years from expected disease onset and genetic status were 
followed-up with t-tests to assess potential differences between the genetic carriers and non- 
carriers in the years prior to and after expected disease onset, across the baseline and follow-up 
periods. Significant results were also followed up with analysis of regional ventricular volumes 
(i.e. left and right). Given reported grey matter asymmetries in PGRN mutation carriers [10-12], 
we also computed and examined a laterality index, defined as the absolute difference between the 
left and right ventricular volumes divided by the total ventricular volume [3]. All statistical 
analyses were conducted using SAS
® 
(Version 9.4). 
 
3.3. Results 
3.3.1 Participants 
A total of 106 participants met the inclusion criteria. After processing in FreeSurfer, 4 
participants were removed prior to statistical analysis: 1 due to scaling errors, 1 with extensive 
segmentation errors, and 2 found to be extreme outliers (1 carrier and 1 non-carrier from PGRN 
families; mean volumes >3 SD), leaving 102 participants from 43 family cohorts, entered into the 
statistical model (Table 3.1). 
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Table 3.1: Demographic characteristics of study participants (N=102) 
 
 
Preclinical 
Carrier (n=46) 
Non-Carriers 
(n=56) 
Preclinical 
carriers vs. Non- 
carriers 
Genotype   p=0.74 
C9orf72 13 13  
PGRN 29 36  
MAPT 4 7  
Sex   p=0.52 
Female 25 34  
Male 21 22  
Years from expected 
disease onset at baseline 
Mean (SD) 
-13.34(12.65) -9.14 (15.60) p=0.14 
Age (SD) 44.66 (11.14) 50.56 (15.64) p=0.03* 
Years of education (SD) 14.20 (3.47) 14.34 (3.51) p=0.84 
 Group differences were assessed using chi-square tests and t-tests. *significant at p<0.05 
 
3.3.2 Preclinical Carriers vs. Non-Carriers 
The final model included the genetic status by time to disease onset (linear) interaction, 
which illustrates differences between the genetic groups at differing points of time to disease 
onset. A diagnostic analysis identified two high-influential participants (non-carriers) who were 
subsequently removed (see Table B.8), resulting in a main effect of genetic status and a genetic 
status by time from disease onset interaction. Additionally, visual inspection of the scatterplot 
indicated an extreme case (non-carrier). Table 3.2 shows the model estimates, p-values and 
confidence intervals for the main effects [visit, genetic status, time from disease onset (linear and 
quadratic term)], and the interaction between time from disease onset and genetic status. 
Unadjusted post-hoc t-tests demonstrated differences in total ventricular volume between 
preclinical carriers and non-carriers beginning two years prior to expected disease onset, or 
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beginning at 4 years prior to expected disease onset when one extreme case (non-carrier) was 
removed from the model (Figure 3.1). Table 3.3 shows the model estimates for the total 
ventricular volume and total left and right volumes at specific years prior to expected disease 
onset (-25 years to 10 years). To create parsimonious models, we excluded sites (n=11) as a 
random effect and only accounted for family membership. In a confirmatory analysis, we 
included site as a random effect in the final model to examine the potential influence of data 
collection from multiple sites. Confirmatory analysis supported that site was not significant 
(p=0.32). In the supportive analysis, with age used instead of expected years to disease onset, a 
significant genetic group by age interaction was found. Post-hoc tests demonstrated that in 
comparison to non-carriers, pre-symptomatic carriers showed greater ventricular volume 
beginning at age 49. 
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Table 3.2: Total ventricular volume estimates for preclinical (n=46) and non-carriers (n=53), with 
no influential cases (n=2) or extreme case (n=1) 
 
Fixed Effects Estimate SE p-value CI (95%) 
Intercept 0.38 0.34 0.27 -0.31, 1.07 
Visit 0.0004 0.01 0.97 -0.02, 0.02 
 
 
(Baseline and 1-year follow-
up; ref=follow-up) 
 
 
   
 
 
 
Genetic Status 0.35 0.15 0.02* 0.05, 0.66 
(ref=non-carrier)     
Time from -0.02 0.01 0.07 -0.05, 0.002 
disease onset     
Time from disease 
onset
2
 
0.0007 0.0002 0.0001* 0.0004, 0.001 
Time from 0.02 0.007 0.02* 0.003, 0.03 
symptom     
onset*Genetic Status     
 
Random Effects 
 
Estimate 
 
SE 
 
p-value 
 
Family 0.02 0.04 0.33  
Membership     
Participant 0.37 0.07 <.0001*  
Residual 
0.004 0.0005 <.0001* 
 
SE=standard error; Genetic Status (preclinical carrier vs. non-carrier); CI=Confidence interval; 
*significant at p<0.05; Time from disease onset2= Quadratic term for time from disease onset 
variable; ventricular volume is presented as a percentage of the participant’s total intracranial 
volume; The interaction between time from disease onset and genetic status illustrates 
differences between the genetic groups (preclinical carriers vs. non-carriers) at differing 
points of time to disease onset.  
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Figure 3.1: Total ventricular volume by estimated years from expected disease onset in pre- 
symptomatic carriers (blue, n=46) and non-carriers (red, n=53).  
 
 
Ventricular volume is expressed as a percentage of intracranial volume. To prevent disclosure of 
genetic status, individual data points are not plotted. Differences are noted beginning at 4 years 
prior to disease onset as indicated by the dashed line (p=0.04). 
 
 
Table 3.3. Total ventricle volume estimates from post-hoc test between preclinical mutation 
carriers (n=46) and non-carriers (n=53) by time to expected disease onset with no influential 
cases (n=2) or extreme case (n=1) 
 
 
Total Ven 
-25 years -20 years -15 years -10 years -5 years 0 years 5 years 10 years 
Total Ventricle 
Estimate -0.10 -0.010 0.08 0.17 0.26 0.35 0.44 0.53 
SE 0.16 0.14 0.13 0.13 0.14 0.15 0.18 0.20 
p-value 0.54 0.94 0.53 0.18 0.05 0.02* 0.01* 0.01* 
Total Left Ventricle 
Estimate -0.07 -0.02 0.03 0.08 0.13 0.18 0.23 0.28 
SE 0.08 0.07 0.06 0.06 0.06 0.07 0.08 0.10 
p-value 0.39 0.80 0.60 0.18 0.05* 0.02* 0.01* 0.01* 
Total Right Ventricle 
Estimate -0.05 -0.01 0.03 0.07 0.11 0.15 0.19 0.23 
SE 0.09 0.07 0.07 0.07 0.07 0.08 0.09 0.11 
p-value 0.59 0.94 0.62 0.28 0.12 0.06 0.04* 0.03* 
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*significant at p<0.05; ventricular volume is presented as a percentage of the participant’s total 
intracranial volume.  
 
3.3.3 Manually Edited Versus Fully Automated Ventricular Volumes 
Manual edits to the ventricular segmentations performed in FreeSurfer were made on all 
study participants for each time point (mean differences in edited vs. unedited volumes are 
reported in supplementary analysis). Substitution of the fully automated ventricular volumes 
produced by FreeSurfer into the final models resulted in similar findings, demonstrating that for 
preclinical carriers vs. non-carriers, significant differences were observed at 4 years prior to 
disease onset (Tables B.9a-b in Appendix B). See Table B.6 for annualized change of unedited 
ventricular volume. 
 
3.3.4 Total Ventricular Expansion over 1 year 
To assess potential differences in ventricular expansion over the 1-year interval, an 
additional model was evaluated that included the same family and participant random effects as 
above and the following fixed effects: visit, years to disease onset (linear and quadratic terms), 
genetic status and an interaction between visit and genetic status. Significant visit by genetic 
status interaction was followed-up by simple effects estimation. There was a significant time by 
genetic status interaction (p=0.03); however, follow-up tests did not reach significance (all p’s> 
0.18). Annual rates of change of total ventricular volume are presented in Table.7, as a function of 
genetic status and years to expected disease onset. 
 
3.3.5 Mutation Type 
Given previously reported differences in atrophy patterns across the different genotypes, 
we conducted an exploratory analysis to assess potential differences in total ventricular volume 
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and in the laterality index between the genotypes. Specifically, utilizing the final models from 
previous analysis (with the extreme case and two influential cases), we included genotype 
(C9orf72, PGRN, MAPT) and the interaction between genotype and genetic status as fixed effects 
in the model. There was no significant interaction between genotype and genetic status (p=0.10). 
There was no significant interaction between genetic status and genotype for the laterality index 
(p=0.63). 
 
3.4 Discussion 
In this multi-center cohort of individuals from families with genetic FTD, we found that 
ventricular volume enlargement is detectable in the preclinical period, on average four years prior 
to the anticipated onset of symptoms. We also provide the first estimates of annualized rates of 
ventricular expansion in preclinical gene carriers compared to biologically related non-carriers. 
We also examined ventricular volume changes across the preclinical and prodromal to 
symptomatic stages of the disease, which offers a unique opportunity to explore ventricular 
volume changes throughout the disease continuum. This method has also been employed by other 
studies [3]
 
delineating cross-sectional grey matter volumes in a genetic cohort. When all mutation 
carriers (symptomatic & preclinical) were included in the model, ventricular volume changes 
emerged 12 years prior to disease onset. This is in contrast to the model including only preclinical 
participants. Importantly, the preclinical model allows the examination of subtle changes that 
emerge a few years prior to disease onset, unbiased by the increased rate of change that may occur 
during the symptomatic period. Thus, the different model estimates and the earlier detection of 
ventricular volume changes in the combined model of symptomatic patients with the 
preclinical individuals likely reflects the increased the rate of change of ventricular volume as 
the disease progresses. We suggest that the preclinical carrier vs. non-carrier model identifying 
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measurable differences 4 years prior to anticipated disease onset offers the more accurate 
depiction of ventricular volume changes throughout the preclinical period. 
Ventricular volume expansion has been well documented in patients with symptomatic 
sporadic and genetic forms of FTD [13-15]. The annual mean rates of expansion for symptomatic 
mutation carriers in this GENFI cohort rate range from 6-11% and are in line with those reported 
in a series of 6 symptomatic C9orf72 carriers (mean annualized rate of ventricular expansion 
of~9%) [14]
 
and in 21 MAPT symptomatic carriers (~9%) [16]. The expansion rate is slightly 
lower than that reported previously in a cohort of patients with sporadic FTD (mean 11-14%) 
[13]
 
despite similarities in the mean age of symptomatic participants. Prior small series of 
preclinical mutation carriers have not detected significant differences in ventricular expansion 
rates in 7 C9orf72 preclinical carriers (mean age 41) over a six month interval [17], or in 9 
preclinical MAPT carriers (1 year interval) [16]. 
The varied and dramatic atrophy patterns observed in FTD can introduce difficulties for 
automated segmentation programs [18]. We focused our analysis on total ventricular volume in 
particular, as in the preclinical state, the laterality and exact brain regions that may display the 
earliest signs of atrophy are not certain, even within a genetic mutation. Such advantages of 
whole brain measurements, such as total ventricular volume, for tracking outcomes have been 
previously described [13,19,20]. Despite theoretical concerns about lesser sensitivity due to 
averaging across brain regions, this study supports the potential for total ventricular volume 
measurements to provide an unbiased approach to capture accelerated rates of atrophy in 
preclinical and early symptomatic stages of disease. Our comparison of time-intensive, detailed 
manual editing of all scans included in the study relative to the fully automated segmentation 
with no editing produced remarkably similar results, further supporting the feasibility of total 
ventricular volume as a practical measure of disease onset and progression in multi-center clinical 
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trials in FTD. 
Despite the relatively large sample for a cohort of preclinical FTD mutation carriers, 
subgrouping by mutation type and years to expected disease onset resulted in significant 
variability in some estimates. While significant variability in rates of atrophy has been reported 
within mutation groups and even within families [21], in the current study, the variability may 
potentially be due at least in part to the sample size of subgroups. Due to subgroup sample size, 
the examination of differences between carriers of C9orf72, PRGN and MAPT was exploratory, 
and did not reach significance. Examination of subregions of ventricular expansion identified the 
third ventricle as one of the earliest markers in symptomatic patients (Appendix A, supplementary 
analysis). While we did not identify a significant interaction between genetic status and time to 
expected disease onset for the third ventricle in preclinical carriers, inspection of the post-hoc 
tests indicate early expansion of the third ventricle (~14 years prior to expected disease onset) in 
this cohort as well. Together these findings suggest that enlargement of the third ventricle in 
preclinical C9orf72 carriers may be one of the first neuroimaging derived markers, due to early 
thalamic atrophy [22].  
An additional potential limitation of this study is the use of the estimated age at disease 
onset, calculated by subtracting the mean age of disease onset within the family from the 
participant’s age at the time of testing. While previous work has demonstrated a strong 
association between patient’s age at disease onset and mean familial age at disease onset [3],
 
it 
has been observed that age of disease onset within families is particularly variable in GRN 
mutations and somewhat variable in C9ORF72. Although we found similar results when current 
age or actual age at disease onset was substituted into the models, we cannot yet confirm how 
accurately the anticipated age at disease onset represents the actual age in the majority of 
individuals in the pre-symptomatic cohort. Data anticipated from collaborations across large FTD 
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cohorts including LEFFTDS, ARTFL, GENFI and DINAD examining individual age at disease 
onset with family age of disease onset, parent age of disease onset, and other potential mediator 
factors will be helpful in the future to improve such models. Furthermore, differences between the 
pre-symptomatic carriers and non-carriers were based on group-wise estimates and could not yet 
be applied on an individual basis. Data collection of additional longitudinal timepoints continues 
for the GENFI cohort which will inform future estimates of individual rates of change in 
ventricular volumes. 
Overall, the present study shows ventricular volume differences during the preclinical 
period in genetic FTD pathophysiology and support the potential of application of ventricular 
volume as one index of disease onset in the prodromal stages of FTD. Future longitudinal follow 
up of this GENFI cohort, as well as comparison with anticipated results from other familial FTD 
cohorts such as LEFFTDs (https://memory.ucsf.edu/lefftds), and with complementary measures 
such as rates of change in total brain volume will enable further modeling according to specific 
genotype and confirm the rates of change. 
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Chapter 4: Neural Correlates of Reversal Learning in Frontotemporal Dementia 
4.1 Introduction 
Frontotemporal Dementia (FTD) is a progressive neurodegenerative disorder that 
primarily affects the frontal and temporal lobes, resulting in profound alterations in personality 
and social behaviour (Neary, 1998). Disinhibition is one of the core symptoms in FTD and 
emerges quite early during the disease process [1]. Patients with disinhibition often lack social 
etiquette (e.g. making rude comments), engage in impulsive or careless actions (gambling, 
overspending), or new criminal behaviours (e.g. shoplifting). [1,2]. Importantly, despite negative 
social and legal consequences, patients with FTD continue to engage in these behaviours, 
implicating a possible difficulty in flexibly altering behaviour when provided negative feedback. 
In patients with FTD, disinhibition as reported by caregivers has been correlated with degree of 
atrophy or hypoperfusion in frontotemporal regions, most commonly in the orbitofrontal cortex, 
inferior frontal gyrus, anterior cingulate gyrus, and insula [3,4]. Despite knowledge of these 
anatomic associations with symptoms of disinhibition, effective treatments for such symptoms in 
patients with FTD are lacking. Here we propose to demonstrate the neural mechanisms 
underlying these symptoms by examining the real-time neural correlates of reversal learning, a 
classic cognitive paradigm that indexes flexible responding to negative feedback and for which 
the mediating neural regions are well established.  
Reversal learning is a classic measure of adaptive behaviour flexibility, specifically 
assessing the ability to alter behaviour when reinforcement contingencies change [5]. Through 
trial and error, participants learn stimulus-reward contingencies (acquisition phase), selecting 
stimuli associated with reward and avoiding stimuli associated with punishment. During the 
reversal phase, the reinforcement contingencies change, such that the stimuli that were 
previously associated with punishment are now associated with a reward, and those initially 
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associated with punishment are now rewarded. Functional neuroimaging studies have implicated 
the ventromedial prefrontal cortex/orbital frontal cortex (vmPFC/OFC), ventrolateral PFC 
(vlPFC) and dorsomedial PFC (dmPFC) during reversal learning. Specifically, when a reversal 
error is made, the vmPFC/OFC demonstrates a decrease in activity [6,7], suggesting a role in 
prediction error signalling which signals discrepancy between the expected and actual reward 
[8]. In contrast, the vlPFC, dmPFC and dlPFC demonstrate increased activity in response to 
reversal errors [6,9-12]. Consistent with the suggested role of the dlPFC in attention and 
cognitive control during instances of conflict such as during reversal errors, the dlPFC augments 
the representation of relevant stimulus cues and reinforcement information to guide flexible 
behaviour [12,13]. As well, it has been suggested that during reversal learning the vlPFC 
interacts with the caudate to increase the salience of alternative motor responding [6,12].  
In patients with ventral frontal lesions, deficits in reversal learning are associated with 
increased behavioural problems including disinhibition, irritability, inflexibility and 
perseveration (Rolls et al, 1994). Patients with FTD exhibit reversal learning impairments [14-
16], and the number of reversal errors has been correlated with atrophy within the anterior 
cingulate cortex (ACC; BA 24) and the medial/lateral OFC (BA 11, 47) [15]. This finding 
suggests that reversal learning impairments in FTD may be related to a failed suppression of a 
previously rewarded response mediated by vlPFC and ACC, and/or impaired processing of 
unexpected negative feedback by ventromedial PFC. Critically, no study has delineated the 
functional neural correlates of reversal learning performance in patients with FTD. Assessing the 
functional integrity of the key regions involved in reversal learning may provide insights into the 
fundamental pathophysiological mechanisms underlying behavioural inflexibility in FTD. 
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Furthermore, the results of the current study may have implications in the selection of 
therapeutic targets and future outcome markers for symptomatic treatments. 
 
4.2 Methods 
4.2.1 Participants 
 Twenty-seven patients with FTD and 24 controls were enrolled in the study. Five patients 
were unable to complete the scan and withdrew, 2 controls withdrew due to claustrophobia, and 
1 control participant’s data was unusable due to computer problems resulting in 22 patients and 
21 controls with fMRI scans available for analysis. All patients met the diagnostic criteria for 
probable or definite bvFTD or svPPA with significant behavioural features [1,17]; diagnoses 
were made by a behavioural neurologist (ECF). Patients were recruited through the Cognitive 
Neurology and Alzheimer’s Research Centre at Parkwood Hospital in London, Ontario, Canada, 
and control participants were recruited through advertisements to caregivers at local FTD support 
groups and from the clinic’s volunteer pool. All participants and caregivers of patients provided 
written informed consent. This study was approved by the Health Science Research Ethics Board 
at Western University, London, Ontario, Canada. 
 
4.2.2 Measures 
To assess cognitive functioning, patients and controls completed the Addenbrooke’s 
Cognitive Examination-Revised (ACE-R) [18], Montreal Cognitive Assessment [19], Trail 
Making Test, Clock drawing [20], Prose recall, and Phonemic and Semantic Fluency. 
Additionally, caregivers of patients completed the Frontal Behavioural Inventory with a trained 
research assistant (FBI) [21]. The FBI is a 24-item inventory used to assess behaviour and 
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personality changes and each item is rated on a 4 point rating scale where higher scores indicate 
more severe behavioural changes (0=none; 1=mild, occasional, 2=moderate; 3-severe, most of 
the time).  
 
4.2.3 fMRI Task 
Participants completed an fMRI-adapted deterministic reversal learning task (Figure 4.1) 
which consists of acquisition and reversal phases. A deterministic design was selected based on 
our prior piloting in patients with FTD where we observed significant impairment in learning the 
initial reinforcement associations when probabilistic feedback was given. For the current study, 
on each trial, participants were presented with a pair of objects (colored Snodgrass images of 
animals or furniture pieces [22] and were instructed to select one of the objects in each pair. 
Participants were informed if their response selection was correct, they would win 100 points, 
and conversely, if their response selection was incorrect they would lose 100 points (acquisition 
phase). Subsequently participants were instructed that at some point during the task, the object in 
the pair associated with a correct response may change, and they should adjust their response 
accordingly. All participants completed practice trials outside of the scanner to ensure 
comprehension of task instructions.  
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Figure 4.1: Schematic of fMRI reversal learning task.  
 
Schematic of the reversal learning task. During the acquisition phase, patients learn the stimulus-
response contingencies. During the reversal phase, the stimulus-response contingencies would 
change 
 
Participants completed four runs of the task; each run consisted of a reversal block (10 or 
15 trials of acquisition phase, followed by 10 or 15 trials of reversal phase), and a non-reversal 
block (consisting of 20 trials of acquisition phase only). Non-reversing blocks were included to 
prevent participants from anticipating a contingency change across the runs. The order of the 
blocks was randomly presented in each run, and each run and block consisted of new stimuli. On 
each trial, the participants were presented with the response screen depicting the pair of objects 
for varying durations (2500ms, 4000ms, or 5500ms), the feedback screen (1500ms) and the 
fixation cross presented in the center of the screen (for 1000ms, 2500ms, or 5500ms). One of 
each object in a pair was presented randomly on the left and right side of the screen at 8 possible 
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locations. Participants responded using their index finger on their left and right hand to select the 
button that corresponded to the location of the correct object (left or right). 
 
4.2.4 Imaging Acquisition 
All participants completed the imaging task using a 3T Siemens Magnetom Prisma 
scanner with a 32-channel head coil at Robarts Research Institute, Western University. 
Functional images were acquired using a T2*gradient echo-planar imaging sequence [repetition 
time (TR)= 2500ms, echo time (TE)= 30ms, field of view (FoV)= 240mm, flip angle =90 
degrees, 37 interleaved slices of 2 x 2x 3mm voxel resolution, 3mm slice thickness, 153 volumes 
per run]. In addition, a high resolution T1-weighted anatomical scan was obtained subsequent to 
the functional scan: [TR= 2300ms, TR= 2.98ms, FoV= 256mm, flip angle =9 degrees, 192 
interleaved slices of 1mm isotropic voxels]. 
 
4.3 Statistical Analysis 
4.3.1 Task Behavioural Performance 
For each task phase (acquisition, reversal), the percentages of correct responses and non-
responses as a function of the total number of trials per phase were analyzed. Visual inspection 
of histogram and Q-Q plots indicated non-normal data; thus, a Mann Whitney U Test and a 
Wilcoxon Signed-Rank Test was conducted to examine differences between and within the 
patient and control groups, respectively.  
Behavioural performance was also examined within the patient group based on the 
different atrophy patterns (frontal vs. temporal predominant). Patient’s MRI images were 
classified according to their predominant atrophy pattern by a behavioural neurologist (ECF), 
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resulting in 8 patients with frontal predominant atrophy, 10 with temporal predominant atrophy, 
and 1 with frontotemporal atrophy. To delineate potential differences between frontal and 
temporal atrophy patterns specifically, the patient with frontotemporal atrophy was not included 
in the analysis. Given the small sample size of the sub-groups, Kruskal-Wallis and Dunn-
Bonferroni post-hoc tests were used as an exploratory analysis to compare behavioural 
performance across the frontal and temporal predominant atrophy groups and controls. 
 
4.3.2 Frontal Behavioural Inventory (FBI) 
We examined whether patients with different atrophy patterns (frontal vs. temporal 
predominant) exhibited differences in caregiver reported behaviours associated with reversal 
learning deficits [5]. Specifically, a reversal learning composite score was created from the 
following FBI items: inflexibility, perseverations/obsessions, impulsivity/poor judgement, 
irritability, and aggression. A Mann Whitney U Test was used to examine differences between 
the patient atrophy groups.  
 
4.3.3 Imaging 
4.3.3.1 fMRI     
Imaging data were preprocessed and analyzed in Analysis of Functional Neuroimages 
(AFNI) [23]. Nonlinear registration was completed to the MNI template using AFNI’s 
@SSwarper. Additionally, all volumes were registered to the functional volume closest to the 
anatomical (last volume of the final run). Three participants’ anatomical images were acquired 
prior to the functional runs, thus the 3rd EPI volume of the first run was used for registration. 
Volumes were spatially smoothed using a 4mm full width at half maximum isotropic Gaussian 
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kernel. Additionally, time series data were normalized by dividing the signal intensity of voxels 
at each time point by the mean signal intensity of that voxel for all the runs and multiplying it by 
100; thus, the regression coefficients represented the percent signal change from the mean 
activity. Within task runs, volumes were censored if the derivatives of the six generated motion 
parameters had a Euclidean norm greater than 2.0mm. To further account for movement, motion 
derivates were included as regressors in the model. For the voxel time series, TRs with at least 
10% of voxels too far from the trend (calculated using AFNI’s mean absolute deviations) was 
deemed an outlier and removed. Regressors characterized the response type (correct or incorrect) 
by phase type (acquisition or reversal) were created for both the choice (stimuli 
presentation/decision-making phase) and feedback screens and for reversing pairs and non-
reversing pairs, resulting in 24 regressors. The blood-oxygen level dependent (BOLD) response 
was fitted to each regressor to conduct linear regression modelling. To account for voxel-wise 
correlated drifting, a baseline and linear drift and AFNI’s default polynomial trend were 
modelled to the time series of each voxel. Linear regression modelling resulted in a beta-
coefficient and an associated t-statistic for each voxel for each regressor. To correct for multiple 
comparisons, AFNI’s updated 3dClustSim at a cluster defining threshold of p=0.05, was used on 
the entire brain with a threshold of p<0.001 (22 contiguous voxels).  
Three patients were removed due to excessive movement; thus 19 patients and 21 
controls were included in the behavioural and functional analysis. Additionally, one patient only 
completed three runs and thus a comparative run was removed from a control scan in order for 
both groups to have the same number of trials. A 2 Group (patients vs. controls) x 2 Phase 
(acquisition x reversal) x 2 Response accuracy (correct vs. incorrect) repeated measures ANOVA 
was conducted in AFNI using 3dMVM, and the significance threshold was set to p<0.001. 
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Significant interactions were followed by uncorrected paired and independent t-tests in SPSS at 
p<0.05 to examine differences in percent BOLD signal change. As an exploratory analysis, 
voxel-wise grey matter tissue probabilities were entered as a covariate in the fMRI analysis to 
account for grey matter volume differences that may influence the fMRI signal (see Method C.1, 
Table C.1, Table C.2, Figure C.1).  
 
4.3.3.3 Region of Interest Analysis 
An exploratory region of interest (ROI) analysis was conducted to examine whether 
patients with different atrophy patterns (frontal vs. temporal predominant) demonstrated different 
BOLD signal during the choice and feedback epochs in the regions known to be involved in 
response reversal. An ROI approach was used instead of an ANOVA with group included as a 
between-subject factor, due to the small sample in each atrophy group.  
Anatomical ROIs were created using the CA_ML_18_MNIA atlas in AFNI. For the 
choice epoch, ROIs included the left vlPFC (orbitalis), and left dorsolateral PFC 
(triangularis/opercularis) that encompassed the clusters found below. A 3 group (frontal, 
temporal, control) x 2 response accuracy (correct, incorrect) x 2 phase (acquisition, reversal) and 
a 3 group (frontal, temporal, control) x 2 response accuracy (correct, incorrect) was used to 
delineate group effects in the left vlPFC and left dlPFC, respectively. One-way ANOVAs were 
completed to delineate group differences.  
For the feedback epoch, the following ROIs were used to partition the large clusters 
found (see results below), into specific regions known to be uniquely involved in reversal 
learning [6,9,10]: left and right ventrolateral PFC, dorsolateral PFC, ventromedial PFC (superior 
orbital gyrus, rectal gyrus and mid orbital gyrus), and dorsomedial PFC (anterior and middle 
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cingulate cortex). A 3 group (frontal, temporal, controls) x 2 response accuracy (correct, 
incorrect) repeated measures ANOVA was completed to identify group differences for the ROIs. 
Uncorrected one-way ANOVAs and paired t-tests for each group were completed to delineate 
differences in BOLD activity between correct and incorrect response feedback.  
 
4.4 Results 
4.4.1 Demographic  
Nineteen patients and 21 controls were included in the behavioural and functional imaging 
analysis. At the time of testing, patients were on average 63 years of age and controls were 64 
years of age. Patients were diagnosed at a mean age of 62. Ten patients were diagnosed with 
behavioural-variant FTD (bvFTD), seven patients were diagnosed with semantic dementia (SD), 
one patient presented with progressive nonfluent aphasia (PNFA), and one patient presented with 
bvFTD/SD (Table 1 for demographic and neuropsychological performance). There were no 
significant differences for age at testing, sex, handedness, or years of education between the 
patients with FTD and controls. 
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Table 4.1: Demographic and Neuropsychological Characteristics 
 
Demographic  
 Patients Controls Contrasts 
 19 21  
Age at testing, years (SD) 63.3 (5.4) 64.1 (13.9) t(26.5)= -0.23. p=0.82 
 
Sex (Male, Female) 10, 9 10, 11 X2=0.1, p=0.8 
 
Handedness (left, right) 0, 19 2, 18* Fisher’s = 2.5, p=0.5 
 
Education (years) 13.8 (1.8) 14.4 (2.8) t(38)= -0.77, p=0.45 
 
Age at diagnosis (SD) 61.6 (5.6) - - 
 
Disease duration, Yrs (SD) 1.8 (1.9) - - 
 
Atrophy Pattern  - - 
 
   Frontal 8 - - 
 
   Temporal 10 - - 
 
   Frontotemporal 1 - - 
 
Diagnosis  - - 
 
   bvFTD 10 - - 
 
   SD 7 - - 
 
   PNFA 1 - - 
 
   SD & bvFTD 1 - - 
 
Neuropsychology 
 Patients Controls Contrasts 
 n Mean (SD) n Mean (SD)  
      
MoCA 18 19.0 (5.0) 18 26.9 (2.0) t(22)= -6.3, p<0.001 
 
ACER (total) 19 64.2 (17.8) 21 88.7 (21.1) t(38) = -3.9. p<0.001 
Prose immediate Recall 16 4.1 (3.8) 18 10.72 (3.1) t(32)= -5.6, p<0.001 
 
Prose delayed recall 18 3.2 (3.7) 18 10.3 (2.6) t(32) = -6.5, p<0.001 
Semantic fluency 19 10 (5.9) 18 22.0 (4.2) t(35) = -7.1, p<0.001 
Phonemic fluency 17 21.6 (14.4) 19     40.5 (12.4) t(34) = -4.2, p<0.001 
Trail A 18 50.7 (15.0) 
 
18 27.6 (7.5) t(25)= 5.9, p<0.001 
Trail B 14 121.3 (58.5) 18 63.3 (16.4) t(14.6)= 3.6, p=0.003 
Clock draw 18 8.2 (2.5) 18 9.6 (0.8) t(20.3) = -2.4, p=0.03 
Clock (copy) 16 9.3 (1.1) 17 9.7 (0.5) t(19.7)= -1.3, p=0.2 
FBI Composite Score 19 6.4 (3.5) - - - 
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*Handedness was absent for one control participant 
bvFTD=behavioural variant FTD; SD=semantic dementia; PNFA=progressive non-fluent 
aphasia; MoCA=Montreal Cognitive Assessment; ACER= Addenbrooke’s Cognitive 
Examination; FBI=Frontal Behavioural Inventory 
 
4.4.2 Task Behavioural Performance 
4.4.2.1 Patients vs. Controls 
The control group made more correct responses relative to patients during the acquisition 
phase (U=81.0, p=0.001) and reversal phase (U=95.5, p=0.004). Of note, two patients had 51% 
or fewer correct responses during acquisition and reversal phase; when removed from the 
analysis the group differences remained (Acquisition: U=81, p=0.003; Reversal: U=95.5, 
p=0.012).  
As expected, controls made more correct responses during the acquisition relative to the 
reversal trials (Z= -3.2, p=0.002). Patients showed a trend to make more correct responses during 
the acquisition relative to the reversal stage (Z= -1.9, p=0.06Figure 4.2a; Table C.3).  
 
4.4.2.2 Frontal predominant atrophy, temporal predominant atrophy and controls 
Controls made more correct responses relative to the temporal (Z=-2.48, p=0.04) and 
frontal atrophy (Z=-3.42, p=0.002) group during acquisition (Mean ranks: Control = 25.5, 
Temporal= 15.1, Frontal=10.0). During reversal, controls made more correct responses relative 
to the frontal group (Z=-2.79, p=0.02); no differences were found between the control and 
temporal group (Z= -2.09, p=0.11; Mean ranks: Control=24.5, Temporal=15.7, Frontal=11.9; 
Figure 4.2b).  
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Figure 4.2: Percent correct responses during acquisition and reversal trials 
 
Boxplots of percent correct and non-responses during acquisition and reversal phases for (a) 
patients and controls and (b) frontal, temporal atrophy groups and controls. (a) For the 
acquisition and reversal phase controls made more correct responses relative to patients. Patients 
made more non-responses relative to controls.  (b) During acquisition, controls made more 
correct responses relative to the temporal and frontal groups.  
 
4.4.3 FBI 
Patients with temporal and frontal atrophy did not exhibit differences in the FBI-reversal 
learning composite score (U=34.0, p=0.63).  
 
 
 
92 
 
4.4.4 fMRI 
4.4.4.1 Choice Epoch 
The repeated measures ANOVA of BOLD signal during the choice phase revealed a 
significant 3-way interaction within the left vlPFC/anterior insula (Table 4.2), where controls 
exhibited greater activity relative to patients during acquisition error responses (t= (38), -4.4, 
p<0.0001) and reversal correct responses (t= (38), -3.6, p=0.001; Figure 3a). Controls showed 
greater activity in vlPFC/anterior insula during acquisition for incorrect relative to correct 
responses (t=(20), -4.6, p<0.001), while in patients BOLD signal did not differ for acquisition 
correct vs. incorrect responses (t= (18), 1.0, p=0.31). During reversal, in this region the opposite 
pattern emerged, where controls did not exhibit a difference in BOLD activity between the 
response accuracy (t= (20), 1.5, p=0.16), while patients demonstrated greater activity for errors 
relative to correct responses (t= (18), -2.22, p=0.04). Additionally, a group x response accuracy 
interaction emerged where controls exhibited greater BOLD activity during incorrect responses 
relative to patients within the left dorsal lateral PFC (t= (38), -4.6, p<0.001; Table 4.2, Figure 
3b). There was also a significant interaction between phase and response accuracy within the 
dorsal lateral and medial PFC, vlPFC, and striatum (see Table 4.2).   
 
4.4.4.2 Feedback Epoch 
A main effect of response accuracy was observed in two large clusters that encompassed 
the right lateral and ventromedial PFC, right insula and bilateral dmPFC (cluster 1), and left 
insula and left ventromedial and lateral PFC (cluster 2) where activity was greater for incorrect 
relative to correct responses (Figure 4.3c-d, Table 4.2). 
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Figure 4.3: Neural regions demonstrating significant effects during choice and feedback epochs  
 
Group x phase x response accuracy during the choice epoch in the left vlPFC/anterior insula for 
controls versus patients (a), group x response accuracy interaction in the left dlPFC for controls 
versus patients (b), main effect of accuracy for incorrect versus correct responses for the right (c) 
and (d) left lateral PFC.  
 
 
Table 4.2: Regions demonstrating differential BOLD Signal Responses 
 
 
Choice Phase 
 
Fixed Effects Region L/R BA X Y Z t-value # 
voxels 
Direction 
Group Middle temporal 
gyrus 
L 22 60.4 32.1 3.8 -4.1 57 Ctrl>Pat 
 Inferior frontal 
gyrus 
L 47 32.4 -28.5 0.1 -4.0 50 Ctrl> Pat 
 Inferior frontal 
gyrus 
R 9 -53.4 -4.3 35.8 -4.6 27 Ctrl > Pat 
 
Reinforcement Inferior frontal 
gyrus 
L 6/9 41.3 -0.7 33.2 -4.3 27 Corr<incorr 
 
Phase Left inferior frontal 
gyrus 
L 9 43.1 -4.9 34.6 4.1 276 Acq > Rev 
 Left medial frontal 
gyrus 
L 6 5.6 -15.4 48.8 4.8 229 Acq > Rev 
 Lentiform nucleus 
& putamen 
L  17.4 -8.9 -2.4 4.0 221 Acq > Rev 
 Inferior frontal 
gyrus 
L 47/13 31.2 -25.4 -3.2 3.4 130 Acq > Rev 
 Inferior frontal 
gyrus 
R 9 -39.6 -6.8 31.4 4.4 110 Acq > Rev 
 Lentiform 
nucleus/putmane 
R  -15.0 -7.6 -1.6 3.0 95 Acq > Rev 
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 Inferior frontal 
gyrus 
R 47 -30.7 -23.2 -2.6 4.2 76 Acq > Rev 
 Cingulate gyrus R 32 -9.2 -17.9 38.4 4.2 72 Acq > Rev 
 Superior occipital 
gyrus 
R 19 -31.9 77.3 22.7 3.8 69 Acq > Rev 
 Inferior parietal 
lobe 
L 40 33.1 48.5 43.7 2.5 34 Acq > Rev 
 Superior parietal 
lobe 
L 7 29.8 56.8 49.9 5.1 33 Acq > Rev 
 Inferior parietal 
lobe 
L 40 53.0 45.2 49.0 5.4 24 Acq > Rev 
 Precuneus L 39 28.6 68.4 31.4 3.8 23 Acq > Rev 
 
Phase x 
reinforcement 
Cingulate gyrus L 32 3.9 -20.9 45.5 -3.1 253 Acquisition 
Corr<Incor 
 
Reversal 
Corr>Incorr 
 Inferior frontal 
gyrus 
L 9 44.0 -3.1 35.9 -3.6 208 Acquisition 
Corr< Incorr 
 
Reversal 
Corr>Incorr 
 Lentiform 
nucleus/Putamen 
L  17.3 -9.4 -2.9 -3.7 199 Acquisition 
Corr< Incorr 
 
Reversal 
Corr>Incorr 
 Inferior frontal 
gyrus 
L 47 34.3 -25.7 -5.1 -4.8 96 Acquisition 
Corr< Incorr 
 
Reversal 
Corr>Incorr 
 Lentiform 
nucleus/putamen 
R  -14.4 -8.2 -3.6 -4.5 51 Acquisition 
Corr< Incorr 
 
 Middle frontal 
gyrus 
L 46 42.9 -28.3 21.8 -4.8 51 Acquisition 
Corr< Incorr 
 
Reversal 
Corr>Incorr 
 Cingulate gyrus R 32 -7.7 -16.8 41.3 -3.8 46 Acquisition 
Corr< Incorr 
 
Reversal 
Corr>Incorr 
 Inferior parietal 
lobule 
L 40 34.1 51.7 43.1 -2.8 40 Acquisition 
Corr< Incorr 
 
Reversal 
Corr>Incorr 
 Cingulate gyrus L 32 10.4 -19.7 33.1 -3.5 34 Acquisition 
Corr< Incorr 
 
Reversal 
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Corr>Incorr 
 Inferior frontal 
gyrus 
R 9 -36.3 -7.7 29.7 -4.2 33 Acquisition 
Corr< Incorr 
 
Reversal 
Corr>Incorr 
 Middle frontal 
gyrus 
L 9 36.9 0.5 61.5 -4.4 23 Acquisition 
Corr< Incorr 
 
Reversal 
Corr>Incorr 
 
Group x 
reinforcement 
Inferior frontal 
gyrus 
L 9 42.4 -4.7 34.0 3.7 27 Incorrect 
Ctrl>pat 
 
3-way interaction Inferior/middle 
frontal gyrus 
L 47 40.1 -31.6 -1.1 4.7 22 Incorrect acq 
Ctrl> Pay 
 
Correct rev 
Ctrl > Pat 
 
 
Feedback Phase 
 
Fixed Effects Region L/R BA X Y Z t-value # 
voxels 
Direction 
Reinforcement Right 
Inferior, middle, 
superior frontal 
gyrus/insula 
 
Left superior, 
medial frontal 
gyrus/cingulate 
gyrus/anterior 
cingulate 
R/L 47/46/9/ 
10 
/8/6/13/ 
45/32 
-28.9 -26.6 31.9 0.3 9521 Incorr > corr 
 Superior, middle, 
inferior frontal 
gyrus/insula/ 
precentral gyrus 
L 47/13/10
/ 
9/6/8/44/
45 
42.4 -20.9 23.2 -5.1 5020 Incorr > corr 
 Inferior parietal 
lobe 
L 40 35.3 59.5 39.3 -6.9 4994 Incorr > corr 
 Superior parietal 
lobe 
R 7 -43.0 57.8 45.3 -3.9 3083 Incorr > corr 
 Inferior occipital 
gyrus 
R 18 -51.2 54.8 -
11.8 
-1.0 1282 Incorr > corr 
 Cuneus R 18 -0.6 82.7 8.4 -3.2 885 Incorr > corr 
 Fusiform gyrus L 19 28.0 66.4 -
28.5 
-2.9 631 Incorr > corr 
 Thalamus R  0.7 5.3 9.2 -3.7 612 Incorr > corr 
 Fusiform gyrus L 19 45.5 69.3 -
14.8 
-3.2 296 Incorr > corr 
 Lingual gyrus R 18 -12.6 82.4 -
25.2 
-4.5 147 Incorr > corr 
 Cingulate gyrus L 23 1.6 30.5 28.4 -4.6 85 Incorr > corr 
 
 
96 
 
 Superior frontal 
gyrus 
R 11 -21.8 -44.8 -
15.0 
-4.9 77 Incorr > corr 
 Cingulate gyrus L/R 23 1.2 14.1 31.1 -4.0 58 Incorr > corr 
 Middle occipital 
gyrus 
L 18 35.2 91.6 5.9 -4.3 51 Incorr > corr 
 Superior frontal 
gyrus 
L 11 23.2 -42.1 -
15.3 
-4.9 43 Incorr > corr 
 caudate R  -26.2 46.2 15.6 4.8 39 Corr>Incorr 
 Nodule L  -0.3 56.4 -
35.6 
-4.2 28 Incorr > corr 
 Posterior cingulate R  -0.1 42.5 7.6 -3.9 28 Incorr > corr 
 Superior temporal 
gyrus 
R 39 -44.2 57.7 23.2 -3.9 26 Incorr > corr 
 Middle occipital 
gyrus 
R 19 -47.9 79.5 1.3 -4.3 23 Incorr > corr 
 Parahippocampal 
gyrus 
L  8.6 38.2 4.6 -4.6 23 Incorr > corr 
 
Phase Inferior occipital 
gyrus 
R 18 -37.8 84.9 -
20.8 
4.1 109 Acq> Rev 
 Middle occipital 
gyrus 
L 19 54.1 75.7 -1.6 4.4 48 Acq> Rev 
 Cuneus R 18 -2.5 94.9 10.2 3.8 45 Acq> Rev 
 
Group x Phase Superior/middle 
frontal gyrus 
L 10 26.5 -55.7 -
10.0 
-4.5 34 Acquisition 
Ctrl>pat 
 
Reversal 
Ctrl< Pat 
 Inferior parietal 
lobule 
R 40 -41.9 47.5 56.6 -3.9 23 Acquisition 
Ctrl > Pat 
 
Phase x 
Reinforcement 
Inferior occipital 
gyrus 
R 18 -25.9 90.0 -
20.1 
-4.3 56 Acquisition 
Corr< Incorr 
 
Reversal 
Corr>Incorr 
 Fusiform gyrus R 19 -43.8 80.4 -
21.4 
-4.4 40 Acquisition 
Corr< Incorr 
 
Reversal 
Corr<Incorr 
 Middle occipital 
gyrus 
R 19 -48.7 77.6 -9.8 -4.1 36 Acquisition 
Corr< Incorr 
 
Reversal 
Corr>Incorr 
 
 Lingual gyrus L 18 3.6 79.6 -9.6 -3.7 28 Acquisition 
Corr< Incorr 
 
Reversal 
Corr>Incorr 
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 Inferior parietal 
lobule 
R 40 -57.1 57.3 45.6 -3.7 23 Acquisition 
Corr< Incorr 
 
Reversal 
Corr<Incorr 
 
 Middle occipital 
gyrus 
L 19 53.7 77.4 77.4 -4.2 22 Acquisition 
Corr< Incorr 
 
Reversal 
Corr>Incorr 
 
Thresholded at p<0.001 (t-value=3.570). All clusters survive correction for multiple comparison 
at p<0.05. Table displays regions, hemisphere (L, left; R, right), Brodmann area (BA), Montreal 
Neurological Institute (MNI) coordinates (x, y, z) at center of mass, maximum neural activity for 
the cluster (t-value), cluster size in voxels, and the direction of activity [Control (ctrl), Patient 
(pat), Acquisition (acq), Reversal (rev), Correct (corr), Incorrect (incorr)]. Focus point and 
regions of BA according to TT_Daemon: Talairach-Tournoux atlas. The ANOVA was 
completed separately for the choice and feedback phase.  
 
  
4.4.4.3 Exploratory ROI Analysis 
4.4.4.3.1 Choice Epoch 
To examine potential differences between the atrophy groups within the resulting clusters 
found during the choice epoch, anatomical ROIs were created for the left vlPFC and dlPFC. A 
main effect of group emerged within the left vlPFC [F(2,35)=5.9, p=0.006] and left dlPFC 
[F(2,35)=8.2, p=0.001]. Post-hoc tests revealed that the control group exhibited greater BOLD 
signal relative to the frontal group (marginally for the vlPFC) and the temporal group. No 
differences were found between the frontal or temporal group (Figure 4.4a-b).  
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Figure 4.4: BOLD signal change across the control and atrophy groups during the choice epoch 
 
Mean percent BOLD signal change during choice epoch within the (a) left dlPFC and (b) vlPFC. 
Error bars represent SEM. Asterisks indicate p<0.05. (a) Control group exhibited greater BOLD 
signal changes compared to the frontal and temporal group and (b) the temporal group only. 
 
4.4.4.3.2 Feedback Epoch 
Anatomical ROIs were used to partition the larger clusters found for the feedback epoch 
and differences between the atrophy groups and controls were assessed. A group by response 
accuracy interaction was observed in the right dlPFC [F(2,35)=3.5, p<0.05] and right vlPFC 
[F(2,35)=3.8, p<0.05]. For both regions, a one-way ANOVA for incorrect responses revealed 
trends (dlPFC: [F(2,37)=2.5, p=0.095]; vlPFC: [F(2,37)=3.7, p=0.06]); post-hoc tests revealed 
that in both regions, controls exhibited greater error-related BOLD activity relative to the frontal 
predominant atrophy group (dlPFC: control – frontal mean difference= 0.24, p=0.034; vlPFC: 
control-frontal mean difference= 0.36, p=0.02). No differences were found between the atrophy 
groups (dlPFC: frontal-temporal mean difference= -0.20, p=1.0; vlPFC: frontal-temporal mean 
difference= -0.30, p=0.08) or between controls and the temporal group (dlPFC: control-temporal 
mean difference= 0.03, p=0.75; vlPFC: control-temporal mean difference= 0.058, p=0.67). For 
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the dlPFC, no significant main effect of group was found for correct responses. Within the vlPFC 
a main effect of group was observed (F(2,37)=4.1, p=0.025), and an unexpected pattern emerged 
for correct responses in which the temporal predominant atrophy group showed enhanced 
activity relative to controls (Control-temporal mean difference= -0.14, p=0.007; Figure 4.5a-b). 
As the significant group x response accuracy may have been driven by group differences 
between correct and incorrect responses, we computed a difference scores between the BOLD 
signal for correct and incorrect responses and conducted a one-way ANOVA to delineate the 
effect of group. For the dlPFC and vlPFC, a main effect of group emerged (dlPFC: [F(2, 37) = 
3.45, p=0.04], vlPFC: [F(2,27)= 3.78, p=0.03]). For both regions, controls showed larger 
differences between correct and incorrect responses relative to the frontal group (dlPFC: control-
frontal mean difference= -0.25, p=0.01; vlPFC: control-frontal mean difference = -0.42, p=0.01). 
No differences were found between controls and the temporal group (dlPFC: control-temporal 
mean difference: -0.08, p=0.32; vlPFC: mean difference= -0.20, p=0.18), or between the frontal 
and temporal groups (dlPFC: frontal-temporal mean difference= 0.16, p=0.15; vlPFC: mean 
difference=0.2, p=0.22). 
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Figure 4.5: BOLD signal change across the control and atrophy groups during the feedback 
epoch 
 
Mean percent BOLD signal change during the feedback epoch within the right (a) dlPFC and (b) 
vlPFC during correct and incorrect trials. Error bars represent SEM. Asterisks indicate p<0.05. 
Post-hoc comparisons revealed that controls exhibited greater error-related BOLD activity 
relative to the frontal predominant atrophy group in the dlPFC (a) and vlPFC (b) for incorrect 
responses. For correct responses, patients with temporal atrophy exhibited greater activity 
relative to controls (b).  
 
 
4.5 Discussion 
Patients with FTD frequently engage in disinhibited and perseverative behaviours even 
when faced with negative feedback- whether social, legal or financial. Here we used reversal 
learning, a classic cognitive paradigm previously associated with such behaviours, to determine 
the functional pathophysiology leading to impaired reversal learning in patients with FTD. 
Reversal learning deficits have been previously shown to be correlated with behavioural 
problems in other populations [5]. We found that during a classic reversal learning paradigm, 
patients show reduced BOLD responses in the vlPFC and dlPFC. Furthermore, we also 
demonstrated differing BOLD responses to error feedback between patients with frontal versus 
temporal atrophy. These results extend the current knowledge of the underlying functional 
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deficits of behavioural flexibility in FTD and have implications for the selection of outcome 
markers and therapeutic targets for future clinical trials of symptomatic treatments.  
During choice selection, patients demonstrated reduced responding within the 
vlPFC/insula to acquisition errors and correct reversal trials. During reversal learning, the vlPFC 
is implicated in selecting among competing response options. Specifically, during instances of 
conflict, the anterior cingulate cortex increases the representation of stimulus-motor features 
within the vlPFC, which, in conjunction with the caudate, flexibly controls motor responses [6]. 
Following this model, enhanced vlPFC activity is predicted to occur during instances of response 
competition including response inhibition [12]. Enhanced vlPFC has been found for correct 
reversals during choice selection across early relearning trials [24]. Greater response competition 
and response inhibition may occur during early learning trials where stimulus-response 
associations are still being formed relative to later learning trials where these associations are 
more established [24]. The functional contributions of the vlPFC is consistent with the current 
results demonstrating enhanced activity in healthy controls during instances of response 
competition to an incorrect stimulus or a previously rewarded stimulus. Overall, the reduced 
BOLD activity in the vlPFC in patients suggests that during response competition, deficient 
inputs and/or processing within the vlPFC may result in impaired flexible motor control when 
selecting among several potential choice options.  
Impairments in response competition highlights a potential role for serotonergic 
modulation as a pharmacological target for reversal learning deficits in FTD. Hughes, et al. [25] 
showed that increasing serotonin in patients with bvFTD through the administration of an acute 
dose of citalopram, restored activity within the right inferior frontal gyrus as measured by MEG 
during response inhibition. Additionally, reducing the availability of serotonin through 
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tryptophan depletion significantly reduced right orbito-inferior prefrontal activity in healthy 
controls during an inhibitory motor control [26]. Based on the current study results and previous 
findings, it may be predicted that serotonin may augment neural activity within the vlPFC during 
response competition, which may reduce symptoms of disinhibition in patients. In fact, 
Herrmann, et al. [27] demonstrated that citalopram (serotonin reuptake inhibitor), was effective 
in treating behavioural symptoms including disinhibition, depression and irritability over a 6-
week period. Further work is needed to elucidate the possible interactions between the effects of 
serotonin on vlPFC, response inhibition and disinhibition, and determine the implications for 
other disorders that feature similar behavioural disinhibition.  
During errors in the choice phase, patients with FTD exhibited decreased activity relative 
to controls within a second region of PFC, specifically the dlPFC. Previous work has shown that 
within the dlPFC BOLD signal increases during instances of decision-making conflict including 
non-reversal errors, reversal errors and correct reversals [6,9,12]. One account suggests that 
during instances of decision conflict, the dmPFC/ACC engages the dlPFC to increase top-down 
attentional control of task-relevant features [28-31]. In these situations, increasing the salience of 
relevant task features may facilitate the detection of alternative cues to guide alternative 
behaviour [12,13]. Moreover, during response selection, the dlPFC (BA 9) demonstrates 
enhanced activity during early relative to late reversal trials [24]. This enhanced activity is 
consistent with the idea that the dlPFC is implicated in resolving decision conflict; for example, 
early reversal trials may place greater demands and greater conflict relative to later reversal trials 
wherein greater learning has taken place [24]. In patients with FTD, deficient inputs to the 
dlPFC, possibly from the dmPFC/ACC during instances of decision conflict (i.e. error feedback 
during the choice phase), may be associated with deficits in increasing attention to relevant 
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stimuli to resolve these conflicts and subsequently reverse a maladaptive response. Relative to 
healthy controls, patients with FTD are less averse to negative stimuli (e.g. unpleasant odour) 
and expend less effort to avoid negative stimuli [32]. Given these findings, it may be predicted 
that during decision-making, patients with FTD experience difficulties engaging to negatively 
valanced stimuli, such as error feedback, and therefore subsequent alternative motor responses 
are not generated. One potential intervention may include behavioural strategies that generate 
explicit consideration of various behavioural options and the key features to help guide optimal 
decision making. Another strategy may include increasing the salience of the negative 
information. For example, Kumfor, et al. [33] found that increasing the intensity of negative 
facial expressions improved emotion recognition performance in patients with bvFTD to a 
similar degree as controls.  
As potential deficient inputs to the dlPFC, possibly from the ACC during instances of 
decision conflict, understanding the neurochemical mechanisms underlying conflict monitoring 
within the ACC have important implications in pharmacological targets for behavioural 
symptoms in FTD. Some evidence suggests that dopaminergic mechanisms are involved. 
Increased dopamine transmission has been found within the ACC during performance of a set-
shifting task [34]. Additionally, elevated levels of dopamine via amphetamine administration, 
increases the error-related negativity (ERN) signal, an event-related potential originating within 
the ACC and is elicited after making an incorrect response [35]. Likewise, haloperidol 
(dopamine antagonist) attenuates the ERN signal [36]. Overall, these studies suggest 
dopaminergic involvement in the ACC during conflict monitoring and may suggest a potential 
avenue for pharmacological treatment in FTD. Importantly though, other research has suggested 
the involvement of other neurotransmitters during instances of conflict [37]. For example, 
 
 
104 
 
increasing the availability of norepinephrine amplifies the ERN signal during a flanker task [38]. 
Further work is needed to elucidate and extend the current knowledge of the roles of 
neurotransmitters involved in conflict monitoring within the ACC.  
 
4.5.1 Atrophy Patterns 
As the bulk of functional and lesion studies of reversal learning have implicated regions 
of prefrontal cortex in successful reversal learning performance, it was predicted that patients 
with frontal predominant atrophy would have greater neural and behavioural deficits during 
reversal learning relative to patients with temporal predominant atrophy and to controls. 
Behaviourally, patients with frontal predominant atrophy made more errors relative to healthy 
controls; no differences were found between patients with temporal atrophy and controls. 
Additionally, controls were found to exhibit greater BOLD activity relative to the frontal group 
for incorrect responses during the feedback stage within the dlPFC and vlPFC, while BOLD 
patterns were similar between controls and the temporal atrophy group.  
Patients with bvFTD and SD show distinct behavioural and neuropsychological profiles; 
however, both frontal and temporal lobe atrophy groups experience disinhibited symptoms 
[39,40]. Furthermore, recent work demonstrated associations between temporal predominant 
atrophy and perseverative and compulsive behaviours in patients with FTD [41]. Coupled with 
previous studies, our findings indicate that disinhibited behaviours in temporal predominant FTD 
may be due to distinct cognitive mechanisms than those associated with frontal predominant 
FTD. For instance, it has been proposed that disinhibited behaviours in semantic dementia may 
in part arise from disruptions in expressive and receptive vocabulary resulting in maintaining 
fixed and rigid routines and thinking patterns in an effort to maintain control and understanding 
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during daily experiences [40,42]. Patients with temporal predominant atrophy also demonstrate 
disinhibition that appears distinct from language or compulsions, such as inappropriate approach 
and overly personal disclosures to strangers. Such behaviours may reflect deterioration of the 
anterior temporal lobe and its connections and with orbitofrontal cortex. In contrast, disinhibited 
symptoms in the frontal group likely arise from disruptions primarily within the frontal cortex 
[4,43]. These potentially different cognitive mechanisms underlying disinhibited symptoms in 
the atrophy groups illustrate the potential need for different markers to index these mechanisms 
and therapeutic approaches.  
 
4.5.2 Behavioural Performance  
 Patients made more errors relative to controls during the acquisition and the reversal 
stage. Previous reversal learning studies in FTD populations included a learning criterion during 
the acquisition stage in which participants needed to reach prior to switching to the reversal stage 
[14,16,44]. In the current study no learning criterion was employed to ensure that participants 
had a similar number of acquisition and reversal trials for the fMRI analysis.  
 
4.5.3 Limitations 
Although all patients met the consensus criteria for probable or definite FTD, genetic or 
autopsy confirmation of frontotemporal dementia in this cohort has not been established for all 
patients; thus, patients with diseases other than FTLD may have been included in the study. 
Another potential limitation is the limited sample size within each of the atrophy subgroups. It is 
recognized that reversal learning is one of several tasks indexing behavioural flexibility; future 
studies utilizing other fMRI-adapted tasks are suggested in order to obtain a comprehensive 
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understanding of the neural deficits underlying behavioural flexibility and disinhibition in 
patients with FTD.  
 
4.5.4 Conclusion 
The current investigation provides insights into the regions related to inflexible decision 
making and responding in FTD. Patients with FTD and frontal predominant atrophy 
demonstrated deficits in learning and reversing stimulus-reinforcement contingencies with 
reduced BOLD activity in vlPFC/insula and dlPFC. Although patients with FTD with frontal 
predominant atrophy and temporal predominant atrophy exhibit similar caregiver-reported 
symptoms, our results indicate the neural mechanisms underlying these symptoms arise from 
different mechanisms. Future studies probing additional tasks of flexible behavioural responding 
and inhibition may further elucidate the neural regions and cognitive mechanisms underlying 
these behaviors in patients with temporal predominant atrophy and inform tailored therapeutic 
approaches.  
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Chapter 5: General Discussion 
5.1. Introduction 
FTD is a neurodegenerative disorder for which there is no known cure. Clinical trials for 
symptomatic and disease-modifying treatments are being developed, highlighting the importance 
identifying disease markers to (1) indicate when treatments should be administered (2) act as 
outcome markers to elucidate treatment efficacy, and (3) serve as potential targets for treatments 
or interventions. Given the current gaps in knowledge, the objective of this thesis is to elucidate 
elements of the pathophysiology of FTD from the preclinical to the symptomatic disease stage. 
The central hypothesis is that potential markers for clinical trial designs will be identified in 
preclinical and symptomatic patients with FTD. The results of this thesis support the central 
hypothesis and demonstrate that FTD-related changes occur prior to disease onset, and that 
functional neural deficits indexing FTD symptoms are detectable during the symptomatic disease 
stage. The current thesis identifies potential markers that may be used to evaluate the clinical 
effects of future therapeutic interventions and to identify possible targets for future treatments.  
Study I delineated the initial symptoms within each of the three most common mutation 
groups (C9orf72, GRN, MAPT) in symptomatic patients with FTD and in preclinical mutation 
carriers. Consistent with reports of symptomology during the course of the disease [1,2], 
symptomatic MAPT carriers frequently endorsed initial disinhibition and memory impairments, 
and symptomatic GRN carriers endorsed initial language-based symptoms most often. The 
second objective for study I was to examine whether preclinical mutation carriers demonstrated 
greater or unique behavioural/cognitive symptoms relative to biologically related non-mutation 
genetic carriers. At an average of 14 years prior to expected disease onset, preclinical MAPT 
carriers endorsed poorer mood and sleep symptoms, C9orf72 carriers exhibited greater abnormal 
behaviours, and GRN carriers exhibited better mood relative to non-carriers. Over time, GRN 
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carriers exhibited poorer everyday skills relative to mutation non-carriers. These findings 
confirm our predictions that the initial symptoms occurring at the onset of FTD vary between 
and within genetic mutation groups, and that preclinical mutation carriers demonstrate aberrant 
behavioural/cognitive functioning prior to disease onset that is distinct from the initial symptoms 
that mark the start of clinical FTD.  
In addition to behavioural and cognitive changes occurring during the preclinical period 
of FTD, study II found that preclinical mutation carriers exhibited larger ventricular volumes (i.e. 
greater atrophy), compared to biologically related mutation non-carriers beginning four years 
prior to expected disease onset. In contrast to the previous study’s findings, no specific gene 
mutation patterns were found. These results provide further evidence that pathological 
neuroanatomical changes begin and are detectable in the preclinical period, prior to disease 
onset.  
As disinhibition and poor behaviour flexibility is one of the earliest and debilitating 
symptoms in FTD, study III aimed to delineate the functional neural correlates underlying these 
symptoms. The current study found that during a decision-making task, patients exhibited 
reduced functional activity within the vlPFC and dlPFC as they selected between two choice 
options. These neural regions have been implicated during the initiation of motor responses to 
adjust current behaviour and increasing attention to task relevant stimuli [3,4]. Moreover, we 
also found that patients with frontal relative to temporal predominant atrophy demonstrated 
different patterns of neural activity relative to controls when receiving error-related feedback. 
These results demonstrate that patients with FTD exhibit aberrant neural functioning relative to 
healthy controls during a reversal learning task. Furthermore, these results also suggest that 
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different cognitive mechanisms may underlie disinhibition and behaviour flexibility in patients 
with frontal and temporal lobe atrophy patterns.  
 
5.2 Preclinical Disease Period: The Need for Biomarkers 
 
5.2.1 The Applicability of Biomarkers 
Ideally, disease modifying treatments should be administered during the preclinical or 
prodromal stage of the disease, prior to the occurrence of irreversible neuronal dysfunction or 
loss. This highlights the needs for the identification of biomarkers during the earliest stage of the 
disease to evaluate the clinical effects of treatments and to indicate when treatments should be 
initiated [5]. Specifically, assessing at-risk individuals from families with genetic FTD is the 
ideal cohort to evaluate disease progression from the preclinical period to the symptomatic 
disease stage [6]. The results of Study I and Study II illustrate that FTD-related changes occur at 
the behavioural and neuroanatomical level beginning at an average of 14 years prior to expected 
disease onset in carriers of a pathogenic mutation. Similar to other neurodegenerative diseases 
[7,8], the pathophysiological mechanisms of FTD begin prior to the emergence of clinical 
symptoms, and thus, provides an opportunity for therapeutic treatments to intervene.  
 
5.2.2 Preclinical Changes in Behaviour and Cognition 
Recent evidence indicates that FTD-related changes in behavioural and cognition emerge 
and can be detected during the preclinical disease period. Relative to mutation non-carriers, 
MAPT and GRN preclinical carriers exhibit declines in various aspects of cognition including 
memory, language, and social cognition, starting eight years prior to expected disease onset [9]. 
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As well, asymptomatic C9orf72 carriers demonstrate impaired gestural praxis abilities 25 years 
prior to disease onset [10]. Although symptom characteristics have been compared across the 
main mutation groups in patients [1,11], gene-specific symptoms during the preclinical and 
prodromal disease period have not been investigated. This knowledge can potentially inform the 
selection of outcome measures to evaluate the effectiveness of treatments targeting specific 
mutations or pathologies, or basket-design trials where common symptoms arising from different 
pathologies are grouped together. Furthermore, previous work was limited to assessing 
symptoms based on aspects of cognition and broad neuropsychiatric functioning. Given these 
limitations, study I expanded the current knowledge by evaluating the frequency and type of 
symptoms that occur in genetically at-risk individuals using a comprehensive list of FTD-related 
symptoms across various domains (e.g. behaviour, language, cognitive, psychiatric, motor). At 
an average of 14 years prior to expected disease onset, MAPT preclinical mutation carriers 
endorsing worse sleep, mood and motivation, C9orf72 carriers endorsed greater abnormal 
behaviours and stereotypic/motor symptoms, and GRN carriers endorsed better mood. 
Additionally, over time, GRN preclinical mutation carriers demonstrated worse everyday skills 
which involve a range of cognitive features (e.g. difficulty using electrical appliances, difficulty 
writing, difficulty making a hot drink, problems managing finances). The results of study I 
coincide with the previous literature demonstrating that disease related alterations emerge and 
can be detected early during the preclinical disease period, and that gene-specific pathological 
processes begin prior to disease onset. We expanded previous work by detecting disease-related 
alterations using questionnaire measures which offers a pragmatic method that can be readily 
employed in clinical trials to evaluate disease onset and progression. Furthermore, we illustrate 
behavioural and cognitive differences between the preclinical and non-mutation carriers several 
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years earlier than previously reported. Therefore, we suggest that measures assessing these gene-
specific symptoms (MAPT: sleep, mood, motivation; C9orf72: abnormal behaviours, 
stereotypic/motor symptoms; GRN: mood and everyday skills), may be used as outcome 
measures in future clinical trials to evaluate the effectiveness of treatments. 
Although we found that preclinical mutation carriers exhibited specific symptoms prior to 
disease onset, the frequency of the most common initial symptoms endorsed by affected patients 
(apathy, disinhibition, memory impairments, decreased fluency and impaired articulation), were 
found to be similar across preclinical mutation carriers and non-carriers. These results may 
suggest that specific symptoms may emerge just prior to or at disease onset. Similarly, during a 
four-year follow-up, Jiskoot, et al. [12] found that preclinical MAPT and GRN carriers who 
remained asymptomatic during the study period (“non-converters”), exhibited similar global 
cognitive functioning and neuropsychiatric features relative to non-carriers. Importantly, 
mutation carriers who “converted” during the follow-up period exhibited poorer cognitive and 
neuropsychiatric functioning relative to non-convertors and non-carriers. The results of study I 
raise an intriguing possibility that other symptoms are present during the preclinical period 
which may differ than the symptoms that emerge at disease onset. Nevertheless, these preclinical 
symptoms will be important to assess treatment efficacy during the preclinical period and to aid 
in the selection of targets for potential symptomatic treatments.  
 
5.2.3 Preclinical Changes using Neuroimaging 
Recent evidence has detected pathogenic alterations in brain structure during the 
asymptomatic disease stage. Investigations of genetically at-risk families have shown different 
cortical involvement within each of the common FTD-related mutations. For example, MAPT 
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carriers demonstrate early involvement of the anterior/medial temporal lobes; C9orf72 carriers 
show a diffuse pattern of atrophy including subcortical regions of the hippocampus, thalamus 
and cerebellum; in GRN carriers, studies often report inconsistent results with only some studies 
finding structural changes during the preclinical disease period [13].  
 Ventricular volume has been proposed as a potential biomarker to index neuronal 
atrophy. Relative to grey matter volume, the contrasting intensity between the ventricle and 
surrounding tissue, makes the assessment of ventricular volume an efficient tool to be quantified 
with visual scales and automatic segmentation software [14]. Furthermore, the ventricles are less 
susceptible to scanner inhomogeneities as they located within the center of the brain and the 
magnet’s isocenter [14,15]. Consequently, it has been proposed that ventricular volume 
measurements may be less variable relative to whole brain volumes and have more statistical 
power to detect changes over time [15]. Several studies have reported greater ventricular volume 
(i.e. greater neuronal loss) in patients with FTD, across the different phenotypes and genotypes, 
relative to healthy controls [16,17]. Although ventricular volume measurements have been 
considered in symptomatic patients, this measure has yet to be explored in genetically at-risk 
family individuals. Due to the methodological advantages, measurement of ventricular volume 
may offer an efficient tool to assess neurodegenerative changes during the preclinical disease 
period. Study II addressed this knowledge gap by examining ventricular volume in asymptomatic 
carriers of C9orf72, GRN or MAPT mutations relative to biologically related non-carriers. 
Critically, we found that beginning four years prior to expected disease onset, preclinical 
mutation carriers demonstrated greater ventricular volumes relative to non-carriers. Furthermore, 
supporting the proposed methodological advantages of ventricular volume segmentations, we 
found that results produced by a fully automated segmentation software were comparable to the 
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results completed using time-sensitive manual edits. Overall, these findings illustrate that 
measurements of ventricular volume are a robust tool to assess structural alterations during the 
preclinical disease period.  
In contrast to previous literature [13], we did not find differences between genotypes in 
the total ventricular volume or between left and right ventricular volumes. We did not observe 
differences between genetic groups in the laterality index (absolute value between the left and 
right ventricles), which is in contrast to the predicted asymmetry atrophy pattern found in GRN 
mutation carriers [1]. One possibility may be that differences in neuronal loss across genotypes, 
particularly for GRN mutation carriers, may be detected just prior to or at disease onset. For 
example, Jiskoot, Panman, Meeter, Dopper, Donker Kaat, Franzen, van der Ende, van Minkelen, 
Rombouts, Papma and van Swieten [12] found that starting two years prior to disease onset, 
preclinical MAPT and GRN mutation carriers who “converted” into the symptomatic disease 
stage, exhibited lower grey matter volumes within regions of the frontal and temporal cortex, 
relative to preclinical non-convertors; structural changes were absent for preclinical carriers who 
remained asymptomatic during the study period.  
As alterations in cortical/subcortical volumes and cortical thickness have been detected 
earlier than four years prior to disease onset, we suggest that assessments of grey matter volumes 
may be used to track disease progression and/or be used as outcome measures to assess treatment 
efficacy [10,18-20]. Additionally, other neuroimaging modalities including assessing white 
matter integrity reveal FTD-related alterations early during the preclinical disease period [6,21]. 
For example, Jiskoot, et al. [22] detected white matter integrity changes 30 years prior to 
expected disease onset in preclinical C9orf72 and MAPT carriers. Additionally, studies assessing 
GRN and MAPT carriers detected structural and functional connectivity changes in the absence 
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of grey matter alterations [23,24]. As well, Feis, et al. [25] differentiated preclinical C9orf72, 
GRN and MAPT carriers from non-carriers using a multimodal MRI-based classification system 
that encompassed measures of radial diffusivity and white matter density. Although the authors 
assessed anatomical MRI, DTI and resting-state functional MRI in their classification system, the 
best performing classification model included only aspects of white matter integrity, supporting 
the notion that white matter alterations are an early marker of FTD pathology. While white 
matter changes have been reported earlier compared to ventricular volume changes, we suggest 
that given the relative ease, automaticity and reliability of ventricular volume measurements, in 
comparison to white matter analytic methods, direct comparisons of the sensitivity and 
specificity of ventricular volume to these other indices in clinical populations that may have 
more hetereogenous comorbidities and white matter changes would be valuable. Importantly, 
measures of ventricular volume, in addition to other neuroimaging modalities, may be applied as 
an outcome measure to assess the efficacy of disease-modifying treatments.  
 
5.3 Symptomatic Disease Period: Identifying treatment targets 
5.3.1 The Need for Treatment Targets 
Currently, there are no approved disease-modifying therapies that alter the course of the 
disease or prevent disease progression [26]; instead, off-label use of medications that alter 
neurotransmission has been used for symptom management with mixed success [27]. To further 
advance the development of symptomatic treatment, measurements that aid in the selection of 
promising therapeutic targets are warranted. 
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5.3.2 Potential Treatment Targets for Symptomatic Disease Period 
We found that across the genetic forms of FTD, the most common early symptoms were 
apathy, disinhibition, memory impairments, decreased fluency, and impaired articulation. Gene-
specific patterns also emerged, with C9orf72 and MAPT carriers endorsing disinhibition, apathy 
and memory symptoms most frequently, and GRN carriers endorsing apathy, impaired 
articulation and decreased fluency early during the disease. At present, there are no effective 
treatments for these initial symptoms in FTD. Relatedly, two key challenges in clinical trial 
design for FTD have been identified: (1) heterogeneity of clinical symptoms leading to 
difficulties in assessing treatment efficacy and (2) the rarity of FTD leading to recruitment 
challenges, which necessitate the need for biomarkers that can optimize treatment effects [28].  
 Recently, symptomatic treatment options for FTD have begun to consider the anatomical 
and functional neural deficits underlying FTD-related symptoms. A small number of studies 
have used functional imaging to delineate whether potential treatments modulate neural activity 
related to target symptoms. For example, based on previous work suggesting that the integrity of 
the inferior frontal gyrus and serotonin regulation is critical for appropriate response inhibition, 
Hughes, et al. [29] investigated whether increasing serotonin levels in patients with bvFTD 
restores neural responding within the inferior frontal gyrus during a response inhibition task. As 
well, it has been shown that oxytocin administered to patients with FTD modulates aberrant 
neural activity in brain regions related to empathy and emotional processing [30]. This work 
indicates potential implications for the results of Study III which assessed the neural correlates of 
behavioural flexibility in patients with FTD and healthy controls. Patients exhibited reduced 
functional activity within the vlPFC and dlPFC during the choice phase of the task, as they 
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selected between two different options. These neural regions have been implicated during the 
initiation of motor responses to adjust current behaviour and increasing attention of task relevant 
stimuli during error responses, respectively [3,4]. Potential interventions targeting the 
psychopharmacology contributions of these neural systems may be one avenue to augment 
neural responding within the vlPFC and dlPFC to ameliorate these symptoms in FTD. For 
example, increasing levels of serotonin has been found to enhance neural responding within the 
right inferior frontal gyrus which is associated with response inhibition [29]. We also found that 
patients with frontal relative to temporal predominant atrophy exhibited different neural 
responding when they received error-related feedback. Relative to controls, patients with frontal 
lobe atrophy demonstrated lower neural activity to error-feedback; no differences emerged 
between the control and temporal atrophy group, or between the frontal and temporal atrophy 
group. These results suggest that different cognitive mechanisms underlie impaired disinhibition 
and behavioural flexibility in the frontal and temporal patient groups, which may necessitate 
different therapeutic targets. Furthermore, changes in the neural activity in the vlPFC and dlPFC 
during reversal learning may be used as an outcome marker in proof of concept challenge studies 
and brief clinical trials to identify the potential of treatments targeting poor behavioural 
flexibility. 
 
5.4 Limitations and Future Directions 
The current thesis provides novel insights into the preclinical and symptomatic period of 
frontotemporal dementia that have implications for future clinical trial designs; however, certain 
limitations need to be addressed. Consistent with previous studies assessing preclinical changes 
in genetically at-risk family members of patients [31], the predicted age at disease onset for 
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preclinical mutation carriers was calculated using the mean age at disease onset within the 
participant’s family for Study I and Study II. Although patient’s age at disease onset is 
significantly correlated with the mean familial age at disease onset [31], there is a high 
variability in the contribution of family membership to predicted age of onset by mutation group 
[32]. Given these results, in study I and study II sensitivity analyses were conducted substituting 
the calculated age at expected disease onset for the participants current age, which yielded 
similar results. The continuation of longitudinal data collection in preclinical mutation carriers 
will be helpful to predict the age of clinical symptom occurrence. For example, Jiskoot, Panman, 
van Asseldonk, Franzen, Meeter, Donker Kaat, van der Ende, Dopper, Timman, van Minkelen, 
van Swieten, van den Berg and Papma [11] longitudinally followed preclinical mutation carriers 
who became symptomatic within the study window (i.e. convertors), and thus was able to 
determine the age in which these individuals became symptomatic. The continuation of 
longitudinal data collection from large FTD cohorts including GENFI, LEFTDS and ARTFL 
will be helpful in predicting more precise expected age at disease onset for preclinical mutation 
carriers and further improving the modeling of these symptoms and imaging markers.   
 As study I and study II examined differences in preclinical mutation carriers and 
biologically related non-mutation carriers, we were not able to examine the preclinical period in 
individuals with sporadic FTD. Examining preclinical autosomal dominant FTD gene mutation 
carriers provide a unique insight into the behavioural and neuroanatomical changes that lead to 
the conversion from the asymptomatic to the symptomatic disease stage [28]. Importantly 
though, the results from the genetically at-risk studies will provide new insights into the potential 
earliest changes in sporadic FTD [28].  
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 Another limitation in Study II is the lack of knowledge of which genetically at-risk 
individuals were aware of their genetic status (carrier vs. non-carrier), which may impact their 
own and their informant’s perspective on and reporting of cognitive and behavioural symptoms. 
Future studies using genetically at-risk participants should examine how one’s awareness of their 
genetic status influences the presence and severity of FTD-related symptoms during the 
preclinical period.  
 Across all three studies, the FTD related changes in the potential markers were 
demonstrated at the group level; however, prior to their applicability for clinical trials, these 
potential markers will need to be validated at the individual level for at-risk and symptomatic 
patients. The continuation of multicenter research with large cohorts will be an asset for future 
validation at the individual level [6].  
 Lastly, as FTD is a heterogeneous disorder, the combination of different biomarkers may 
provide additive predictors of early deficits and allow accurate tracking of disease progression 
and severity. Future research should focus on the multimodal combination of different 
biomarkers (i.e. neuroimaging, behavioural and fluid markers) to further our knowledge on 
disease onset and monitoring disease progression and treatment response [6].  
 
5.5 Conclusion  
In conclusion, FTD is a debilitating disorder that leads to great societal, patient and 
caregiver burden. The heterogeneity of clinical symptoms and the rarity of FTD disorders leads 
to recruitment challenges and conveys the need for appropriate markers that can efficiently 
detect treatment effects [28]. Additionally, markers of preclinical changes may aid in the 
selection of potential targets for treatments and help determine when treatments (disease-
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modifying or symptomatic), should be initiated. The current thesis provides novel insights into 
behavioural and neuroanatomical changes during the preclinical disease stage and functional 
neural deficits underlying behavioural difficulties during the symptomatic disease stage.  
Using a large cohort of preclinical mutation carriers and biologically related non-
mutation carriers, we found that mutation carriers endorsed greater symptomology during the 
preclinical period relative to non-carriers. Measures of these specific symptoms may be used to 
select treatment targets and as outcome measures to evaluate the effectiveness of treatments in 
future clinical trials. Furthermore, we found that preclinical mutation carriers exhibited greater 
ventricular volumes relative to non-carriers beginning four years prior to disease onset. 
Quantification of total ventricular volume may be applied in clinical trials to assess whether 
disease-modifying treatments slow down the progression of the disease during the preclinical 
stages. Lastly, we found that symptomatic patients exhibited altered neural activity within the 
vlPFC and dlPFC during choice selection in a decision-making task indexing behavioural 
flexibility. These neural changes may be used in proof of concept clinical trials to investigate 
symptomatic treatment effects on these altered neural regions.  
Ongoing longitudinal investigations assessing symptomatic mutation carriers and 
genetically at-risk mutation carriers will be instrumental in increasing our understanding of the 
biology of FTD from the preclinical, prodromal and affected disease stages. These findings may 
be applied to future clinical trial designs to help assess the efficacy of treatments and to 
determine potential symptomatic treatment targets. 
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Appendix A: Chapter 2 (Study 1) Supplementary Material 
Method Section 1.0: GENFI Symptom Domains and Descriptions 
Based on novel findings in the FTD literature, 31 additional symptoms, as indicated by an 
asterisk, were included in March 2015 (modified symptom listed below). This symptom list was 
based on and adapted from a consortium of validated scales including the Clinical Dementia 
Rating Scale (CDR [1]; FTLD-CDR [2], Social Impairment Rating Scale [3], Neuropsychiatric 
Inventory [4], Frontal Behavioural Inventory [5], Progressive Aphasia Severity Scale [6], 
Progressive Supranuclear Palsy Rating Scale [7], and Autonomic Symptoms Questionnaire (used 
in [8]. Further information can be gathered from the GENFI assessment manuals; see 
http://genfi.org.uk/. 
 
Behaviour Symptoms 
(1) Disinhibition 
(2) Apathy 
(3) Loss of sympathy/empathy 
(4) Ritualistic/compulsive behaviour 
(5) Hyperorality and appetite changes 
(6) Poor response to social/emotional cues* 
(7) Inappropriate trusting behaviour* 
 
Neuropsychiatric Symptoms 
(1) Visual hallucinations 
(2) Auditory hallucinations 
(3) Tactile hallucinations 
(4) Delusions 
(5) Depression 
(6) Anxiety 
(7) Irritability/Lability* 
(8) Agitation/Aggression* 
(9) Euphoria/Elation* 
(10) Aberrant motor behaviour* 
(11) Hypersexuality* 
(12) Hyperreligiosity* 
(13) Impaired sleep* 
(14) Altered sense of humour* 
Language Symptoms 
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(1) Impaired articulation 
(2) Decreased fluency 
(3) Impaired grammar/syntax 
(4) Impaired word retrieval 
(5) Impaired speech repetition 
(6) Impaired sentence comprehension 
(7) Impaired single word comprehension 
(8) Dyslexia 
(9) Dysgraphia 
(10) Impaired functional communication 
 
Cognitive Symptoms 
(1) Memory impairment 
(2) Impaired orientation* 
(3) Impaired judgement/problem-solving 
(4) Problems with community affairs* 
(5) Problems at home or with hobbies* 
(6) Impaired personal care* 
(7) Person recognition difficulty* 
(8) Impaired topographical memory* 
(9) Visuo-spatial or perceptual impairment 
(10) Impaired attention/concentration 
(11) Bradyphrenia* 
 
Motor Symptoms 
(1) Dysarthria 
(2) Dysphagia 
(3) Tremor 
(4) Slowness 
(5) Weakness 
(6) Gait disorder 
(7) Falls 
(8) Functional difficulties using hands* 
 
Autonomic Symptoms 
(1) Impaired blood pressure* 
(2) Gastrointestinal symptoms* 
(3) Impaired thermoregulation* 
(4) Urinary symptoms* 
(5) Altered responsiveness to pain* 
 
 
 
 
Other Physical Symptoms 
(1) Altered perception of sounds or music* 
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(2) Altered perception of smell or taste* 
(3) Persistent unexplained physical symptoms* 
(4) Impaired breathing* 
 
Clinical Features 
(1) Seizures 
(2) Stroke or TIA 
(3) Traumatic brain injury 
(4) Hypertension 
(5) Hypercholesterolaemia 
(6) Diabetes mellitus 
(7) Smoking* 
(8) Excess alcohol use* 
(9) Recreational drug use* 
(10) Autoimmune disease* 
 
 
 
Result Section 2.0: Analysis of symptom endorsement in symptomatic patients who 
completed the different versions of the GENFI symptom list 
 
Summary of Results 
As only a single initial symptom was selected for the symptomatic patients, we first 
investigated whether a different pattern of results was reported for symptomatic patients who 
used the original vs. modified GENFI symptom list (which included more symptom options), by 
evaluating the pattern of symptom endorsement at baseline in both version groups (Table B.1, 
B.2 and see detailed description of analysis below). Across the symptomatic cohort, the most 
frequent symptoms within each list were items that were present in both versions of the GENFI 
symptom list: disinhibition, apathy, decreased fluency, memory impairment, impaired 
articulation and impaired word retrieval. Thus, subsequently, data from both cohorts for the main 
analysis were combined. 
 
Analysis 
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Of the symptomatic patients, 76 completed the original and 109 completed the modified 
GENFI symptom list. Disinhibition (Original: 38.8%; Modified: 4.6), apathy (Original: 28.9%; 
Modified: 19.3%), decreased fluency (Original: 7.9; Modified: 8.3%), impaired articulation 
(Original: 5.3%; Modified: 5.5%), memory impairment (Original: 5.3%; Modified: 16.5%) were 
the most commonly endorsed symptoms in both cohorts. Of note, 5.3% of the “original cohort” 
endorsed impaired word retrieval. Chi-squared tests or Fisher’s exact tests were completed on 
each cohort to examine differences in symptom endorsement between the genetic groups.  
 
Original Cohort: A greater proportion of MAPT carriers endorsed disinhibition relative to 
C9orf72 and GRN carriers (X2=11.1, p=0.004). Additionally, only GRN carriers endorsed 
impaired articulation (no C9orf72 and MAPT carriers endorsed impaired articulation, though this 
contrast was only significant for C9orf72 carriers [p=0.01, Fisher’s]). No differences were found 
for apathy (X2=2.2, p=0.3), decreased fluency (p=0.47, Fisher’s), and memory impairment 
(p=0.27, Fisher’s). 
 
Modified Cohort: A greater proportion of MAPT carriers endorsed disinhibition (p=0.03, 
Fisher’s) and memory impairments (p=0.04, Fisher’s) more often than C9orf72 and GRN 
carriers. Furthermore, GRN carriers endorsed decreased fluency more frequently relative to 
C9orf72 and MAPT carriers (p<0.001, Fisher’s). No differences were found for apathy (p=1.0, 
Fisher’s) and impaired articulation (p=0.09, Fisher’s).  
 
Overall, the pattern of results across both cohorts were similar; both groups displayed the 
same predominant symptoms, and similar differences between the mutation groups. Although no 
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significant group differences were found for impaired articulation in the “modified cohort,” both 
“original” and “modified” cohorts demonstrated analogous pattern of results in which GRN 
carriers showed the highest endorsement (Original: C9orf72=0, GRN=~17%, MAPT=0; 
Modified: C9orf72: 2%, GRN=12%, MAPT=0). Additionally, in the “modified cohort”, memory 
impairments occurred more frequently amongst the MAPT carriers and GRN carriers endorsed 
decreased fluency most often. Different disease subtypes (Table A.1b) and increased samples 
size in the “modified cohort” (Original: N=76, Modified: N=109) and thus greater 
recruiting/testing sites and families, may have contributed to these slight differences. Importantly 
however, the inclusion of additional symptoms in the modified list did not detract reporting of 
symptoms found only in the original version.  
 
Potential Limitation 
Minor discrepancies in symptom endorsement reported in each version may be the result 
of varying sample sizes, differing proportions of FTLD sub-types, and re-categorization of 
symptoms from the original list into more specific symptoms in the modified list (e.g. including 
“poor response to social/emotional cues” and “inappropriate trusting behaviour” in the modified 
list may have been categorized as “disinhibition” in the original list). Importantly though, the 
inclusion of additional symptoms in the modified symptom list did not detract reporting of 
symptoms found only in the original version.  
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Method Section 3.0: Analysis for CBI-R change score 
To improve the distribution of the residuals we attempted several statistical methods (see 
below). As the results of the total CBI-R change score were similar across these various 
techniques, we reported the results from the linear mixed model in the manuscript.  
 
1. To improve the distribution of the residuals in the linear mixed model we included an 
additional fixed effect (gender) and weighted family membership. These additional 
predictors did not improve model fit and thus were not included in the current analysis to 
maintain a parsimonious model.  
2. Additionally, we binned the change score into distinct categories (scores 0 or below were 
categorized as one group, and the remaining scores were grouped based on 20% 
intervals). Using these categories, we ran a general linear mixed model with 
multinominal distribution, and a zero inflated model with a random effect. None of these 
models ran successfully.  
3. Using the 6 groups from above, we ran an ordinal regression (with random effects) but 
this model did not meet the assumption of proportionality. As well, we ran a logistic 
regression comparing each group to a reference group (no change or improvement in 
symptoms); the residuals did not improve.  
4. Subsequently, we categorized the change score into two groups (group 1= participants 
whose symptoms deteriorated over time, group 2= participants who symptoms improved 
or did no change over time) and ran a general linear mixed model with a binary 
distribution and random effects. The residuals did not improve.  
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Table A.1 Symptom endorsement (%) for symptomatic patients who completed the different versions of the GENFI Symptom List  
 
 Original GENFI symptom list GENFI modified GENFI symptom list 
 Total 
(N=76) 
C9orF72 
(N=34) 
GRN 
(N=24) 
MAPT 
(N=18) 
Total 
(N=109) 
C9orF72 
(N=53) 
GRN 
(N=41) 
MAPT 
(N=15) 
Behavioural         
Disinhibition 36.8 35.3 16.7 66.7 4.6 1.9 2.4 20.0 
Apathy 28.9 29.4 37.5 16.7 19.3 18.9 19.5 20.0 
Loss of 
sympathy/emp
athy 
1.3 2.9 0.0 0.0 1.8 0.0 4.9 0.0 
Ritualistic/co
mpulsive 
behaviour 
1.3 2.9 0.0 0.0 0.9 1.9 0.0 0.0 
Hyperorality 
and appetite 
changes 
1.3 0.0 4.2 0.0 1.8 3.8 0.0 0.0 
Poor response 
to 
social/emotion
al cues** 
    0.9 1.9 0.0 0.0 
Inappropriate 
trusting 
behaviour** 
    0.9 1.9 0.0 0.0 
Neuropsychiat
ric 
        
Visual 
hallucinations 
1.3 2.9 0.0 0.0 0.9 1.9 0.0 0.0 
Auditory 
hallucinations 
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Tactile 
hallucinations 
0.0 0.0 0.0 0.0 0.9 1.9 0.0 0.0 
Delusions 0.0 0.0 0.0 0.0 1.8 1.9 2.4 0.0 
Depression 2.6 0.0 8.3 0.0 3.7 3.8 2.4 6.7 
Anxiety 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Irritability/La
bility** 
    0.9 1.9 0.0 0.0 
Agitation/Agg
ression** 
    0.0 0.0 0.0 0.0 
Euphoria/Elat
ion** 
    0.0 0.0 0.0 0.0 
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 Original GENFI symptom list GENFI modified GENFI symptom list 
 Total 
(N=76) 
C9orF72 
(N=34) 
GRN 
(N=24) 
MAPT 
(N=18) 
Total 
(N=109) 
C9orF72 
(N=53) 
GRN 
(N=41) 
MAPT 
(N=15) 
Aberrant 
motor 
behaviour** 
    0.0 0.0 0.0 0.0 
Hypersexualit
y** 
    0.0 0.0 0.0 0.0 
Hyperreligiosi
ty** 
    0.0 0.0 0.0 0.0 
Impaired 
sleep** 
    0.0 0.0 0.0 0.0 
Altered sense 
of humour** 
    0.9 1.9 0.0 0.0 
Language         
Impaired 
articulation 
5.3 0.0 16.7 0.0 5.5 1.9 12.2 0.0 
Decreased 
fluency 
7.9 11.8 8.3 0.0 8.3 0.0 22.0 0.0 
Impaired 
grammar/synt
ax 
0.0 0.0 0.0 0.0 1.8 0.0 4.9 0.0 
Impaired 
word retrieval 
5.3 5.9 8.3 0.0 3.7 3.8 4.9 0.0 
Impaired 
speech 
repetition 
0.0 0.0 0.0 0.0 0.9 1.9 0.0 0.0 
Impaired 
sentence 
comprehensio
n 
0.0 0.0 0.0 0.0 1.8 0.0 4.9 0.0 
Impaired 
single word 
comprehensio
n 
0.0 0.0 0.0 0.0 0.9 1.9 0.0 0.0 
Dyslexia 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Dysgraphia 0.0 0.0 0.0 0.0 1.8 1.9 2.4 0.0 
Impaired 
functional 
communicatio
n 
1.3 0.0 0.0 5.6 0.9 1.9 0.0 0.0 
Cognitive         
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 Original GENFI symptom list GENFI modified GENFI symptom list 
 Total 
(N=76) 
C9orF72 
(N=34) 
GRN 
(N=24) 
MAPT 
(N=18) 
Total 
(N=109) 
C9orF72 
(N=53) 
GRN 
(N=41) 
MAPT 
(N=15) 
Memory 
Impairment 
5.3 5.9 0.0 11.1 16.5 15.1 9.8 40.0 
Impaired 
judgement/pr
oblem solving 
1.3 2.9 0.0 0.0 3.7 3.8 2.4 6.7 
Visuo-spatial 
or perceptual 
impairment 
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Impaired 
attention/conc
entration 
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Impaired 
Orientation** 
    
2.8 
 
1.9 
4.9 
 
0.0 
 
Problems with 
community 
affairs** 
    0.9 1.9 0.0 0.0 
Problems at 
home or with 
hobbies** 
    0.0 0.0 0.0 0.0 
Impaired 
personal 
care** 
    0.0 0.0 0.0 0.0 
Person 
recognition 
difficulty** 
    0.0 0.0 0.0 0.0 
Impaired 
topographical 
memory** 
    0.0 0.0 0.0 0.0 
Bradyphrenia
** 
    0.0 0.0 0.0 0.0 
Motor         
Dysarthria 0.0 0.0 0.0 0.0 0.9 1.9 0.0 0.0 
Dysphagia 0.0 0.0 0.0 0.0 0.9 1.9 0.0 0.0 
Tremor 0.0 0.0 0.0 0.0 0.9 1.9 0.0 0.0 
Slowness 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Weakness 0.0 0.0 0.0 0.0 3.7 7.5 0.0 0.0 
Gait disorder 0.0 0.0 0.0 0.0 1.8 3.8 0.0 0.0 
Falls 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
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 Original GENFI symptom list GENFI modified GENFI symptom list 
 Total 
(N=76) 
C9orF72 
(N=34) 
GRN 
(N=24) 
MAPT 
(N=18) 
Total 
(N=109) 
C9orF72 
(N=53) 
GRN 
(N=41) 
MAPT 
(N=15) 
Functional 
Difficulties 
using hands** 
    2.8 3.8 0.0 6.7 
Autonomic         
Impaired 
blood 
pressure** 
    0.0 0.0 0.0 0.0 
Gastrointestin
al 
symptoms** 
    0.0 0.0 0.0 0.0 
Impaired 
thermoregulat
ion** 
    0.0 0.0 0.0 0.0 
Urinary 
symptoms** 
    0.0 0.0 0.0 0.0 
Altered 
responsiveness 
to pain** 
    0.0 0.0 0.0 0.0 
Other 
Physical 
        
Altered 
perception to 
sounds or 
music** 
    0.0 0.0 0.0 0.0 
Altered 
perception of 
smell or 
taste** 
    0.0 0.0 0.0 0.0 
Persistent 
unexplained 
physical 
symptoms** 
    0.0 0.0 0.0 0.0 
Impaired 
breathing** 
    0.0 0.0 0.0 0.0 
Other 
Disorders 
        
Seizures 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Stroke or TIA 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Traumatic 
brain injury 
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
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 Original GENFI symptom list GENFI modified GENFI symptom list 
 Total 
(N=76) 
C9orF72 
(N=34) 
GRN 
(N=24) 
MAPT 
(N=18) 
Total 
(N=109) 
C9orF72 
(N=53) 
GRN 
(N=41) 
MAPT 
(N=15) 
Hypertension 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Hypercholeste
rolaemia 
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Diabetes 
mellitus 
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Smoking**     0.0 0.0 0.0 0.0 
Excess alcohol 
use** 
    0.0 0.0 0.0 0.0 
Recreational 
drug use** 
    0.0 0.0 0.0 0.0 
Autoimmune 
disease** 
    0.0 0.0 0.0 0.0 
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Table A.2 Demographic details for symptomatic patients completing different versions of the 
GENFI Symptom List  
 
 Original Symptom List Modified Symptom List 
N 76 109 
 
Genotype 
  
   C9orF72  34 53 
   GRN 24 41 
   MAPT 18 15 
 
Sex   
   Female 28 49 
   Male 48 60 
 
Handedness   
   Right 71 103 
   Left 5 4 
   Ambidextrous 0 2 
 
Diagnosis   
   Alzheimer’s Disease 1 0 
   ALS 0 6 
   Behavioural variant FTD 56 70 
   Corticobasal syndrome 1 2 
   Dementia-NOS 3 2 
   FTD-ALS 3 6 
   Other 0 2 
   Primary progressive aphasia 12 20 
   Progressive supranuclear palsy 0 1 
 
Total number of families 68 103 
 
Total number of sites 12 19 
 
Age (SD) 62.9 (8.2) 61.8 (8.8) 
 
Age of onset (SD) 58.3 (8.6) 57.9 (8.9) 
 
Education, Yrs (SD) 12.0 (4.3) 12.4 (3.7) 
ALS= Amyotrophic lateral sclerosis
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Table A.3. Baseline (N=588) and Change Score (N=336) for CBI-R Total Score with age 
substituted for Years to Expected Symptom Onset 
 
 Baseline#  Change Score  
 Estimate (95% CI) p-value Estimate (95% CI) p-value 
Pre-symptomatic 1.48 (0.57, 3.85) 0.42 1.76 (-0.92, 4.44) 0.2 
 
Age 1.02 (1, 1.03) 0.02 0.046 (0.01, 0.08) 0.01 
 
Baseline Score - - -0.15 (-0.21, -0.1) <.0001 
GS*Age 0.99 (0.97, 1.02) 0.63 -0.028 (-0.08, 0.03) 0.33 
 
 
Random Effects Estimate p-value   
Intercept (family) 1.36 <.0001 - - 
 
Scale 0.32 <.0001 - - 
 
Residual - - 10.12 <.0001 
• Statistics are from the Solution for Fixed Effects Table 
• #Baseline data was modeled with a negative binomial distribution with a log link function. 
Estimates and confidence intervals of fixed effects are exponentiated (base e) and indicate 
the incident rates. Estimates below 1 indicate an inverse relationship between the variable 
and outcome 
• GS= genetic status; CI=confidence interval; GS*age= genetic status by age interaction 
• For the main effect of genetic status and GS*age interaction= reference group are the non-
carriers 
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Table A.4. CBI-R total change score with outliers by genetic status and by genotype (N=342) 
 
 Genotype  
 Estimate (95% CI) p-value 
C9orf72 -1.98 (-4.24, 0.27) 0.08 
 
GRN 0.39 (-1.20, 1.99) 0.63 
 
MAPT -0.12 (-2.5, 2.28) 0.92 
 
YEO 0.06 (0.01, 0.11) 0.01 
 
Baseline score -0.16 (-0.23, -0.09) <.0001 
 
C9orf72*YEO -0.17 (-0.28, -0.05) 0.0062 
 
GRN*YEO -0.03 (-0.12, 0.07) 0.57 
 
MAPT*YEO -0.04 (-0.18, 0.11) 0.59 
 
Random Effects Estimate  p-value 
Family 0.51 0.30 
 
Residual 18.7 <0.001 
• Statistics are from the Solution for Fixed Effects Table 
• YEO= years from expected disease onset; CI=confidence interval 
• For the main effect of genotype and the genetic mutation*YEO interactions= reference 
group are the non-carriers 
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Table A.5: Symptom endorsement (%) in symptomatic patients and at-risk family members (GENFI symptom list) 
 
 Symptomatic Patients 
N=185 
 Preclinical 
N=317 
Non-carrier 
N=320 
 
 Total 
(N=185) 
C9orF72 
(N=87) 
GRN 
(N=65) 
MAPT 
(N=33) 
Group 
Contrasts 
Symptom 
Endorsement  
Symptom 
Endorsement 
Group Contrasts 
Behavioural         
Disinhibition 
17.8 14.9 7.7 45.5 
X2= 22.2, 
p<0.001 MAPT 
> C9orf72 & 
GRN 
3.5 1.9 
X2= 1.6, p=0.2 
Apathy 23.2 23.0 26.2 18.2 X2= 0.8, p=0.7 4.10 4.38 X2=0.9, p=1.0 
Loss of sympathy/empathy 1.6 1.1 3.1 0.0  2.52 1.88  
Ritualistic/compulsive 
behaviour 
1.1 2.3 0.0 0.0 
 
1.89 1.25 
 
Hyperorality and appetite 
changes 
1.6 2.3 1.5 0.0 
 
1.26 1.25 
 
Poor response to 
social/emotional cues** 
0.9 1.9 0.0 0.0 
 3.13 1.23  
Inappropriate trusting 
behaviour** 
0.9 1.9 0.0 0.0 
 3.65 0.61  
Neuropsychiatric         
Visual hallucinations 1.1 2.3 0.0 0.0  1.89 0.00  
Auditory hallucinations 0.0 0.0 0.0 0.0  0.32 1.25  
Tactile hallucinations 0.5 1.1 0.0 0.0  0.63 0.00  
Delusions 1.1 1.1 1.5 0.0  0.32 0.94  
Depression 3.2 2.3 4.6 3.0  14.20 13.75  
Anxiety 0.0 0.0 0.0 0.0  16.09 13.13  
Irritability/Lability** 0.9 1.9 0.0 0.0  11.98 14.11  
Agitation/Aggression** 0.0 0.0 0.0 0.0  5.21 3.68  
Euphoria/Elation** 0.0 0.0 0.0 0.0  2.60 0.61  
Aberrant motor behaviour** 0.0 0.0 0.0 0.0  3.13 0.61  
Hypersexuality** 0.0 0.0 0.0 0.0  0.52 0.0  
Hyperreligiosity** 0.0 0.0 0.0 0.0  1.04 0.0  
Impaired sleep** 0.0 0.0 0.0 0.0  14.58 12.27  
Altered sense of humour** 0.9 1.9 0.0 0.0  2.60 1.23  
Language         
Impaired articulation 5.4 
1.1 13.8 0.0 
p=0.001*# 
GRN > C9orf72 
& MAPT 
1.58 1.88 X2= 0.08, p=0.77 
Decreased fluency 8.1 
4.6 16.9 0.0 
p=0.005*# 
GRN > C9orf72 
& MAPT 
2.52 3.13 X2=0.21, p=0.65 
Impaired grammar/syntax 1.1 0.0 3.1 0.0  0.95 1.25  
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Impaired word retrieval 4.3 4.6 6.2 0.0  7.26 10.63  
Impaired speech repetition 0.5 1.1 0.0 0.0  0.00 0.31  
Impaired sentence 
comprehension 
1.1 
0.0 3.1 0.0 
 0.95 0.31  
Impaired single word 
comprehension 
0.5 
1.1 0.0 0.0 
 0.95 0.31  
Dyslexia 0.0 0.0 0.0 0.0  1.89 1.56  
Dysgraphia 1.1 1.1 1.5 0.0  1.26 2.50  
Impaired functional 
communication 
1.1 
1.1 0.0 3.0 
 0.63 0.31  
Cognitive         
Memory Impairment 11.9 11.5 6.2 24.2 p=0.46*# 10.41 12.50 X2= 0.69, p= 0.41 
Impaired judgement/problem 
solving 
2.7 
3.4 1.5 3.0 
 1.58 1.56  
Visuo-spatial or perceptual 
impairment 
0.0 0.0 0.0 0.0  0.95 0.31  
Impaired 
attention/concentration 
0.0 0.0 0.0 0.0  5.99 8.75  
Impaired Orientation** 2.8 1.9 4.9 0.0  2.08 0.0  
Problems with community 
affairs** 
0.9 1.9 0.0 0.0  1.04 0.6  
Problems at home or with 
hobbies** 
0.0 0.0 0.0 0.0  1.04 1.23  
Impaired personal care** 0.0 0.0 0.0 0.0  0.52 0.0  
Person recognition 
difficulty** 
0.0 0.0 0.0 0.0  1.04 3.07  
Impaired topographical 
memory** 
0.0 0.0 0.0 0.0  2.60 2.45  
Bradyphrenia** 0.0 0.0 0.0 0.0  2.60 3.68  
Motor         
Dysarthria 0.5 1.1 0.0 0.0  0.63 0.94  
Dysphagia 0.5 1.1 0.0 0.0  1.26 0.94  
Tremor 0.5 1.1 0.0 0.0  2.21 5.63  
Slowness 0.0 0.0 0.0 0.0  0.32 1.56  
Weakness 2.2 4.6 0.0 0.0  0.63 0.00  
Gait disorder 1.1 2.3 0.0 0.0  0.32 0.94  
Falls 0.0 0.0 0.0 0.0  0.00 0.63  
Functional Difficulties using 
hands** 
2.8 
3.8 0.0 6.7 
 1.0 0.0  
Autonomic         
Impaired blood pressure** 0.0 0.0 0.0 0.0  5.73 4.29  
Gastrointestinal symptoms** 0.0 0.0 0.0 0.0  2.60 5.52  
Impaired thermoregulation** 0.0 0.0 0.0 0.0  4.17 5.52  
Urinary symptoms** 0.0 0.0 0.0 0.0  4.69 4.29  
 
 
145 
 
Altered responsiveness to 
pain** 
0.0 0.0 0.0 0.0  1.04 1.84  
Other Physical         
Altered perception to sounds 
or music** 
0.0 0.0 0.0 0.0  0.52 1.84  
Altered perception of smell or 
taste** 
0.0 0.0 0.0 0.0  2.1 2.5  
Persistent unexplained 
physical symptoms** 
0.0 0.0 0.0 0.0  2.1 0.0  
Impaired breathing** 0.0 0.0 0.0 0.0  0.5 1.2  
Clinical Features         
Seizures 0.0 0.0 0.0 0.0  1.58 0.94  
Stroke or TIA 0.0 0.0 0.0 0.0  0.32 0.63  
Traumatic brain injury 0.0 0.0 0.0 0.0  9.46 11.56  
Hypertension 0.0 0.0 0.0 0.0  12.62 11.56  
Hypercholesterolaemia 0.0 0.0 0.0 0.0  9.78 11.56  
Diabetes mellitus 0.0 0.0 0.0 0.0  2.21 2.19  
Smoking** 0.0 0.0 0.0 0.0  27.08 34.97  
Excess alcohol use** 0.0 0.0 0.0 0.0  4.69 4.91  
Recreational drug use** 0.0 0.0 0.0 0.0  9.38 11.0  
Autoimmune disease** 0.0 0.0 0.0 0.0  5.73 6.75  
**Indicates sub-symptoms collected using the modified GENFI symptom list (Symptomatic: N=109; Preclinical=192, Non-carriers N=163) 
*#Fisher’s Exact Test was used as the expected count was less than 5 
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Table A.6. Initial symptoms of symptomatic patients from the same family 
 
Number of 
participants 
within each 
family 
Gene First symptoms reported Congruency 
Score (%) 
2 GRN apathy (n=1), fluency (n=1) 0 
2 GRN apathy (n=1) & fluency (n=1) 0 
2 GRN apathy (n=1) & articulation (n=1) 0 
3 GRN apathy (n=2) & memory impairment (n=1) 33 
5 
GRN apathy (n=1) & hyperorality and appetite change (n=1), 
depression (n=1) & articulation (n=2)  
10 
3 C9orf72 disinhibition (n=1) & depression (n=1) & tremor (n=1) 0 
2 C9orf72 apathy (n=1) & fluency (n=1) 0 
2 C9orf72 disinhibition (n=1) & memory impairment (n=1) 0 
2 C9orf72 depression (n=1) & memory impairment (n=1) 0 
2 MAPT apathy (n=1) & memory impairment (n=1) 0 
2 MAPT disinhibition (n=2) 100 
2 MAPT memory (n=2) 100 
3 
MAPT apathy (n=2) & impaired judgement/problem-solving 
(n=1) 
33 
3 MAPT disinhibition (n=2) & depression (n=1) 33 
The average congruency score across the cohort was 19%. This was calculated as the number of congruent 
combinations divided by the number of possible pairwise combinations  
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Table A.7. Initial symptoms of symptomatic patients with the same specific genotype 
 
Gene Gene Type Number of 
participants 
First Symptom Reported Congruen
cy Score 
(%) 
MAPT Q351R 2 memory impairment (n=2) 100 
MAPT G272V 3 disinhibition (n=2), depression (n=1) 33 
MAPT P301L 7 disinhibition (n=3), apathy (n=3), impaired judgement/problem 
solving (n=1) 
29 
MAPT R406W 7 disinhibition (n=3), apathy (n=1), memory impairment (n=3) 29 
MAPT IVS10+16 9 disinhibition (n=5), apathy (n=1), memory impairment (n=3) 36 
GRN C149fs 2 Disinhibition (n=1), impaired articulation (n=1)  0 
GRN G35fs 2 Apathy (n=1), decreased fluency (n=1) 0 
GRN Q130fs 
(388_391d
elCAGT) 
2 Apathy (n=1), impaired grammar/syntax (n=1) 0 
GRN C31fs 4 Apathy (n=1), loss of sympathy/empathy (n=1), impaired 
articulation (n=1), decreased fluency (n=1) 
0 
GRN S82fs 5 Apathy (n=1), hyperorality and appetite changes (n=1), 
depression (n=1), impaired articulation (n=2) 
10 
GRN IVS7-
1G>A 
8 Apathy (n=2), loss of sympathy/empathy (n=1), decreased 
fluency (n=1), impaired word retrieval (n=1), impaired 
sentence completion (n=1), memory impairment (n=2) 
7 
GRN T272fs 24 Disinhibition (n=1), apathy (n=10), impaired articulation 
(n=5), decreased fluency (n=4), impaired grammar/syntax 
(n=1), impaired word retrieval (n=1), dysgraphia (n=1), 
impaired judgement/problem solving (n=1) 
22 
The average congruency score was 33% for MAPT and 20 for GRN. This was calculated as the 
number of congruent combinations divided by the number of possible pairwise combinations  
 
 
148 
 
Table A.8. Baseline symptom endorsement on the GENFI symptom list (%) by gene mutation type in at-riskŧ 
family members 
 
 C9orf72 GRN MAPT 
 Preclinical 
(n=117) 
Non-
carrier 
(n=115) 
Contrast 
(test 
statistic, 
p-value) 
Preclinical 
(n=144) 
Non-
carrier 
(n=144) 
Contrast 
(test 
statistic, 
p-value) 
Preclinical 
(n=56) 
Non-
carrier 
(n=61) 
Contrast 
(test 
statistic, p-
value) 
Sub-symptoms*          
Disinhibition 6.0 1.7 0.17# 2.1 2.1 1.00# 1.8 1.6 1.00# 
Apathy 6.8 6.1 X2=0.05, 
p=0.82 
2.8 3.5 1.00# 1.8 3.3 1.00# 
Decreased fluency 1.7 6.1 0.10# 2.8 0.7 0.37# 3.6 3.3 1.00# 
Impaired 
articulation 
1.7 0.9 1.00# 1.4 3.5 0.44# 1.8 0 0.48# 
Memory 
impairment 
13.7 13.9 X2=0.002, 
p=0.96 
8.3 11.8 X2=0.96, 
p=0.33 
8.9 11.5 X2=0.21, 
p=0.65 
• *Reflects the sub-symptoms that were most frequently endorsed as “first symptoms” by symptomatic patients 
• # Fisher’s Exact Test was used as the expected count was less than 5 
• ŧ At-risk: preclinical carriers and non-carriers 
• No differences were found between the preclinical mutation groups (Disinhibition: Fisher’s Exact Test 
p=0.21; Apathy: Fisher’s Exact Test, p=0.23; Memory X2=2.14, p=0.4; Fluency: Fisher’s Exact Test p=0.64; 
Articulation : Fisher’s Exact Test p=1.0) 
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Table A.9. Symptom endorsement (%) between the first and final visit for at-risk individuals (GENFI symptom list) 
 
 Pre-symptomatic Mutation Carriers Non-carriers   
 Total 
(N=196) 
Mean time 
interval, 
Yrs (SD) 
Mean 
YEO 
(SD)# 
C9orf72 
(n=58) 
GRN 
(n=95) 
MAPT 
(n=43) 
Total 
(N=202) 
Mean time 
interval, 
Yrs (SD) 
Mean 
YEO 
(SD)# 
C9orf72 
(n=62) 
GRN 
(n=103) 
MAPT 
(n=37) 
Group 
Contrasts 
Genotyp
e 
Contrast
s 
Disinhibition               
No change 96.9 2.6 (1.3) 
Min: 0.8 
Max: 5.6 
-14.1 
(11.2) 
98.3 96.8 95.3 98.0 2.5 (1.5) 
Min: 0.8 
Max: 5.6 
-11.6 
(13.3) 
98.4 97.1 100 p=0.8 C9orf72: 
p=1.0 
 
GRN: 
p=0.847 
 
MAPT: 
p=1.0 
Increase 
symptom 
endorsement 
2.0 2.4 (1.7) 
Min: 0.9 
Max: 4.5 
-7.4 
(17.1) 
1.7 2.1 2.3 1.0 3.3 (1.7) 
Min: 2.1 
Max: 4.5 
-6.4 (21.4) 1.6 1.0 0.0 
Decrease in 
symptom 
endorsement 
1.0 3.4 (2.8) 
Min: 1.4 
Max: 5.4 
-0.8 
(14.3) 
0.0 1.0 2.3 1.0 3.0 (2.7) 
Min: 1.1 
Max: 4.9 
-19.0 (1.0) 0.0 1.9 0.0 
Apathy               
No change 95.4 2.6 (1.3) 
Min: 0.8 
Max: 5.6 
-14.2 
(11.2) 
94.8 95.8 95.3 95.5 2.5 (1.4) 
Min: 0.8 
Max: 5.6 
-11.7 
(13.2) 
95.2 96.1 94.6 p= 0.9 C9orf72: 
p=1.0 
 
GRN: 
p=1.0 
 
MAPT: 
p=0.8 
Increase 
symptom 
endorsement 
2.0 3.4 (1.8) 
Min: 1.7 
Max: 5.2 
-1.0 
(11.9) 
0.0 3.2 2.3 2.5 3.5 (2.3) 
Min: 1.0 
Max: 5.6 
0.6 
(13.46) 
0.0 2.9 5.4 
Decrease in 
symptom 
endorsement 
2.6 3.1 (1.8) 
Min: 1.1 
Max: 5.0 
-9.2 
(12.5) 
5.2 1.1 2.3 2.0 2.1 (1.9) 
Min: 1.0 
Max: 4.9 
-21.9 (3.4) 4.8 1.0 0.0 
Decreased 
fluency 
              
No change 96.4 2.6 (1.4) 
Min: 0.8 
Max: 5.6 
-13.9 
(11.4) 
98.3 97.9 90.7 96.5 2.5 (1.5) 
Min: 0.78 
Max: 5.6 
-11.9 
(13.3) 
95.2 96.1 100 p=0.9 C9orf72: 
p=0.746
319 
 
GRN: 
p=1.0 
 
MAPT: 
p=0.247 
Increase 
symptom 
endorsement 
2.6 1.8 (1.0) 
Min: 0.9 
Max: 3.3 
-17.7 
(7.0) 
1.7 2.1 4.7 2.0 1.0 (0.1) 
Min: 1.0 
Max: 1.1 
-1.4 (10.3) 1.6 2.9 0.0 
Decrease in 
symptom 
endorsement 
1.0 2.2 (1.2) 
Min: 1.4 
Max: 3.1 
0.2 
(12.8) 
0.0 0.0 4.7 1.5 3.2 (2.0) 
Min: 1.0 
Max: 4.9 
-7.4 (10.2) 3.2 1.0 0.0 
Memory 
impairments 
              
No change 85.7 2.6(1.3) 
Min: 0.9 
Max: 5.4 
-14.0 
(11.0) 
86.2 87.4 81.4 85.1 2.5 (1.5) 
Min: 0.8 
Max: 5.6 
-12.6 
(12.5) 
82.3 85.4 89.2 X2=0.7, 
p=0.7 
C9orf72: 
p=0.5 
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 Pre-symptomatic Mutation Carriers Non-carriers   
 Total 
(N=196) 
Mean time 
interval, 
Yrs (SD) 
Mean 
YEO 
(SD)# 
C9orf72 
(n=58) 
GRN 
(n=95) 
MAPT 
(n=43) 
Total 
(N=202) 
Mean time 
interval, 
Yrs (SD) 
Mean 
YEO 
(SD)# 
C9orf72 
(n=62) 
GRN 
(n=103) 
MAPT 
(n=37) 
Group 
Contrasts 
Genotyp
e 
Contrast
s 
Increase 
symptom 
endorsement 
8.7 3.0 (1.8) 
Min: 0.8 
Max: 5.56 
-11.6 
(14.2) 
10.3 6.3 11.6 7.4 2.7 (1.8) 
Min: 0.9 
Max: 5.6 
-4.2 (14.8) 8.1 6.8 8.1 GRN: 
X2=0.2, 
p=0.9 
 
MAPT: 
p=0.7 
Decrease in 
symptom 
endorsement 
5.6 3.0 (2.0) 
Min: 1.0 
Max: 5.5 
-13.9 
(13.1) 
3.4 6.3 7.0 7.4 2.1 (1.5) 
Min: 1.0 
Max: 5.3 
-7.9 (17.3) 9.7 7.8 2.7 
Articulation 
Impairments 
              
No change 96.9 2.6 (1.4) 
Min: 0.8 
Max: 5.6 
-14.0 
(11.3) 
98.3 95.8 97.7 96.5 2.5 (1.5) 
Min: 0.8 
Max: 5.6 
-11.5 
(13.2) 
100 93.2 100 p= 0.7 C9orf72: 
p=0.483 
 
GRN: 
p=0.791 
 
MAPT: 
p=1.0 
Increase 
symptom 
endorsement 
2.6 2.8 (1.7) 
Min: 1.0 
Max: 5.5 
-5.8 
(13.9) 
1.7 3.2 2.3 2.0 2.8 (2.1) 
Min: 1.0 
Max: 4.9 
-4.6 (14.7) 0.0 3.9 0.0 
Decrease in 
symptom 
endorsement 
0.5 -- -- 0.0 1.1 0.0 1.5 1.3 (0.4) 
Min: 1. 
Max: 1.7 
-27.3 (5.4) 0.0 2.9 0.0 
• Number of participants for each maximum visit: Maximum of 2 visits: N=178 (n=80 pre-symptomatic; n=98 non-carrier); Maximum of 3 visits: 
N=130 (n=72 pre-symptomatic; 58 non-carriers); Maximum of 4 visits: N=57 (n=30 pre-symptomatic; 27 non-carriers); Maximum of 5 visits: 
N=25 (n=10 pre-symptomatic; n=15 non-carriers); Maximum of 6 visits: N= 8 (n=4 pre-symptomatic; n=4 non-carriers) 
• *Sub-symptoms are coded as 0=no change in symptom endorsement, 1=increase in symptom endorsement, -1 decrease in symptom endorsement 
• #YEO=Years from expected symptom onset. Values represent estimates from the initial visit. Mean YEO is only reported for categories where 
n>1 to prevent disclosure of genetic status 
 
 
 
151 
 
Table A.10: Sensitivity and Specificity Scores (%) for Gene Composite Indices 
 
 C9orf72/MAPT Composite Index GRN Composite Index 
Gene Group Sensitivity 
 (95% CI) 
Specificity  
(95% CI) 
Sensitivity 
 (95% CI) 
Specificity 
 (95% CI) 
*Symptomatic vs. Non-carrier 
C9orf72  96.4 (89.9-99.3) 80.4 (71.4-87.6) 89.3 (80.6-95.0) 91.2 (83.9-95.9) 
GRN 96.6 (88.1-99.6) 80.4 (71.4-87.6) 98.3 (90.8-100.0) 91.2 (83.9-95.9) 
MAPT  93.6 (78.6-99.2) 80.4 (71.4-87.6) 80.7 (62.5-92.6) 91.2 (83.9-95.9) 
**Preclinical vs. Non-carriers (Beginning -5 years of expected disease onset) 
C9orf72  20.0 (6.8 - 40.7) 80.4 (71.4 - 87.6) 12.0 (2.6 - 31.2) 91.2 (83.9 - 95.9) 
GRN 14.3 (4.8 - 30.3) 80.4 (71.4 - 87.6) 8.6 (1.8 - 23.1) 91.2 (83.9 - 95.9) 
MAPT 18.2 (2.3 - 51.8) 80.4 (71.4 - 87.6) 9.1 (0.2 - 41.3) 91.2 (83.9 - 95.9) 
^Preclinical vs. Non-carriers (Beginning -2 years of expected disease onset) 
C9orf72  20.0 (4.3 - 48.1) 78.4 (67.3 - 87.1) 13.3 (1.7 - 40.5) 90.5 (81.5 - 96.1) 
GRN 15.4 (4.4 - 34.9) 78.4 (67.3 - 87.1) 11.5 (2.5 - 30.2) 90.5 (81.5 - 96.1) 
MAPT 28.6 (3.7 - 71.0) 78.4 (67.3 - 87.1) 14.3 (0.4 - 57.9) 90.5 (81.5 - 96.1) 
^^Preclinical vs. Non-carriers (Beginning 0 years of expected disease onset) 
C9orf72 23.1 (5.0 - 53.8) 76.2 (63.8 - 86.0) 15.4 (1.9 - 45.5) 90.5 (80.4 - 96.4) 
GRN  22.2 (6.4 - 47.6) 76.2 (63.8 - 86.0) 16.7 (3.6 - 41.4) 90.5 (80.4 - 96.4) 
MAPT 33.3 (4.3 - 77.7) 76.2 (63.8 - 86.0) 16.7 (0.4-64.1) 90.5 (80.4 - 96.4) 
*As symptomatic carriers were older than non-carriers the following comparison only includes 
non-carriers who were at least -5 years from disease onset. Symptomatic carriers: C9orf92: n=84, 
GRN: n=58, MAPT: n=31; Non-carriers n=102 
**Preclinical: C9orf92: n=25, GRN: n=35, MAPT: n=11; Non-carriers n=102 
^Preclinical: C9orf92: n=15, GRN: n=26, MAPT: n=7; Non-carriers n=74 
^^Preclinical: C9orf92: n=13, GRN: n=18, MAPT: n=6; Non-carriers n=63 
CI= 95% confidence intervals 
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Table A.11: Mean (SD) Composite Scores for At-Risk Groups 
 
 C9orf72/MAPT Composite Index GRN Composite Index 
 Preclinical Non-carrier Preclinical Non-carrier 
At-risk from -5 years to expected onset 
C9orf72  0.2 (0.5)  
0.3 (0.6) 
0.2 (0.5)  
0.1 (0.5) GRN 0.2 (0.5) 0.1 (0.6) 
MAPT 0.3 (0.6) 0.2 (0.6) 
At-risk from -2 years to expected onset 
C9orf72  0.3 (0.6)  
0.3 (0.7) 
0.2 (0.6)  
0.1 (0.5) GRN 0.2 (0.5) 0.2 (0.36) 
MAPT 0.4 (0.8) 0.3 (0.8) 
At-risk from -0 years to expected onset 
C9orf72  0.3 (0.6)  
0.3 (0.7) 
0.2 (0.6)  
0.1 (0.5) GRN 0.3 (0.6) 0.3 (0.8) 
MAPT 0.5 (0.8) 0.3 (0.8) 
Only one symptom was selected as the initial symptom for affected patients 
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Appendix B: Chapter 3 (Study 2) Supplementary Material 
 
Results Section 1.0: Additional analysis with all genetic mutation carriers relative to non-
mutation carriers 
Participants 
A total of 127 participants met the inclusion criteria. After processing in FreeSurfer, 4 
participants were removed prior to statistical analysis: 1 due to scaling errors, 1 with extensive 
segmentation errors, and 2 found to be extreme outliers (1 carrier and 1 non-carrier from PGRN 
families; mean volumes >3 SD), leaving 123 participants from 56 family cohorts, entered into 
the statistical model (Table A.1).  
 
Carriers vs. Non-carriers 
In the comparison of all carriers (symptomatic and preclinical) relative to non-carriers, the final 
model included a genetic status by time to disease onset (linear) interaction (Table A.2). Due to 
the significant correlation between age and expected years to disease onset, (r=0.91, p<0.0001), 
age could not be included in the model due to multi-collinearity. There was a significant genetic 
status by time to disease onset (linear) interaction. In a sensitivity analysis with one potentially 
highly-influential participant removed (carrier), the significance of the main effects and 
interaction did not change and thus their data remained in the analysis. Additionally, visual 
inspection of the scatterplots demonstrated an extreme case (non-carrier). Unadjusted post-hoc t-
tests of the genetic status by time to disease onset interaction demonstrated greater ventricular 
volume in carriers relative to non-carriers starting at 10 years prior to expected disease onset, or 
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at 12 years prior to expected disease onset when one extreme case (non-carrier) was removed 
from the model (Figure A.1, Table A.3).  
 
Years from Actual Disease onset: The above analysis used calculated years to expected disease 
onset for all participants as in the prior GENFI study. To confirm that the results were similar 
when the age of disease onset was used for symptomatic carriers, the above analysis was 
repeated using actual time from disease onset, calculated by subtracting the age at disease onset 
from the participant’s current age at the time of the baseline and follow-up scans. The above 
analysis was repeated using the final model with the same extreme case removed, substituting 
actual time from disease onset for all symptomatic carriers and for three preclinical carriers who 
became symptomatic during the 1year interval between baseline and follow up. Similar to the 
previous results, there was a significant genetic status by years to onset interaction, where 
carriers showed greater volumes beginning 10 years prior to disease onset relative to non-carriers 
(Table A.4).  
 
Manually Edited Versus Fully Automated Ventricular Volumes 
Manual edits to the ventricular segmentations performed in FreeSurfer were made on all study 
participants for each time point (mean differences in edited vs. unedited volumes are reported in 
supplementary analysis). Substitution of the fully automated ventricular volumes produced by 
FreeSurfer into the final models resulted in similar findings, demonstrating that for all carriers 
vs. non-carriers, significant differences were observed at 12 years prior to expected disease onset 
(Tables A.5a-b). See Table A.6 for annualized change of unedited ventricular volume.  
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Total Ventricular Expansion over 1 year 
To assess potential differences in ventricular expansion over the 1-year interval, an additional 
model was comprised that included the same family and participant random effects as above and 
the following fixed effects: visit, years to disease onset (linear and quadratic terms), genetic 
status and an interaction between visit and genetic status. A sensitivity analysis for all carriers vs. 
non-carriers identified one high-influential participant (carrier) but their removal d id not change 
the significance of the main effects and interaction and thus, they were retained. Carriers as a 
whole demonstrated greater ventricular volume at baseline (p=0.03) and follow-up (p=0.003) 
relative to non-carriers. Additionally, carriers showed significant ventricular expansion between 
baseline and follow up (p<0.001), whereas non-carriers did not (p=0.23). Annual rate of change 
of total ventricular volume is presented in Table A.7, as a function of genetic status and years to 
expected disease onset. 
 
Mutation Type 
Specifically, utilizing the final models from previous analysis (with the extreme case removed 
for carriers vs. non-carriers comparison), we included, genotype (C9orf72, PGRN, MAPT) and 
the interaction between genotype and genetic status as fixed effects in the model. Significant 
interactions were decomposed using simple effects estimation. For total ventricular volume, for 
all carriers vs. non-carriers, the interaction between genotype and genetic status did not reach 
significance (p=0.10). Additionally, there was no significant interaction between genetic status 
and genotype for the laterality index (p=0.18). 
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Table B.1: Demographic characteristics of study participants (N=123) 
 Symptomatic 
(n=21) 
Preclinical 
Carrier 
(n=46) 
Non-Carriers 
(n=56) 
All Carriers vs. 
Non-carriers 
 
Preclinical 
carriers vs. 
Non-carriers 
 
Genotype    p=0.18 p=0.74 
 C9orf72 13 13 13   
 PGRN 5 29 36   
 MAPT 3 4 7   
Sex    p=0.27 p=0.52 
 Female 9 25 34   
 Male 12 21 22   
Years from 
expected disease 
onset at baseline 
Mean (SD)  
5.16 (5.0) 
 
-13.34 (12.65) 
 
-9.14 (15.60) 
 
p=0.55 p=0.14 
Age (SD)  
 
64.37 (6.19) 44.66 (11.14) 50.56 (15.64) p=0.92 p=0.03* 
Years of 
education (SD) 
 
13.09 (4.11) 14.20 (3.47) 14.34 (3.51) p=0.46 p=0.84 
Group differences were assessed using chi-square tests and t-tests. *significant at p<0.05 
Symptomatic carriers (n=18) include 3 progressors 
 
 
Table B.2: Estimates for total ventricular volume of carriers (n=67) and non-carriers (n=55) with 
no extreme case (n=1) 
 
Fixed Effects Estimate SE p-value CI (95%) 
Intercept -0.70 0.56 0.22 -1.83, 0.43 
Visit 
(ref=follow-up) 
-0.04 0.02 0.07 -0.08, 0.003 
GS (ref=non-
carriers)  
0.70 0.17 <.0001* 0.37, 1.04 
Time from 
disease onset 
-0.06 0.02 0.006* -0.10, -0.02 
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Time from 
disease onset2 
0.001 0.0003 <.0001* 0.0008, 0.002 
Time from 
disease onset*GS 
0.03 0.01 0.001* 0.01, 0.05 
Random Effects Estimate SE p-value  
Family  
Membership 
 
0.18 0.17 0.13  
Participant 0.58 0.13 <.0001*  
Residual 0.02 0.003 <.0001*  
SE=standard error; GS=Genetic Status (carrier vs. non-carrier); CI=Confidence interval; 
*significant at p<0.05 
 
 
Table B.3. Estimated difference in ventricle volume between mutation carriers (n=67) and non-
carriers (n=55) by time from expected disease onset 
 
 -25 years -20 years -15 years -10 years -5 years 0 years 5 years 10 years 
 
Total Ventricle+ 
Estimate -0.12 0.06 0.22 0.38 0.54 0.70 0.86 1.02 
SE 0.22 0.19 0.17 0.15 0.15 0.17 0.20 0.23 
p-value 0.64 0.7699 0.1929 0.0144* 0.0006* <.0001* <.0001* <.0001* 
 
Total Left Ventricle++ 
Estimate -0.06 0.02 0.11 0.19 0.27 0.36 0.44 0.52 
SE 0.11 0.09 0.08 0.07 0.07 0.08 0.09 0.11 
p-value 0.57 0.79 0.17 0.01* 0.0003* <.0001* <.0001* <.0001* 
 
Total Right Ventricle++ 
Estimate -0.06 0.01 0.08 0.15 0.21 0.28 0.35 0.42 
SE 0.12 0.10 0.09 0.08 0.08 0.09 0.11 0.12 
p-value 0.65 0.91 0.38 0.08 0.01* 0.003* 0.001* 0.001* 
 
Third Ventricle 
Estimate 0.002 0.007 0.01 0.02 0.02 0.03 0.04 0.04 
SE 0.006 0.006 0.005 0.004 0.004 0.005 0.006 0.007 
p-value 0.79 0.18 0.007* <.0001* <.0001* <.0001* <.0001* <.0001* 
SE=standard error; *significant at p<0.05 
+ Total volume is comprised of the left and right lateral, inferior, and third and fourth ventricles 
++ Total left and right ventricles are composed of the lateral and inferior ventricles 
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Table B.4: Estimates for total ventricular volume using actual years to disease onset for carriers. 
Using final model with no extreme case (N=122) 
 
Fixed Effects Estimate SE p-value CI (95%) 
Intercept -0.03 0.56 0.95 -1.15, 1.08 
Visit 
(ref=follow-up) 
-0.04 0.02 0.04* -0.08, -0.003 
GS (ref=non-
carriers)  
0.60 0.18 0.0009* 0.25, 0.95 
Real time from 
disease onset 
-0.04 0.02 0.08* -0.08, 0.005 
Real time from 
disease onset2 
0.001 0.0003 0.0005* 0.0005, 0.002 
Time from 
disease onset*GS 
0.03 0.01 0.010* 0.006, 0.05 
Random Effects Estimate SE p-Value  
Family 
Membership 
0.12 0.17 0.23  
Participant 0.68 0.15 <.0001*  
Residual 0.02 0.003 <.0001*  
SE=standard error; GS=Genetic Status (carrier vs. non-carrier); *significant at p<0.05 
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Table B.5a: Estimates for carriers (n=67) and non-carriers (n=55) for unedited ventricular 
volumes with no extreme case (n=1) 
 
Fixed Effects Estimate SE p-value CI (95%) 
Intercept -0.72 0.55 0.19 -1.83, 0.38 
Visit 
(ref=follow-up) 
-0.04 0.02 0.06 -0.08, 0.002 
GS 
(ref=non-carrier)  
0.72 0.17 <.0001* 0.39, 1.06 
Time from 
disease onset 
-0.06 0.02 0.004* -0.10, -0.02 
Time from 
disease onset2 
0.001 0.0003 <.0001* 0.0009, 0.002 
Time from 
disease onset*GS 
0.03 0.009 0.0007* 0.01, 0.05 
Random Effects Estimate SE p-Value  
Family 
Membership 
0.19 0.17 0.13  
Participant 0.58 0.13 <.0001*  
Residual 0.02 0.003 <.0001*  
SE=standard error; GS=Genetic Status (carrier vs. non-carrier); *significant at p<0.05 
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Table B.5b: Estimates between carriers (n=67) and non-carriers (n=55) for unedited total 
ventricular volume by time to expected disease onset 
 
 -25 years -20 years -15 years -10 years -5 years 0 years 5 years 10 years 
Estimate -0.12 0.05 0.22 0.39 0.56 0.72 0.89 1.06 
SE 0.22 0.19 0.17 0.15 0.15 0.17 0.20 0.23 
p-value 0.61 0.78 0.19 0.01* 0.0004* <.0001* <.0001* <.0001* 
SE=standard error; *significant at p<0.05 
 
Table B.6. Annual percent change of unedited total ventricular volume by genetic status 
 
Years to 
disease onset 
(baseline) 
Symptomatic (n=18) Preclinical (n=46) and 
Progressors (n=3) 
Non-carriers (n=56) 
 Mean (SD) CI Mean (SD) CI Mean (SD) CI 
Less than -20 - - 1.74 (7.74) -2.10, 5.59 -2.31 (6.83) -5.71, 1.08 
-20 to -10.01 - - 3.28 (2.94)  1.18, 5.38 0.10 (3.04) -2.44, 2.64 
-10 to -0.1 - - 6.88 (9.59) 0.79, 12.98 1.50 (3.92) -0.99, 3.99 
0 to 9.99 11.01 (7.86) 6.26, 15.76 5.96 (7.52)  0.18, 11.74 3.70 (4.65)  0.58, 6.82 
10 and beyond 5.91 (4.50) 0.33, 11.50 - - 3.38 (2.08) 1.45, 5.30 
SD= Standard deviation; CI= 95% confidence interval 
Years to disease onset for symptomatic individuals and progressors are based on actual time at diagnosis.  
 
 
Table B.7. Annual percent change of total ventricular volume by genetic status  
 
Years to 
symptom 
Onset+  
Symptomatic (n=18) Preclinical (n=46) and 
Progressors (n=3) 
Non-carriers (n=56) 
 Mean (SD) CI Mean (SD) CI Mean (SD) CI 
       
Less than -20 - - 1.76 (7.62) -2.03, 5.55 -2.33 (6.89) -5.76, 1.09 
-20 to -10.01 - - 3.39 (2.88)  1.32, 5.45 0.01 (2.91) 2.91, 2.44 
-10 to -0.1 - - 7.27 (10.33) 0.71, 13.83 1.52 (3.85) -0.92, 3.97 
0 to 9.99 10.97 (7.75) 6.29, 15.66 5.68 (7.64)  -0.19, 11.55 3.69 (4.58) 0.61, 6.77 
10 and beyond 6.00 (4.47) 0.45, 11.56 - - 3.15 (1.87) 1.42, 4.89 
SD= Standard deviation; CI= 95% confidence intervals.  
+Years to onset for symptomatic individuals and progressors are based on actual time at diagnosis.  
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Figure B.1 Predicted total ventricular volume by estimated years from expected disease onset in 
carriers (blue, n=67) and non-carriers (red, n=55) no extreme case.  
 
 
Ventricular volume is expressed as a percentage of intracranial volume. To prevent disclosure of 
genetic status, individual data points are not plotted. Differences are noted beginning at 12 years 
prior to disease onset as indicated by the dashed line (p=0.05). 
 
 
 
Table B. 8: Influence Diagnostic Statistics of High-Influential Participants (non-carriers) 
 
Participant PRESS 
Statistic 
Cook’s D MDFFITS COVRATIO Restricted 
Likelihood 
Distance 
1 22.93 0.12 0.13 0.61 1.66 
2 3.84 0.38 0.34 0.86 2.92 
Note: Model does not include the genetic status*time to disease onset quadratic term 
 
 
 
 
 
 
 
 
 
162 
 
 
Table B.9a: Estimates for preclinical carriers (n=46) and non-carriers (n=53) for unedited 
ventricular volumes with no extreme cases (n=1) or influential cases (n=2)  
 
Fixed Effects Estimate SE p-value CI (95%) 
Intercept 0.35 0.35 0.31 -0.34, 1.05 
Visit 
(ref=follow-up) 
-0.0005 0.01 0.96 -0.02  ̧0.02 
GS 
(ref=non-carrier)  
0.36 0.15 0.02* 0.06, 0.67 
Time from 
disease onset 
-0.03 0.01 0.06* -0.05, 0.0009 
Time from 
disease onset2 
0.0008 0.0002 0.0001* 0.0004, 0.001 
Time from 
disease onset*GS 
0.02 0.008 0.02* 0.003, 0.03 
Random Effects Estimate SE p-Value  
Family 
Membership 
0.02 0.04 0.33  
Participant 0.38 0.07 <.0001*  
Residual 0.004 0.0005 <.0001*  
SE=standard error; GS=Genetic Status (carrier vs. non-carrier); *significant at p<0.05 
 
 
 
 
Table B.9b: Estimates between preclinical mutation carriers (n=46) and non-carriers (n=53) for 
unedited total ventricular volume by time to expected disease onset 
 
 -25 years -20 years -15 years -10 years -5 years 0 years 5 years 10 years 
Estimate -0.10 -0.01 0.08 0.18 0.27 0.36 0.45 0.55 
SE 0.16 0.14 0.13 0.13 0.14 0.15 0.18 0.20 
p-value 0.54 0.96 0.52 0.17 0.05 0.02* 0.01* 0.009* 
SE=standard error; *significant at p<0.05 
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Results section 2.0: Assessing regions of the ventricles for all mutation carriers vs. non-
carriers, all preclinical carriers vs. non-carriers 
 
Carriers vs. non-carriers: Regions of the Ventricles 
Upon finding that total ventricular volume showed significant differences as a function of 
genetic carrier status and time to expected disease onset, we were then interested in exploring 
whether regions of the ventricles showed significant changes prior to disease onset using the 
same statistical model for volumes of the left ventricle, right ventricle, third and fourth 
ventricles. For each region, when significant, the interaction between genetic status and years 
from disease onset was followed up with t-tests.  Relative to non-carriers, carriers (with extreme 
case removed) showed greater ventricle volumes in the left ventricle beginning 12 years prior to 
expected disease onset, in the right ventricle at 8 years, and in the third ventricle 17 years prior to 
disease onset. There was no significant interaction between genetic status and years from disease 
onset for the fourth ventricle or the laterality index.  
 
Preclinical carriers vs. non-carriers: Regions of the Ventricles 
Follow up analysis of left, right, third and fourth ventricular volumes with the final model 
with the two high-influential (n=2) and extreme case (n=1) removed demonstrated significant 
differences in the left ventricle beginning at 5 years before expected disease onset, and at 2 years 
after disease onset in the right ventricle. There was no significant genetic status by time to onset 
interaction for the third and fourth ventricles, and the laterality index.  
 
Mean Ventricular Volumes: Manually Edited Versus Fully Automated Segmentations 
We were interested in examining whether there were any significance differences 
between the constructed total ventricular volumes based on manual edits or unedited volumes. 
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Due to the potential differences in the degree of manual editing, differences were assessed 
separately at each visit (baseline and follow-up) for each group (symptomatic carriers, preclinical 
carriers, and non-carriers). Due to the small number of preclinical carriers who became 
symptomatic at follow-up (n=3), these individuals were not included in the following analysis. 
Normality was assessed using the Shapiro-Wilk and Kolmogorov-Smirnov tests using the Proc 
univariate procedure. When normality was violated, a Wilcoxon Signed-Rank test was 
conducted, otherwise a paired-samples t-test was used.  
There were no differences between the edited and unedited volumes at baseline or 
follow-up for preclinical carriers (all p’s> 0.80) and non-carriers (all p’s> 0.146). For 
symptomatic carriers at baseline and follow-up, the edited (Baseline: M=3.037, SD=1.116; 
Follow-up: M=3.370, SD=1.230) and unedited (Baseline: M=3.058, SD=1.113; Follow-up: 
M=3.392, SD=1.227) volumes differed significantly. 
Additionally, spearman’s rank-order correlations were completed on total ventricular 
volume to delineate the relationship between the manual edited and unedited volumes for each 
group. All correlations were significant across all groups: all p’s<0.0001, all rs>0.99.  
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Appendix C: Chapter 4 (Study 3) Supplementary Material 
 
Method C.1 Statistical Analysis for Voxel-based Morphometry Co-variate and Contrast 
To account for grey matter volume differences influencing the fMRI signal, voxel-wise grey 
matter tissue probabilities were entered as a covariate in the fMRI analysis. Grey-matter 
probability maps were acquired using Statistical Parametric Mapping software (SPM12; 
Wellcome Department of Cognitive Neurology, London, UK; http://www.fil.ion.ucl.ac.uk/spm).  
T1-weighted images were converted into NifTI format using the 3dAFNItoNIFTI command in 
AFNI. Next, T1-images were visually inspected and manually realigned to the anterior 
commissure to ensure proper spatial normalization. Following realignment, the images were 
segmented into grey and white matter and normalized to MNI space using the specifications of 
the AFNI @SSwarper MNI template (voxel size: 1x1x1; bounding box: Xstart: -96.5, Xend: 
96.5, ystart: -114.5, yend:114.5, zstart:-96.5, zend: 96.5; smoothing: 4mm full-width at half-
maximum Gaussian kernal). In AFNI, 3dresample was run to ensure the orientation, dimensions 
and voxel size were identical between the resultant VBM images (smwc1.nii) and the 
participant’s fMRI statistics file. Subsequently, the resampled grey-matter probability maps were 
included into the fMRI analysis as a voxel-wise covariate using 3dMVM in AFNI as a between 
subject factor.  
 
Multiple linear regression was conducted to assess regions that showed grey matter volume 
differences between patients with FTD and controls. Individual variation in brain size was 
accounted for by including total intracranial volume (sum of grey matter, white matter, and 
cerebrospinal fluid) as a covariate. AFNI’s 3dFWHMx and 3dClustSim was used to obtain a 
cluster-size threshold at p=0.05, applied to the whole brain at an alpha threshold of p<0.001 (478 
contiguous voxels).  
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Table C.1 Grey Matter Volume Differences Between Controls and Patients with FTD 
Cluster Region Cluster 
size 
(voxels) 
t-
statistic 
X Y Z 
1 Cluster expands across left and right frontal, 
temporal lobes, basal ganglia and 
cerebellum   
 
142075 10.97 30 6 -22 
2 Right middle temporal gyrus 
 
809 7.26 45 9 -36 
3 Left middle occipital gyrus 
 
751 6.29 -38 -88 3 
4 Left superior and middle temporal gyrus 
 
2305 6.17 -51 7 -25 
5 Left superior & medial frontal gyrus 
 
776 5.64 -10 64 11 
6 Right & left cuneus 
 
2545 5.35 1 -87 16 
7 Right inferior parietal lobe 
 
640 5.15 34 -46 42 
8 Left middle & inferior frontal gyrus 
 
1050 5.06 -40 4 31 
9 Right superior & inferior parietal lobe 
 
520 5.00 64 -37 23 
10 Left inferior parietal lobe 
 
614 5.00 -62 -41 39 
11 Right superior and middle temporal gyrus 
and precuneus 
1336 4.57 51 -72 26 
Voxel coordinates are in mm after transformation into standard MNI space.  
Patients with FTD demonstrate less grey matter volume in clusters above 
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Figure C.1 Grey Matter Volume Differences Between Patients and Controls 
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Table C. 2. BOLD Signal Responses While Controlling for Grey Matter Volume  
Choice Phase 
 
Fixed Effects Region L/R BA X Y Z t-value # 
voxels 
Contrast 
Group Inferior frontal gyrus L 47 32 -28.8 0.9 -3.0 53 Ctrl > Pat 
 Middle temporal 
gyrus 
L 22 60.4 31.9 3.7 -3.8 50 Ctrl > Pat 
 Inferior parietal 
lobule 
R 40 -54.0 47.0 27.4 -4.0 23 Ctrl > Pat 
  
Phase Inferior frontal gyrus L 9 43.5 -5.2 34.5 3.1 190 Acq >Rev 
 Medial frontal gyrus L 6 5.2 -13.5 51.5 5.0 168 Acq >Rev 
 Lentiform 
nucleus/putamen 
L  16.2 -10.2 0.2 3.8 159 Acq >Rev 
 Inferior frontal gyrus R 9 -39.9 -6.6 31.0 4.3 95 Acq >Rev 
 Cingulate gyrus R 32 -9.2 -18.7 39.1 3.9 67 Acq >Rev 
 Inferior frontal gyrus L 47 32.0 -26.7 -4.6 4.7 61 Acq >Rev 
 Caudate/lateral 
globus pallidus 
R  -11.8 -6.8 1.3 3.4 36 Acq >Rev 
 Inferior parietal 
lobule 
L 40 52.8 45.4 49.2 5.6 23 Acq >Rev 
 Cingulate gyrus L 32 10.2 -16.5 34.4 4.8 22 Acq >Rev 
  
Phase x 
reinforcement 
Medial frontal gyrus L 8/32 4.1 -19.8 47.9 -4.5 185 Acquisition: 
Incorr> Corr 
 
Reversal: 
Corr >Incorr 
 Inferior frontal grus L 9 44.0 -3.9 35.3 -3.8 155 Acquisition: 
Incorrrr > Corrr 
 
Reversal: 
Corr>Incorr 
 Lentiform 
nucleus/putamen 
L  +16.1 -10.4 -0.3 -3.2 125 Acquisition: 
Incorr> Corr 
 
Reversal: 
Corr>Incorr 
 Inferior frontal gyrus L 47 +35.0 -26.0 -5.0 -4.8 63 Acquisition: 
Incorr> Corr 
 
Reversal: 
Corr>Incorr 
 Cingulate gyrus R 32 -7.9 -17.6 42.2 -5.3 46 Acquisition: 
Incorr> Corr 
 
Reversal: 
Corr>Incorr 
 Middle frontal gyrus L 46 +43.0 -28.8 21.9 -4.7 36 Acquisition: 
Incorr> Corr 
 
Reversal: 
Corr>Incorr 
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 Cingulate gyrus L 32 +10.4 -17.9 33.4 -4.2 27 Acquisition: 
Incorr > Corr 
 
Reversal: 
Corr >Incorr 
Feedback Phase 
 
Fixed Effects Region L/R BA X Y Z t-value # 
voxels 
 
Reinforcement Lateral prefrontal 
cortex 
R  -29.5 -27.3 32.1 0.6 8468 Incorr >Corr 
 Inferior parietal 
lobule 
L 40 34.6  59.6  40.2 -6.2 4584 Incorr >Corr 
 Lateral prefrontal 
cortex 
L  42.9  -21.1 23.3 -4.4 4396 Incorr >Corr 
 Inferior parietal 
lobule 
R 40 -45.9 55.6 39.5 -4.5 3335 Incorr >Corr 
 Cuneus R 17 -1.3 82.8 6.6 -3.9 896 Incorr >Corr 
 Fusiform gyrus R 19 -44.3 70.3 -
18.3 
-4.0 493 Incorr >Corr 
 Declive L  30.7 63.3 -
29.6 
-3.9 474 Incorr >Corr 
 Thalamus R  -0.8 7.3 9.2 -3.3 349 Incorr >Corr 
 Fusiform gyrus L 19 45.4 71.0 -
16.6 
-3.3 145 Incorr >Corr 
 Cingulate gyrus L 23 2.0 24.4 30.5 -3.0 118 Incorr >Corr 
 Posterior cingulate L 30 19.7 63.8 3.8 -3.9 107 Incorr >Corr 
 Declive R  -12.0 82.0 -
23.8 
-4.4 95 Incorr >Corr 
 Superior frontal gyrus R 11 -21.8 -45.8 -
15.6 
-4.7 87 Incorr >Corr 
 Middle occipital 
gyrus 
L 19 34.5 91.5 6.7 -4.1 45 Incorr >Corr 
 Middle temporal 
gyrus 
R 21/22 -47.4  28.3 -5.4 -4.5 42 Incorr >Corr 
 Middle frontal gyrus L 11 23.8 -41.0 -
16.5 
-5.3 40 Incorr >Corr 
 Lingual gyrus R 18 -7.9  75.4 -7.9 -3.0 33 Incorr >Corr 
 Middle occipital 
gyrus 
L 19 44.3  59.6 -8.5 -3.5 32 Incorr >Corr 
 Medial frontal gyrus R 6 -21.3   -2.5 53.6 -4.6 29 Incorr >Corr 
 Parahippocampal 
gyrus 
L 27 8.9 37.4 4.6 -4.8 23 Incorr >Corr 
 Caudate tail R  -25.7  46.0 16.5 4.7 23 Corr > Incorr 
  
Phase Fusiform gyrus R 19 -41.8  80.2  -
21.0 
3.8 83 Acq >Rev 
 Inferior occipital 
gyrus 
R 18 -28.8  90 -
19.4 
3.7 52 Acq >Rev 
 Middle occipital 
gyrus 
L 19 54.4 75.1   -1.7 4.3 42 Acq >Rev 
 Lingual gyrus L 18 3.7 79.6   -8.5 3.3 25 Acq >Rev 
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Group x Phase Superior frontal gyrus L 10/11 27.8 -56.1 -
11.1 
-5.8 50 Acquisition: 
Ctrl > Pat 
 
Reversal: 
Pat >Ctrl 
          
Phase x 
Reinforcement 
Middle occipital 
gyrus 
R 19 -47.1  78.5  -
10.7 
-3.8 87 Acquisition: 
Incorr >Corr 
 
 
 Inferior occipital 
gyrus 
R 18 -26.4  90.1  -
19.7 
-4.4 63 Acquisition: 
Incorr >Corr 
 Lingual gyrus L 18 3.8  78.7    -8.7 -3.7 54 Acquisition: 
Incorr >Corr 
 Cuneus R 18 -4.5  97.2    8.9 -4.6 54 Acquisition: 
Incorr >Corr 
 Cuneus R 19 -0.8  89.5  27.6 -4.2 37 Acquisition: 
Incorr >Corr 
 Fusiform gyrus R 19 -42.9  78.5   -
22.9 
-4.6 25 Acquisition: 
Incorr >Corr 
  
3-way 
interaction 
Superior frontal gyrus L 10/11 26.2 -56.1 -
11.0 
5.9 22 Acquisition 
Incorr: 
Ctrl > Pat 
 
Reversal Corr: 
Pat > Ctrl 
 
Reversal Incorr: 
Pat >Ctrl 
Thresholded at p<0.001. All clusters survive correction for multiple comparison at p<0.05. Table displays 
regions, hemisphere (L, left; R, right), Brodmann area (BA), Montreal Neurological Institute (MNI) 
coordinates (x, y, z) at center of mass, maximum neural activity for the cluster (t-value), cluster size in 
voxels, and the direction of activity [Control (ctrl), Patient (pat), Acquisition (acq), Reversal (rev), 
Correct (corr), Incorrect (incorr)]. Focus point and regions of BA according to TT_Daemon: Talairach-
Tournoux atlas. The ANOVA was completed separately for the choice and feedback phase.  
 
Table C.3. Mean Percent Correct Responses and No Responses  
 Acquisition 
Correct (SD) 
Reversal Correct 
(SD) 
Acquisition No 
Responses 
Reversal No 
Responses 
Patients 83.7 (15) 80.8 (16.3) 5.1 (8.8) 3.7 (10.3) 
Controls 93.9 (2.2) 89.8(4.1) 0.3 (0.8) 0.2 (0.5) 
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